var title_f37_4_37952="Nystatin: Patient drug information";
var content_f37_4_37952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nystatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40947?source=see_link\">",
"       Nystatin (oral): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/55/35700?source=see_link\">",
"       Nystatin (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11810 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37952=[""].join("\n");
var outline_f37_4_37952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40947?source=related_link\">",
"      Nystatin (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/55/35700?source=related_link\">",
"      Nystatin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37953="Transanal endoscopic microsurgery";
var content_f37_4_37953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Transanal endoscopic microsurgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 557px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts&nbsp;the placement of&nbsp;the&nbsp;operating endoscope and cutting instrument used for the local excision of a rectal lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37953=[""].join("\n");
var outline_f37_4_37953=null;
var title_f37_4_37954="Contents: Neonatology";
var content_f37_4_37954=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neonatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neonatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antenatal drug exposure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28746\">",
"           Infants of mothers with substance abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11736\">",
"           Infants with antenatal exposure to serotonin reuptake inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/57/39833\">",
"           Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/56/20359\">",
"           Cardiac causes of cyanosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/2/43048\">",
"           Diagnosis and initial management of cyanotic heart disease in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/1002\">",
"           Management of patent ductus arteriosus in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/50/15145\">",
"           Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/18/8487\">",
"           Craniosynostosis syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/34/44581\">",
"           Facial clefts and holoprosencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/21/6488\">",
"           Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/35/38454\">",
"           Obstetrical management of omphalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/37/10841\">",
"           Overview of craniosynostosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/15/250\">",
"           Syndromes with craniofacial abnormalities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital malformations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/29/7639\">",
"           Lower extremity positional deformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/13/22745\">",
"           Benign skin and scalp lesions in the newborn and young infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/43/6840\">",
"           Skin nodules in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/21/30038\">",
"           Vascular lesions in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/31/15864\">",
"           Vesiculobullous and pustular lesions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/39/2682\">",
"           Clinical features and detection of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/6/97\">",
"           Evaluation and management of neonatal Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/48/44809\">",
"           Infant of a diabetic mother",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/23/26999\">",
"           Neonatal hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/39/41591\">",
"           Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/8/34950\">",
"           Emergency complications of Hirschsprung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23657\">",
"           Gastroesophageal reflux in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/55/31608\">",
"           Intestinal atresia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/5/35928\">",
"           Management of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41205\">",
"           Overview of the development of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28105\">",
"           Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/2/7207\">",
"           Prevention of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/31/32247\">",
"           Spontaneous intestinal perforation of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/4/21576\">",
"           Sucking and swallowing disorders in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/19/20792\">",
"           Anemia of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/40/14986\">",
"           Management of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/6/36968\">",
"           Neonatal polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14490\">",
"           Neonatal thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/16/14600\">",
"           Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperbilirubinemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/60/24519\">",
"           Approach to neonatal cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/18/27943\">",
"           Bilirubin metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/50/16169\">",
"           Causes of neonatal cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/63/25593\">",
"           Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/39/11898\">",
"           Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/60/19400\">",
"           Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39992\">",
"           Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/45/16083\">",
"           Patient information: Jaundice in newborn infants (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/59/21434\">",
"           Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inborn errors of metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27047\">",
"           Inborn errors of metabolism: Classification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/58/24489\">",
"           Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13177\">",
"           Inborn errors of metabolism: Identifying the specific disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/0/10250\">",
"           Inborn errors of metabolism: Metabolic emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/21/27992\">",
"           Chlamydia trachomatis infections in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/47/7928\">",
"           Clinical features and diagnosis of bacterial meningitis in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/16/6410\">",
"           Clinical features and diagnosis of sepsis in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/62/31720\">",
"           Clinical manifestations and diagnosis of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/49/10010\">",
"           Congenital rubella syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/63/36855\">",
"           Congenital rubella syndrome: Management, outcome, and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/17/28951\">",
"           Definition and etiology of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/30/24039\">",
"           Epidemiology and risk factors for Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/0/31749\">",
"           Epidemiology of pediatric HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/34/39462\">",
"           Gonococcal infection in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/63/37881\">",
"           Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/3/3130\">",
"           Natural history and classification of pediatric HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/31/35321\">",
"           Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/48/40713\">",
"           Neonatal herpes simplex virus infection: Management and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/0/21512\">",
"           Neonatal pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13384\">",
"           Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/43/10936\">",
"           Nosocomial viral infections in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/24/28041\">",
"           Overview of TORCH infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/48/9991\">",
"           Prevention of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/38/40550\">",
"           Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16121\">",
"           Treatment and outcome of bacterial meningitis in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/37/26200\">",
"           Treatment and outcome of sepsis in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/51/40760\">",
"           Treatment of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/12/29896\">",
"           Unusual fungal infections in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4278\">",
"           Varicella-zoster infection in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/19/26936\">",
"           Vertical transmission of hepatitis C virus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/7/31863\">",
"           Assessment of neonatal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/21/24922\">",
"           Assessment of the newborn infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27113\">",
"           Clinical features and diagnosis of developmental dysplasia of the hip",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/11/14520\">",
"           Incidence and mortality of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28746\">",
"           Infants of mothers with substance abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/21/20823\">",
"           Large for gestational age newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22713\">",
"           Late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/1/27672\">",
"           Limit of viability",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/31/13814\">",
"           Long-term complications of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/6/34922\">",
"           Long-term neurodevelopmental outcome of premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/23/35188\">",
"           Metabolic emergencies at birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/60/27594\">",
"           Neonatal outcome, complications, and management of multiple births",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14505\">",
"           Neurological examination of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/23/10616\">",
"           Overview of causes of and risk factors for fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/38/21096\">",
"           Perinatal mortality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/19/8502\">",
"           Physiologic transition from intrauterine to extrauterine life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/35/22068\">",
"           Postnatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/26/31142\">",
"           Postterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/57/5016\">",
"           Primary infantile glaucoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/15/31992\">",
"           Short-term complications of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/23/9593\">",
"           Small for gestational age infant",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11738\">",
"           Care of the neonatal intensive care unit graduate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/47/41721\">",
"           Care of the umbilicus and management of umbilical disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/7/27765\">",
"           Discharge planning for high-risk newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/2/39975\">",
"           Etiology, clinical manifestations, and evaluation of neonatal shock",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/60/27591\">",
"           Fluid and electrolyte therapy in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/47/22265\">",
"           Neonatal birth injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/57/39833\">",
"           Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36105\">",
"           Overview of the routine management of the healthy newborn infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/9/10393\">",
"           Postnatal care of hydrops fetalis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/18/35114\">",
"           Prevention and treatment of neonatal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/53/9048\">",
"           Red blood cell transfusions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal resuscitation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17513\">",
"           Overview of cyanosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/61/29656\">",
"           Oxygen monitoring and therapy in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/59/29623\">",
"           Systemic effects of perinatal asphyxia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/2/2088\">",
"           Newborn screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/11/6328\">",
"           Clinical features and electrodiagnosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/24/2442\">",
"           Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42697\">",
"           Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/6/13417\">",
"           Congenital myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/0/4104\">",
"           Diagnosis and classification of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/15/1273\">",
"           Etiology and pathogenesis of infantile spasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30953\">",
"           Etiology and pathogenesis of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/23/41335\">",
"           Etiology and prognosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/54/5994\">",
"           Hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/46/31465\">",
"           Management and complications of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35783\">",
"           Neonatal epileptic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/10/166\">",
"           Neuromuscular junction disorders in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11015\">",
"           Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/7/33913\">",
"           Periventricular leukomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27690\">",
"           Stroke in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/0/13\">",
"           Treatment of neonatal seizures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/21/13657\">",
"           Breast milk expression for the preterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/12/36040\">",
"           Breastfeeding the preterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/39/40567\">",
"           Calcium and phosphorus requirements of newborn infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/15/17658\">",
"           Common problems of breastfeeding and weaning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/1/8217\">",
"           Initiation of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1461\">",
"           Maternal and economic benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/53/43864\">",
"           Maternal nutrition during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/50/27434\">",
"           Parenteral nutrition in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/23/6519\">",
"           Physiology of lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/61/39896\">",
"           n-3 Long chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal and urological disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27114\">",
"           Acute kidney injury (acute renal failure) in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/36/7753\">",
"           Congenital and infantile nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37833\">",
"           Etiology, clinical features, and diagnosis of neonatal hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/59/42936\">",
"           Management of hypertension in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26356\">",
"           Nephrocalcinosis in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/23/44407\">",
"           Prune-belly syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/29/29144\">",
"           Bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/16/21768\">",
"           Clinical features and diagnosis of meconium aspiration syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/23/28026\">",
"           Congenital diaphragmatic hernia in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/5/36951\">",
"           Diaphragmatic paralysis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/14/43235\">",
"           Eventration of the diaphragm in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/13/43223\">",
"           Management of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/24/15753\">",
"           Management of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/39/4729\">",
"           Mechanical ventilation in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/51/25398\">",
"           Outcome of infants with bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/49/31511\">",
"           Overview of neonatal respiratory distress: Disorders of transition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18793\">",
"           Pathogenesis and clinical features of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/4/12360\">",
"           Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/12/19656\">",
"           Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/37/27225\">",
"           Persistent pulmonary hypertension of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/17/3353\">",
"           Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/13/18648\">",
"           Prevention and management of meconium aspiration syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/34/43561\">",
"           Prevention and treatment of respiratory distress syndrome in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27880\">",
"           Prevention of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/33/4631\">",
"           Pulmonary air leak in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/40/17034\">",
"           Pulmonary outcomes of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32804\">",
"           Transient tachypnea of the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-64DE6FBCC3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_4_37954=[""].join("\n");
var outline_f37_4_37954=null;
var title_f37_4_37955="Benzydamine: Patient drug information";
var content_f37_4_37955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzydamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/45/6867?source=see_link\">",
"     see \"Benzydamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Benzydamine&reg;;",
"     </li>",
"     <li>",
"      Dom-Benzydamine;",
"     </li>",
"     <li>",
"      Novo-Benzydamine;",
"     </li>",
"     <li>",
"      PMS-Benzydamine;",
"     </li>",
"     <li>",
"      Tantum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease mouth and throat pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzydamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698698",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If signs get worse or last for more than 7 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When treating a very sore throat, if signs last more than 2 days, or happen with fever, headache, rash, upset stomach, or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse with 1 tablespoon (15 mL) of this drug for 30 seconds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 30 minutes before eating, drinking, using mouthwash, or brushing teeth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695352",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may mix with an equal part of warm water to lower the chance of irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11987 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37955=[""].join("\n");
var outline_f37_4_37955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140265\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014227\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014226\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014231\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014232\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014234\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014229\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014230\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014235\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014236\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/45/6867?source=related_link\">",
"      Benzydamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37956="Fusidic acid: Patient drug information";
var content_f37_4_37956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fusidic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21651?source=see_link\">",
"     see \"Fusidic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fucidin&reg;;",
"     </li>",
"     <li>",
"      Fucithalmic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15673409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fusidic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away eye drops 1 month after opening.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11951 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-D7694A6197-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37956=[""].join("\n");
var outline_f37_4_37956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174940\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673409\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016682\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016681\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016686\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016687\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016689\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016684\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016685\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016690\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016691\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21651?source=related_link\">",
"      Fusidic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37957="Pelvic organ prolapse PI";
var content_f37_4_37957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Pelvic organ prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the tissues that support the organs in a woman&rsquo;s pelvis relax, organs can drop down and bulge into the vagina. In each picture, the black arrow shows how the organs move. In picture A, the organs are normal.&nbsp;Picture&nbsp;B shows prolapse of the bladder (called a &ldquo;cystocele&rdquo; or \"anterior vaginal wall prolapse\"). Picture&nbsp;C shows prolapse of the rectum&nbsp;(called a &ldquo;rectocele&rdquo; or \"posterior vaginal wall prolapse\"). Picture&nbsp;D shows prolapse of the uterus (called uterine prolapse).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37957=[""].join("\n");
var outline_f37_4_37957=null;
var title_f37_4_37958="Chronic villitis";
var content_f37_4_37958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic villitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2XwpdQX2hxCKRZCq7XAcPjPoR7Vi+MLK/0+S3v9LtZby0jDi5WM7pYlxlWRf41GDkdRkYqHwVpFvol7GmiXbNp5Zowkhyp74B68ckE16Eg444P9a2k1CV1sczm6NXmjszzfQ9et77T4bvT5xNHID86thWGeQR2I7g9K3dOvLMl/MleGTOVYfMF+o9P/r1Jd+Ekg1GW/0C6XTbmdt0tuUDW1wx67k7FvVfrzUNrobMD9qs7mwuGYkrDItxFx3B4bH15FNyi9jqVWlUXb+v67mg90suyJFVGXnC/MM/3lPoao6vKLG1jM0Ny9u4P79Y8qG9GAJwfc1RiAtr57aQ3u+I4d1s38uMHoSzAAkk8AVrWWnXUcpazv7gwNy0D2z7SfUZP9aWkSvdh8L0+Zz9vLGwVomDIwEisOhHb/8AVW5P9qvZEuZbJ9qL8qKhOFJ/Pmqt7pGvLexpp2nWbhwWa4up9oiI+6PLAJbP1pbC11uy1eNta1mytLdkJ8i0tz5s2MlizFjgZ6H+VNtPW5pKrGWsWm/67FS+vbOKeVrmJxEEwsanb8/bPt6ipfCml3uoTG9EQhhi5haQYDP2YDuB1+tUfFt9JbX8aWOiSwRyMgkvpGD3CuzcbEfIwACSTzg8c1lWN54jvLa8mtL7UBbTtJBDG9yjRhS5UMrBQwAAznd3xmq5G43NbuULR0v3Op8WXWn6FHH5lpqN9qcjgOtkoJdyCSzHOFHXk1zlxqU1hPZpaaNawssrBluJGKIhGWPynBY5wB0zVBLVNK1MaZbW99cXVpCZN3ml1IPVzlsuzH+vpU+qS3uJFvUtYLYMtyzgkcYwEbPckjkc8c1cYJBGCS5W7npXgbxJZ+JNIhntIWtDgnyMY43EZHHIP0710Lwo80MjZ3xElefUYNeDXmvSeD/H1qIdAvr17zC292JmxdDbkqpI2deCBjFejWfi26vdJtL++02901Zfv2kY865X1bAHKjgkgZxmsKlFp3jsziq4e0r09jodYivGurR7BIzIHUO8n3QucnIHPTOPfFasiJIAHUMAcgGuG1vxHqWl3toNKguNRgeZBcKwBMETHG8nHbrgmuwtLvzZpbeVTHcxAMy5yGB6MD3H8iKzlFpIynTlFJnl3xgsPGGraxbQ+DorhIbW1YzTRbFJkJG1AW68ZPp+OKy9Kb4t6TZzPfaFp2q7goUQTrG4GOcgEBvfPOele4gYHAqhdapa2c5iuTJF0w3lkqc+4rRVnZRsio1ZtKMVex48mu/EzVpf7NtfC8WnwTSYWa7jykKjqTng9zzz6CvXNA0mTSkm8/UrvULiZgzS3G0YwMYUKAAM5OPepLzV7SzeMXDOscgyJdpKD8avo6yIrxkMpGQR0INTOo5LZIVScmtrI8/8DaLdaH4Hht/tCx3JlnmlkDcyZfk57HA7e1S6HqUQ1HUY5LyyghDG1ilWVVZ5sZVNx+Z22ndjt711GraJFqEEqRzz2ckn/LSAjOe5wQRn3xXPp8PbIXVi0t5NNa2bebFbNGm1JcY8xTjIbk8iq54yu5dTb2kJJtvco6j/AMJBbeIraCKYSQ3krx2xhgH+jJs4eUEdm5DH6V1nhfQbbw7pCWFq8kp3NLNPKcvNKxyzsfUmp7mfT9Et2nu5REOAXkJd2/mTWDafEbwvczeTFqSiXfs2SRujZ452kA4561LU5rRaESc6itFaGhqWtXLXb2GhWJvb2MgTSyNst7fP99+pbHO1QT644qHU9UvtP/4/L3SLZTwhlVyXPHOA2QM5FWPD11Als8Zlj8ssZkl8zKuGJJ59jkflXIO+la9ff8JPqug38Oo2LSW1pHcSlBLF1X5AcHdyQCCfXtRGKvsONOztbQ2/EmkajdWSSadeJp16zhpJ4E86F89dyEcA+o/GsLxB4l8OeFZLK18SajfpJINiCKB9mRyxGBwOa0/CPiG51G0kHlpaQL/q/ObBPdl5wVKg9CPpXn/xb8B+J/Gfia1vYJo4vDgiDRvjMtv8o3M6HBJJGBgnA64rSCXNyzdkapyXutnpfhPxt4S1aCRNA1KKRY2+dTG6tk9zuAJ+tdLa31pdBngnjkVMncGHGOv5V5PoHhGx0nTri00UpbaiSqy3kaZy2AGITJxwDj3NWm0d7ODV7fQ9RljtruJxFDPhjG5B3ZbrgnHHalKnBv3X94PDRfXUtandXet3Vy+l30KmOXfKcK4MfRVHX5e5wM1U0y1i1HV7i8mlinNu5hiljQqY4CqsYzkAZJGdw6g15d8MtfvvC3jI6J4jZoLeS6aKSFlG6Fn5GSM9TgduvvXsFnHd6TrctjOtkdN1LfLBHI4DRyDhRkdeAMCtZwcNEb3S2NqfUoNqyxPG8FomY/LXcFOATnH8QHaqnw1uUvn11bR5ZdGE6PZyOMZ3JiQDvwwPtXNnV5dMuLW0extJIrpgLdWZ7dg4b94oVh1AOfmPPauk8DS6iNf1CKPTZotCCqIrmZlALDsgHJHJ5PSspRtFmdSCVN2O3dRI5ikXeMZBI6//AF6pjTYYp4jbW0KruyzEnI5zwO9aXTpR2rnOFSa2IYYRGqYJJUbQSSeKZHaRRrMBuJmJLsSck/0/CrJ+lJ9KBXZ4f8WvhL9tv01vwzbSNO8/mX1mk2wSjHLp6Meh9jXiDavfeHdXuG0G5uNMlSdtipcMRGoBUoQeGI9TX2/wPQCvLPEngXw1f6umpHTo7cu7T+Y0gCSsf4inoffrXZRxFlyz1OrDzb91nHaH40ufE+nXcnir7TBZIv8Aod+lsUcHHQbRgkkE5HHriuk0K2ni0aOKW9upEkUbllIL5J6Z7Dvx+dZ2rWF3ALPUNGRbuxhQLFaAFYwnTKjHzAjPNdroOn/2jYG6uY57YBVYIwyRnrkCipJJXWiOxuEI36f10MzR9Our+5utH1DzY9MLCa0nRwZFfknnt29qb4k8USaHHdWWv6VfW9nIhiW6to/MSUdCSQDtJ9O9dkiw28K3H2lGihyol4UIw6g+vakXUraYx26yyyl8Jl1yGyc7uQf17Vhz3d2rnLKTbuldHlHiLWY7XUtDsbC2uBcTAObmaRlS2i6FsZ689DXWRrbLeCDe1y0tsXmYt8pPY/l1xVrx3o1re6Y17Pb2yyo6+W65AcA5AbB6ZFUPPXTEgskhWSe7Qs7d441HT1x1rXmUoqxXNzxujhhb3+i3z20Fi0thLdsGm37tqEEfnnj8K3VtJV+ywrCiwqdqy4LiJ8HBIx045J9a3bTSnWeWSecOjIZS2DhF9h6nj/OaDNdjTGgtIpSbljBIQdu1cHDH6ZPT1q3U5mVKfu6blXT7JZpotTCmG8kWNSitkHBxgjsfT2NdL/Za/wB2X/vn/wCvWfY2McEUMPmyReUh3iSQuWYDggnvwD+NUP7b1T/oE63/AN8x/wDxVZPmk9GclV3ejsJa3My+J9OsdIsoTHGRdX8oLCOJCDggn5Sx9OvWuvk1OwSMg3sI/wBx9zD8K5OSG71Kwt47mSOBZkAawhOI4WHOC3BJ9ea0JZYNM0a4lgt12+Vm8MUROwDIypA5GOac4p2JlTU2jct9c0i6ysV7BIVbDf7JHY+hGK1Iyk8YkjZHB+66sCPwNeZW93pGo3Nu0NwGe9QpAPKKF1AIJ5HJP4+1T6PeQ+GbLT3sFkktnmEEqYKrGpJycH0xkn3qZUe245YVW916neXkaJGGadmdRwHkPHvjv1pYbuSS3JhheR1BAycZwOuTjvis271a0WFbi3iFyX5DHgEfgOvbFcbPeX/i+Ge2vZ9S0zT0kB/0djAz442kj5sH60o077hChKSvL+vkb3xGh/tTSUs7fVmsb5A2+3ibdvLKRtcLyB6H3715b4d0240LU4NIvL2S4e5sDNzJuaCUEbkD/wAIwMAH2xXatpqaHYx/2TZQxKBuVSmPMx6seWBx3zzzWTPoFlFc3OoaGZz4gkiWS6gjkLF4xjaSCMgAgdM8gdK6Kb5Y8t9DupfuoqN9DcluLufVtLvbxBPAIgsisV3IefmxkFlPHT5s+1WDFa2klvp9tFcWkKo0iIV3LtLZIJYnbk5qK08OXGoS41W3ljtgofzJOMsf4R0yc557VHcJdSata3GnahE9nERJKCm8yoOMZ9Ox+lRdMOWLdosg0/SJrLUr++u/sd5d3DAwiJHAhjGcgux46jgE1p6Boenavrs814UvJIlQvGTlY8DKgD65NV9L1KzihvpfENxHcTW/7yL7MrxJKjFtqmM9XAU8KTxitrSr3WGtYrxDZ26jh9P+zEkA9N0obCt0yOfxok5amdRys0ty74wiWx0C1gtzBEjXkMYln58oM/zEZ7kZUf71UdHWb+0RdTWCWskcflbpZcqzHqQOy4JpPFd3D4g8JaZqOmzQSRfbo5AHYFWZWZSufUNnpz8tZJdll0OKW8yomMRkkG37RKM5wPfJqIr3bdSKcXyWl5kt5NqE0OlWub+RYZ2llubB9ibfmASbIw64bOOnA7iuiS7dTZalZ4ks4cW08p4DwnBDr3JUkZz74rl3hGkeHtQXxJqNq2nz74ZvIZnZ2k4CAr91jkge/tUPhia406z/ALCt7G5t9Jt4BAsN4czL/dbOPmBBx9RVSjdaFcilsesdR/Wo2EcgKHDFSM98GvGPGHjHxL4DazuYp7PUfDE4SFTLAxns88AnBG8ex9MZFdR4E8fSeKdReOK0mNhFAZZdTNu0NuSOCgLH6nrxWboyUeZbHO6DWtzpdSmnnvTZwQwtBCyO4YdgMnPbHSsz/hY3htone1mvLpEdo82tlLMC68FQVUgn6HFYtpqDajKLbQ2ni8NW7sWvXO99RfO7ajHkRqTjP8XQcDJ6HT/DsQhE8kMFtcbVWNoVKlVAJA9uvb1NNxjH4jWUIJLmMO2+JbtbSvL4a1kTJOEkhaII0CEZDPuIwPp61FZa3471TWnF3o1ro+hiFysqTLLMxP3Tu6fgB368Vof2BLfu+y8H9meeLl7W4mMhndTkbiDwu4A+4UDpUYT7Bqt5b2k11qN9IRLctcTAQWwOSCoA5Pov8qq8fspXHGME7RWpDbaZc2VlLPb3Tarr8iGMi8JKKGYcrnlcfWmXvh3/AISCaa317TrMPZMJLeePMbFwfXuOh9/wq6wi0OwuZ1mt7dJpDPPKpZ5Dk56k4HJ6D8qbpM4uNHSaxlnul3HZ9pGDk8nB/uj1NF38Rprvcz9HuL+58H3clwkEOqZCxMEwFjL4JUdsqP5VUsNZjBh0WLX7CK5mkS4hikhZNq5+dI2K7SGIHOepI71sNdL5UrGaPzYxuK/eZiP4Qo5JzjpWLDor69bWl5PfR2lqLlJItOjiXzSwJ3xNk4K7hkEAHr2qlbVs0kl1ILuTUtfvrSLT5dKvdPuJWSaODK3BYZLszg4Kjbjjp09666xsJdE8Ww2tpqNx/Zd0skr2kuZgSxAG1mbMQB3cAYOfyzILabTpXvNOEdsYDK8MSoGNy7gkRvjcwQtz8oBBAHTOaEekeINQntrm8vLuGSeHdd3TKLdbVgMqY1Iz948g56DpSeul7IiVm7X0C1hurHxVNbLHfRWtqTcyFZow0z4KgLk/dbcBz6fSp1uJ7i2kAsy8TAjyeHK/NyN69T0GRx+Vdtrmk6PrNnDBrNrHfxkKysULbjjhsr+NYOu6Q+iabqr2cs0WnvCVRIIwfsoCkEqPX3OQKlTUvUmFVS33MPXvAOiaw9xd6m0Ss0SfvJDteE8BcP1yDjk56+lB1WxhvLDwv4nedtQESMLgpsEhRuhf1ODz+HU4qrDCuo6TpEjxX91HboIxbwbnlZcAKxI6NkZJOPb0rT13wXLPYwfZrL7bGY3guLW7WMySo2OBLn5QMbsY5brV3S0mym1HSTNPXVkjmhstOktri5Y70tp+C6E54J4BBHH0p1pLb6dY/aotUSCaWYK9ut59ojEhOAqgkgHpkDFYttoD6bp66c1zJFq9khNhPMmYSSPkckDnbgZX1Gcc1ovDdaVpNj/as/8Aal9eBYHmtIVjjWcsSJVUD5SMjnrxmostkyWum/6naaXdPdQM00flSq21gOh4BBH4Grlch4W0HW9O16a6vdUR9L+yR28Fiq7mQqB87ufvMe5qx4m8SzWFsf7FsDqlwM/KkgUA8cZrLlu7ROd0+aVoHS9CeT0HU1n3unTSXP2mzu3hmxtKsC8ZH+7XCW2v+JXgkGoSQR3krERm3T91AOMKc5LN1yeBVDXfFXjLR0jvLG2t9Us+HeDb++VRndwPp+vSrVKV7Jo0jh5x1TR3+na9FKpjvikFwrbHHO3PPr0xjvWQ2k3ySXlo8FrqGh3AJVYyFlZT/A2TggevpVHwr4t8LeOpVAD2urBQZbK5zFJjoPTcPpzXb2thBaSl7cGPK7SoPBA6f5FTK8HZqzFJqn0s+3Q5SXR/7NtmtLKdYtM8oIli0Cjy1xgAPnOBjile9j07T4tN0tHjiiTYJN2SV4zjvnPAq34tvoo1mG5ALeIs5bJAY/dBx/nmsWytpZLKCe5tpWllhVu2Vz3x+n0pq7V2b00pRTmSrqyGwksVsxJBtJUyHnJOdx9zStFbvZ24guJGmZlDo5wEycZx6j0FWP7Ts0RZIbJ5HiUM/GArdOv+NWQbPVJ4pZkwTFj/AEjIZnI45HHHFFym+XWzRXv5baPTorRSztDKFkXBIyeQR29KpwRRfbLqR5ZX89FjUFcFAF5UfU961PC2l3ccMU+sQxwanGGzHbH9yRuO0gnuR61tG5tFuokjUNPMxGAuCAOpPp/WpcraI5pTSdoq559r+qSr4ksPC2mrGl1Kgurl+6oCNkY+p5NWnvjptrJc3zFbVWVXkMZyxzgAL9c1hT6bM/xi1e4uBEqyxKpBQh3i2Dbsf6g5A9K0NGtpJDqrz30rXnLQnCruwTtAC8YCgD1zW7SSXyNElyp91cum38y4vDezXstvdSDbhSvkoQAAMDjnuc1W/wCEasv+gpqP/fxf8K1JtVlt57G0gt7p7i6Rg824ssZC5y3GOegHrUfkH/p6/Kp5miUm+tjJjmul1BYXtEWxQNumcmSU7Qc5GMZ4x1rR8O3ck6tdWx1BBcHy2hdFZAAMKQT/ABHnn39qh+zT6vbGLUbKOKwtpxcQXcd6YnlC8qGQDJB5yCcEird4Y7myS6tbiCEM4VGRshOfm47Hiqk+hDal7pJb6mdSmksL6yh3WZwk0jgNuHAIAHDDHUGsjXvDuveI4lhsNRSw5PnXDx+YWA6AYI/P6VsW+l2t74jtLqyleeO3jKTsx3J/s47ZOTxXUQTKi+XGzTN5pTHTacZIPsB3qHPkd4kSqey+Bf8AAON07wZqum+HfsMOri91Fy0jX08WAHONuIwegAx196s6b4fuXh8u51GEXcca/aWVDkEjPIzjBrtvzqC7t/tFvJGr+Wz9WA59qn2snuZwxM9mzk7yUaffSvJLcXu20ZyzYAGQcbQeOg4ArE0uGfW9BtH0DxAlraSsbiRoYA01ygHEeG+7jByfU966fUdPuJ9Mms5bIysY5FyJARICDkAnpn9DXI2l+PDnh2ysP7Lu7LUr23JNu+3baKp24eXoFzk57getaR1Wm/yOyMrxtF6/Iqad4v1HT/7RZ9GvF1GORI7i3WXzVRWJKsp7nHX0pNW1uK+1C8htLW50Wewcs16qbopFOCQUxgg+oPWp7TSWaJp4dWtrmSdDJLLaJiTeOwkJ4jHGEHJ5JNaC2V3DFpcf9s/a51MhuhGoYMGUBcgjPDEkHtxWvup3sa3ipXS1+ZlaDZQJqTBpojrIUygyl1hV3xnaCOCRgkjj6V0OmRx2WuRi11CNHnVpLm2CFklUggn5vmBVhxn1IqK206XTdLtLe0e8urW1JD3OoTtNLk5+56HJJJJ4FRRNrlxDdCSOxsZo3aNdTuLfyYivBVdm7Mnc5yADnrmob5upE/e3N/TNPSTSQby2jC22pvceXH04Y7WPvyCao+IbCC4e3mtdj3FvkwSAZKtuJLYzznJrofD9mNC0nT9PS4mv22Em5lPzSMSWLE++fwApNc8L2OtWnkXBuLZWdJH+yybNxU5APHI9qyUrSMFUSld7HDT3Mum6duume1l3kCK3txK0suMh1RASWznpx71seGdM8QNpQXWbxrmfzDIk10oWQKw4TYvTBz1rq7q2nsdMWHREiSUFUBcZ46ZJ9fc1HotreokM17eRT3Q3JP5a/Kw6qP8AeHHNNzutCvbe7dWILqzttP08nUo7WSwjj3XM1zggADOcEYwMDArFsp01eyt4A9xY6TbKVRYgqJcgDAJ6jafTvUHiO5s/E91cWM4c6bZ3MccjBgEkYEE5P90dD71p3/h7w3q39nXF5JviVvNtlhumSHI9ApwQOBzx+dCXKtdxq0V727IdO8NWHh7SHgtJ5La13NNGhmMnzn/abnAwP/rU2XVr7UbSRbG/XY20GYR4XHOdpx8xPrVyZoda1a801lRIbV1iH/TX5FdsdiBlVx7N2FO1sXVlY3z6cAbobRE0wPzDoQv09B/hSTd9dxxe3NuZ8Vzd6bpUrkLDfznKxyjc6EjCqFAOB3rNi0tlt7KWLXf7O8vMlzZtAryzkkklix3BiQcnp9MVqyajLZrHFdzWsbSuv3sIGkP8O7tkgj1rmNSudU1iRox4LtEnimMEU91chPJYciU7V3OpJ6A1cb/1b9TRRa1/r8TYS9gupo0t7f7eCTueQMT94Ae2CCxBI5Ixx1q5rtntuYGvdUeNDbukWmx4RCD96RsH5gAcDPH1qjYQeM7zxOVmsrCz0WEsBcNIWllXkAgA4BOM46DNbg8P21jqF5qM0qSXEsXztM38Cjk4xyB6dBmk2k9xOcU9zk9N8PabFfWepRofOtbcW0UznKlG5yQSOuB81J478jWFWW+t5NHXSLuCaK/BUo8uc7eORnIXJx1p2raV4Z8SWVvPJI8vh3V5PMEkdw0CtNgKFPGcYTj0q3q2r6TYaSLG90qVtEvxIQmwu+2EqjNk5znAZSeSBnirTd09bluXM07Fq98PjxELPxFp1paW2tMfMgnmd1IjZeVJXk/THGc1f8O6jqNpqFxpGvW1xKkjmSC6dhIozyYXI5yvO0n7w+mKpaZMLwWkelzLbSiVg8JZmlSDBw7bvuuRg9MY4GetVJdSvNRi0m60m2aaG/mliufNbLwFDgL8vRyQTzUWb0Zna6tLb8i9pl9Bp2kT3XhlJ5dBtzIklhDETcQMsjBmiU5ypIyF6YBx6Ds7KaKSwjnjuBNCV3eceMjvn0rl9NvdIOqG/a3VNSggMLTo+0GNc/KxzggEN16YqDV7zTbYw39tqljHaajiUgzKI5RwN+3PzZ4/LmokuZkShzPlZb1vxfbaTdt5s1lFaCJ5SQzS3Em3rtiQdAOTk5wOlQXHjq3ttY02x2G5/tC2+1RTIjRpsGcjJz82BnHFYWlWqaLq8uj6fay6rrUCC4n1WaEAxxysN+04+8VOdoPOK0LqXxLHFqcFtbWk6tcolrGk2RcW2QHZiw+ViC2cA9AAO9XyxWhXs4nX2t5Y63pkTwyK0U33QfvBhz09Riq2l2Vob55kmkeeMkujjDBjnk+9c34Z8Ky+FZbu2tLu8uEnnkmgM8gIiQgZUHrwc/Sur1S7khESRt5e9fvkjOcdPrWUrJ2i9CHG2kHozh/Evii81XxRPo+i3ZtrPTiPtsqqD57njyge2D6dee1LZfb5NTuba80/7FZW7hUuDJv8wbdzNgDhQMfjmsI6TNcm/mWKK2uDKZVYSHYccmVyOeBngeldto9jcSXh1NdTlmsJET9yJc2+zAYuoGc5+praXLFaHU7UlZFe4iudJeC5t0SdnUOd2ThT1wB1OMcVFbWFhLrE1419dNfAh9rB0GTkY2MAcfp+VXbe+MlxdKYDH5THHO/APQg/hzisrVtDuNSWf+1tTmj+dPMMdx5YeMMTtVs5APoOTnrUrz0Iu29WR6vpNlr13f2Wu6OrJtKwXq5LbeqtuHKkH8sc1XfxBrXh4Q2l5e2V3pUqEQXQbbcxoq4AIY4lJ4+YEVPbmC1ubaK11K6il08jfG6syPH3V2ON3A6/lUWoWmm2cGnwadpXmafcyu+YCWjgYjdvIOcA56DGMfSqXZ7Dsm7PVGhdxWuq6Msitcy2qYkdpcIJWHTPHHPf/wDXW3oEktwwmuE8phHmSM5Xywc4+owK4W3imOuro7Wc8sLIZY7iByYXwRjeDwpz2P60njXx3L4HjWzF3FrHie7G22hKhY4VJHLEHJJ4x05odNy91EzjpZdTo/EOu2obVY57W5XTNOhiEhjO0yPIeFQeozz35+lbT/ZtNtIXktSIJHWFYmJdkBH8WenPXrWDNcLbeGJJS62VyfLnkmbDbJe+D9QRn/8AXVNdbvM6VNfTxNp32ZnuiqIE83GdzKxySQSR2BHNRy3WhPs21ZbGq2pNY+MdO0zT57N4roNJJEpd5Aqjr12qoz3/APrVcvoINVivLO21CcSxzKlzPAgeRduCFJUAA4Pua4KHxVpN1riJoFhcXeoXcqRyMeCseM7iey+3f8K6rT7TUdEh1KfTpWne5ufP8kxgY3dVA7kDA/CnKHLa+jHOm42fX/gm1rWkHU9Otm0q5CT22PKkPzFgBgoT71xtre3dlrM1rdm4s5Su0RFQInGMnBHWqvjfxhceFEtL6OIRTzbUaItu86ZjyCPQAH3561EPiDqN3pM95qfhh2jiZVVkkCjB7gMMnnqKqFOfLtdCpxlHzX4nQQeJ9PhtZZnvREqBo87emOuM/hzWd/wltt/0GNP/APHv8Kh0PUhrd0wi0Wa3gziVrmEoAp/u8nOa6f8A4R/RP+ef/kMf4UPljo0KbhB6oyEggh0W3t76SOOBtscbag+XuCBnhF5I9h2BzWH4jtNDvLyI6tZX11HAFaFGhFvZOxIUbQDuY5xxmreo3oc/2hf6U41URgRvcRBvIDMMxZ6LgcnFL/ZWoGQSrcg6PM/mvPLMxkic52oi9NucDgj1NaLTVsUbR3f9fmbtpr1xpE32B9Kh+wwKEikswVU5xtATqB2z7UWOo6xqNzPLd2xg0/zdqrbz7ZVGOS35DAB6VQ8P38N3pEdympmW3SeS28x5CzNsbaWZscknPalsTHcreaZFHLa/Z2dpPs7BF3ZHGOck5GT3qHFK+hHJFdNS7MWtLp9Wh13UobWIBDbzOssMhx6EZB57HJq1pnjiwe7+y6nJHAxMYjuQw8ibzBlNrZ7/AM6p67pGnC1t9MvmjuYZGW5MdzKd52HIwR1YHP1HHNRrpug+IIo/D99pMCWtzA0sSJGFjWOFlAVQDkYLggdMGlaLWopKEo3a+Z3N3eQWtndXDuGjtUaSQJyQFGSMevFeR32j/wDCRzfa/tjS3Ml3FfXlhduJI4igPlxYBO0YIbYe/X0rstLLana6ros8bxuYPKF0p653AD6jBOfzrB0s6SNSvdKsJpbPVoQDceUm027k7mLNnL+Yc8gUU1y3tuOlD2fMlv8AobTPDp8VxJ5srwrjfHbRsS5Ptjp78Vn6V5WqXUl6llLZIrGGCSY/vXUAbn2np6A9T7Cta1stRhuNNildZ7Yhpbu8mVYlZR91UVTwTnv2HPNPs7uFrqARuVmYnAb7ucZAJOOcfpSvpoaKS1aKzxW4MsUkouXWPMkSNiSNTypJH8WAeueARVafS78+JZLKOxmudGFj9ogne6wzzE/dAxj657c+1S6vepYyfbdQ1H/WKIxbxW+5pHJwAfUcj/6wp+sRWV1otzc6wZre2itGb7WkrReXHu7Ecgg9PbNPX7/68hqUlZ3/AK/Ag0q51nQ9HmnuLdYo4iTLCHE4jI5b7nzZIx8oGfatS88WpeaeG0F4ZLrCvmcFY9p68nB6A/8A1qwdBWHTr6NNOtWmOqI10GjcbWcDas8jsctI5HXA7nnpS6Xp6w+FrG51q0lGs3MyTzwysXlhlKFOADhjjjjH3iT3oaW7CSjKV5rX+tzrtV1WWTw8s9hbLcPc4hG+TykjLHazM3UKOTwMnjpnNYHja/HhzwFdP4eiiW8crBEWON2XCls56HnH1psmo3EWjpFpgHn/AGuKJZLiMyJcKWw0ZCk7ML/EQQKb490TVbnwM9laWVpc6i8y/Ir48lSdxMbNjJHbgd+O1KCSkr9yIxjGST2uXN9jFo1tYzLukeJ57gpjb5igExnHQkkFQewqf+zJ5/DsY8P3EmjTQsHjWeNWikUDLKy/3GyckYPeuH0WN01OWy1KATf2mBLco6bowUGHQg8MCCcr159BXobaU8Wrx3d3duLCCLyVtYziFVOMZXtjBySehFOS5epU1yu1zHjsbrwvYP8AZpJrtbW3kksrVZSUkO7cI37swLYVvTFbI1RLjU7O2ns7srdWguWRsHyug2leuRk5xnFV5tZ0JZNlvdwkwHzpJHDeWEYkAM3Q5PTr0pJFvbl5I518iFSGstTiKs8KsBkDIwQeOvUdeRUvX4iWr6vcyhoklpEltHdnUdNji8udbtd80h5KtuPQ5I9zjirGpR3GheG7q5kt/td8yiO0tpH5djxlm7dck9gKgubuSyvbmS91q3uLWwia8litLTdIVHBkZmc8j/ZH4Vbg0y31q7WS3RJYETd9rnDM7MwySATjGCOOKbfWRqpaavQveC9e07UvOsbS8huLm2yrGNsgqpwSueoBPXGDVDxfq2kaN4q0/Ub20uZ7q3hMQeI7gvmHAUL3c89cALn2FUPCNlb6X491CLUbYx3zRGHTJDCFBtxgyKhXjaWUN83Oc1bvzqVx4a1G6utIS1EYcnSo0W4aZgBtfcMH8MZwKLJS02/zM3GKnfp/mReIdJt4IltIrrURqNxcG+tIGk8xbYj7wAxjyunyNxnpg03WpFsBYXdvpeoas7lAHe7XZGucs+zOCVx6ce1J4mDfY9J+w2SHVY9otI79nCxrJsV1YrknHoc1FYrdWd9qenXQ0eEQ7WneGMwrIZMFiAWPJGASMU1t/X6FxWiLJtvE9rpd7dQNZXF3K0gg86Q7mZnVYlPGNuOueQelZ+mrqGiRanpllaWelMMy3l/A0kyF2TJkjUnICkgEH8Kj083NxYXGnNa3emw2kjQtDNJhJWOSrJIRwByfbFSnQ/tenWtsjz3mnw2ZtZN7Ex3CsQQzsDngr9ae2jKt3KthbXTfDy3ubb7JcPHNIl+xjcxSR7mEjKh5AP3vxJpJYtCiS0iuprbyriVY7by408yBZCAAqnlUzj5ulOtNR1LUNBbTNKWC4tb2LdEIblozHEw/h+XcB64yeaVHhtfE+nXGq6P5ksUQtoJIUMkds+0AguOQpIPOKrW7LtLUnuLTWH1C5uFlhCW1xFHayrGXkRgNpV9+AxYHqPlAPrWkNEf7TerqV5IhuQyxi1Yi4iJAwIyBwBzye+e1U9YtfGEnh6zaFre21UuDKVlAjK7246d1K9q6LRvDtr4Z0y5u7eOS6vliaQMXLuxxuKKzZ4JrNystzOU+VbiRGLStXuZpku2e4jjWRxIWWJVG1VA/Ukdyak8R2lzc2UkGnQbZLdldVYfLIOfun19jUaNd6z4es7++jGmtcqhubbzg+1c8IHA+Y88e5rm/H/xHPg+fT7GPRrieW5OyIuPLQj268j0JFRGMpStHchJtrl3NKdbNdGvJr8TWaeVibdGQeOw78njA5qrpup6NdaNLpARmtEj8m4traNjJD5mOXx1HJye2Kn0nxDf2+jQ3/idpIZJwd9uihlXjopwct0+X9auDRYrqeW60uOK0v2hyySIVVgw+UnHOM9R2xVbbmj6qQmgwRatYxPpkyiGACNkljIc4AKb1z6EHOf60t4sP9pQabdyoZJE3EZGUXOM4+vT61X0vRdctza3Exkgu1BW4it5V8ifjqOhU55yakvdHlt9Mk/syxP8AaSgzbpHDs/PIXJ6nHU9OOtJ2vuLmV9X+Q43KwyWtrBCl1D5gtZfKbcI36DIx09zgemapNd6uljdLBo0NzqNs/lhJN3kAeo74/WqsWq6LqV9LpGrGfS9YW3EmHUq2BzjdjD4xnHNczq3jbUobqDw74TsLm71O+B8kzv8ALEM4MhHoACecYq402+n9dxqLueh6dJ9o04SokmJYw0zomCjDggDqBjIqhf8AgXw3LfDXNQs1lllClxcqHGxRwgQ+vHvmrVzq9n4W0uCyurzfepEPMk2/NIehbGOmQcVVspYb2K9Z7hi9uYyZLg5D78YAOeByPzqEpLVaIhpvXZHDeJbLxLd+IdO1PT4re28P2LRpBbBSWEY4b90PvDoC3QZ46V09l4J0m+0832uTOYC7XCxSPwhyfvDvjtWtrsE0trEL6dIblxhYVXdlB2/2f1qaC6lmtgbgi2eYBTDIBt2jjGMcirdSTStoXzNxtFkZhsl0+FLSJ4IZFVRIuFOBzweyketRTbrifTL2LWIbaxjVley2qWu2wQuHzxgnsKZc6lb6jY38SwieCJCnmxybFcrxt9AODVOBdMsfDum2eoWjXs+8XEcogZo4pScqA2MYBwOai1hO/Ul8YaO2raJ5Fk0BnMg8szISpA554zkYPNSPfXFklvp0kMZhkUZdBuaaTAPyd8Z6k8jHatm41q322IaaCO+dtqwYJLE8YGBmscXWpHVG/tCPSrWFGJ8lWLS4HAyfc5PHbr6UJu1miFdrlaIdMujYs6TxiE3P3GedQXx6KTk8k1Jx/wA/+o/9/wBP/ia0jFHJcRX11plpK4X5J3UbwfQH056UeXrf97TP+/R/xobREnFPVfiZTSarJJJdR+V5s4JjtZQDsyuSx/vccAd+Pxr6Q9rJaTpPdXDQpFvvUvSAtpx/EwABOecc59qsR211p9zDbanfGUoRho1+eQE4AB7emTz6U3XbS1vr+OxtkhMOnSrP5OD8kmMqxXqWPON3fH1rRNbE9bf1/X9eRT0d/D1ppDaLod7INPXKboLN5YkdufvnIyTzjmpTp6x2Tz3V/c601lE/nQxRCOaVWH8cfB6dCMUyeT+yoLkrcNbmebzobeYoG+f7+ByDnB461z0Sam2u2CnXI5bl2bcpi2hCvzMM/eGAVx+tWo31v/X3Gii90zT0rxZ4c1HXbewuIZ4pIVCwrJbsHXK5JyRnGD7965PUvGGsxeI5rXwxO6WnmnTkkuLJQbeUngCQ5JVgAcn/AANdvP8AEnTdL1Y2OtXbPbyyxxwXyRKUhLfwyE9BkZDY6Va8b67c6Zc2enW9tLqV3cu3lReYsSvtGSGfGAducdj3x1px92Xw79xx+KzX9fcct4W8V6jcava6ZbX0EdnHcPDJOkYMt9KACYhv+5356YP4V0XizSfD+tq91q9lPa3axKft6RjfasDhfmQ/NtY8Y4+tWJbCHUdQjuICs9ksJBtUtgVMrHDOX+ny8f8A16uWt7p97MYLHY5tP3ZihA2xYHIyeDg4HFTKWvNFWG2ubmWhy/gyx1HT9X1zRbm4uZ4bS3ju7eWdhMblG6yK/plWG3j6CtWw1W31C5upNIL37W0qQS+XCUeIM2CXDgYC4zuGRgVr6HpMdhHZx6VdG1s7AzCSzYsyOWO4SA9QQzNx0IYjsKytg1WKa1laWS3nHlyRxr8rIeoCgjjqMd81LlzNsuLc73L1/cxae73Goh2jTlTAPNIY9wcdTj1702N57+3hEljss7iJv9HvHDmZDxlwDwDnO386rwfbbJtNN/LHb3FtPLBbC3kZIVjcABpYz99goIHYHt0p+q6ZfMdSl/taGKxR1uZLh4uJFKYdTz8q5wQRjv1osib66jLtbOX7RqVmJQZSqRlFAeURYwvtgE4x7YpLm2kvY9Q1CwmW1vLx4lD3HKRKxUMoB4Vymex55PXmzqajT47KLSJLaxtLh/J+2XrEh2IzGEJB5bpz6cc806y0fUjqcmp3NzPpZyIDDJMHjKo/yyBOVUtjjHY80XsrhzKxS0y/leJpvCxkjCTrZiOZFCb1dRLkEZXhSB1zkEYrS8Sagj6lo02g5k1JSsiwlQPNty+1txboMZIPUYzzjFLqtrJcx3cdpBcbIUEkV7abGXzCTlQgyWHTI688djVTwnpmnCx0qe0knvJrGH7JCz7mUK+45bP3lB4XPTj60m18X9fMl2+I0tZ0mGbVHaTcZo54vLiY5RYWb52Re5JZg3sKykvb7UrLUbi80txaTSmOzhtkZLgICoZGB4IJG7J9+tdFqdrPe6cuyR8yRlfNt2y6MAcEA8d+n1+tYsHiMWtndW5eW8ksTHBJdQzbpEjP8UmRjIyQSPUcdaUbtaBG7WmpFsazS7vdZ8qLT0j/AOPNLYPLHGCR8/UEjI6+5HYDB8dWd/4qe3svB2qadPFpt0RcTXMZYWblRtKnoxwegyK7i1axjijvbBUvCibTOzqrvGvCqdo+ZQc/eHXkZryPxZ4b8QJe6T4e0e+umiuzI6XzlmkSJySVcg8lCCAw5IZQcdK0payvezLhrudHD8NdRt9JmutX8RX3iWfaojsZpjBaySZ6yEHLJkk7fr1rroprq7tW07RZIRq9jCLKSSKEx29tKFBZljJ+6SQAB2pn2W50a3tbSRppD5eFIdcs2OWI6D6+9T61piLZstoqrDdbBcTPK8ThQoC7yCCB9emKzcnL4nceml3co/DpNS02N08S6pLqF5dTM4fzDIiE4AVf7q+3vWhaXky3+tyaeJNV1WCQp5X+pEYY8JuYYbaAOe+avaebexEubiBzDEpSbduVkA6tjuBz6ms0Wd3qcd0FkmFxeWrxJIzFIYyT12rwXPXI6heaTd22yJe82xkdt/ZXhKyl8S3t7fS20u92mB8zfz8jeWTuxk46gYB7DGFH4evZreX7Xq4j84BpdUMI8426kbVbdlfMC4XfjJ69a07jToNHlslnshfXSFZpmiYR3EzKm0SHkKzccjjI9cCoJLS11nxVIn9m3Jskt0mSa4H+jq3TawP8fJwBkcE+mbTtrcqOmpHrOpa5pFxZ6Xolhp9zrVxC80TsWkjWMNgEkkfMcjJ74PtTbDU7e01Sxjlngl8TXkDYWIyLE5wSwZAduBg46Vf1iWwl0+z09L0R6ZcQBYrbbtZlQjGwg5x71qxWttp+n2sNtprOyRBPNlVymABgZ5OD6mldJWa/r+ug7rl95bmLAk1l4ktZ7PQ7I3f9mOI7o3HztMTu+zxqTjbxnJ6c/jnaZbr4l8VXg1C5je1063W3uoLI7I7e43h2GVOSwIAJ6dc9xW14l07U0899Fns/7UW2H2aN4si0YsN0pJOCAN2FbqfpV/RbrS9EKWVpY3OCpllvI4gI5HY5Z25ySxGc4+lLm0utxczteKuW9Ne9i0qE6p5VxcSXJCyjjcpJ2HHPIHXFdDEqogA7DknvUapBcxwyJsdFPmRsp6H1FSyMoUmRgE6Ek4rB6s5pO5x/i3VrV7iCy88o5k2W7L3nA3Lt4wSOOD15rD1O/wBSGlRXkr299LOmxVlg+ZzuwNqj6np781zP2C5vfjdq09w91bS6YUkt41X91LEyY3E/nXf3s9hLbwXfl+ewZijBio29yPQcfrXQ0oWS1OuMUkkjCuBPeaM/2yCKW6sJwPLSbYIWYfdx0yARkZOM1ra1e6lb67pUkM0Cl2PmqvdcA4HqKnvdPtY/B9zc2NhE7IGmWGPJDsSMn1zjH5Vk6q17f6LBrWlxwm8Vo8b32qhJAYZwR0JHp9KSdwjJSZ2uga1a6zHcG3YefbSeTOuD8jjtzWoVXHTGBj6Vz3gnwzY+EtGWztgTcXEhmuZpHLPNMR8xJ79MccACuiPrg1jK19DjnbmfLsVpLC3n8v7RBHM0eQrSKCQDVS30zTdLdp7W0hiuJFEbSrGN7AZOM9SK0hIhKDcuXGVBPJx14/GuU8Z3yyWbR29+lpJDIuG3c5OQOBz2OPpRFX0HFOTsVr7WIdW1m40u70uOJIAMTXcYffz/AAjPAz7nPpWJ4pSeWxijsdHg1hvOVgo+7lPmUntgEDHofXpWp4itNPvdNgg1KzN9bQslw7LLl1YcoyIMFsngGsyx8X21nYJcxWcNrFERBHayXXlsQXy7LwdzDPQdSetbRXWKOqKsvdRo6BHofiVxJckTarYyGOeGaY4jnxkqUyNwHbtXGfFXTvEpvTcQg6nBJH5YgibZJAGA/eIPZsAg9Qfy9CuZNH1FluE0u2meYCQzSKFdscAkgZPHrUy3kLRFZEXyAP3yRR8OB6n8aUajhLmQkpJ81jxz4dz67p+hQRa0l3eCaZhLHMVxbRpkLhf4iSD+les+H73VdQsJ/s1q1rDvxHLLtG8Y7L2rl9c8RWvhzWU1KPUruaGSLyE0WGBFV5MkmXe33cAjJ9u9WfBvi248XtqMl7cQW1rbTFEht3P3QM795GWP04q6ilNc9jSd5Lb7zptI8LDTrd0F06SFSDJGo8zBySN3Xr6Vzs3w7gttTfV9Q8S3cchCqJWxHhQOQc8YNZdjqU32dZtO1B5FjmkZrrUItjgfwgjAyAec98V594i+G2u+KpY9Vi1O51eZ3El5FMf3bnPWMfdC4HAHaiEWm7ysZ8lRO/N+B7Faa94bv4BbWfic3bRSGPEI3gMO3C/1qfyIf+fu4/8AAZa5vQtE0rQLaL7PZx6YdgR5HJycep56V0Pkwf8AQRH/AH9FQ7L4S+VR2kbg05Hvvt5IlmIAUOBtQcdPpWBqemaZ/b7zWupJp2oTuZLiJtoNyAMKcH5sDPUUzwTeanB8KrC71O43am9mXV5fnALD93u6buNufxrI0eG4nk+0Xf2S61Ro1jub+WNU3DnjpwvXCjtQk03rtocVCE5XlfRaCX6pD4ij0zUY3e4kUtDdq3yBhn5Nw5VjjgHHFQWOpjXLuGa10uWO5aaVZ5fKKvA0UYyjq4BUsNuScZBGM1Zi06ytJ57mKxsPtU5AmdY9rS7eB84PJ689a6Sw8PaPqtpdyLJqJW6JWdWvJA2cY656gAYI7AVo5pas6KsuVJyPOvFPg+18X+IbKw0+2mintnjku7iOMeWkLg5Vi3DNwcY5HWt7xBdW2kaVqM6zGSSwXzYxcEsVCjAXpnBA5rtriex8K6Pa2lsFRceXD50mNzDA+ZzySc/U1zcuvXxubU39jbfZr/MUb3FvtZXAJCkHqhAPOfahTlK3ZCpzcvetoXND+IPhbVNPjkN3DahY/miljKCIYwecYCnPGeDWVaaZp2o3s+l6Tu8q2jgkmuGRogq/eQ7gBuPA49OpPStTwBq+la1pTvc2tgmr2z/ZL2OGHjev9wEZKEYI/wDrV11vO9xLco8GETG3cuN3t/n1qJPkbSVvmYOXsm1FNepiajvtNHA0+5UGTc8kso3Fz649+gFcXZJF/beNKZzf6XdRm4E7OBAkqAMoXHzHAyM8A88V2XiLeWsrzy1EKMAV3BiG/u4HHauJurjTbmz1E3N+2jCe5jjN9bKY5bqRQR5YZv8AWLg/eXPORziqprQ6aXwepvQweUbQ2q+fMGLQ+Zl9wLbiSSeg65NZ+qX+/V7zQ9cW/h0jzEjWbyQVuZXQv8h5LFcL7dc9Kk1BrO1Vbq/llI09A20A5wQoyUH8eR0//VXQKINRlhuL23V3aEmEyR71APO3af4sH07UXtqwldDdYj0zV7JbXUZoZIrZvtCq0RXY6fdZT6DP3hx71S02w1PVr2JDe29tYxqsiqkrSyXC4wGYcDHHqa0Fi0+G11jz7WePfA1v9q2AvJGSx2JjjAySAPWq7EWXhnSk0xGsoEhSGGW4cGRFYYRWPY5+vPHNSnZWRCuvdRZbSbbS/EAu4ru5hm8lU2Fz5DKMk5QcBjk5I9qlsbqSx1G+lkazS1n2+XChKsrcD5ieATuGOBVa9m1Syii+wWf9sXT7SVZwAHAwGdv4R37+wrP12Oez1KGTUtb3adbky3ccrBiuQDtUKMnHbPIBzmhLm3Y7c2j1HQQhta1a9sYr601GGMW728/+pUqwYOrqcHK9CefUdatQm3jvbqG00eMRXIRjPM6YuyR9c5H9K1PtEWoaYkNjPJc6dqVmxS6gI3AsMbge3H5YrkvDfhx/D1nDY6c9xfspjhZbqXzEB+Ys4B+6cE5x7U009yo+8ncsRyxWGr2NhLpk48thJZXKLmOWco28tjhUjXglhjnjJqa2uNZs7ae/lgi1q9tcW9nbWxEe4E7mdx2YjoPReeTWpPq+mafpMWo6tfu9pJMbeJYwZUlbJA2BRzyDzj19jWXoGouLK7utL895LmZo40mj2mLaSC5yck849OOM80atXsPdPQ1PEFvYS3c89rKs1/cR5AMpZlAXA2EnCDI5x3PNY+nTarLbGz13w59uklX7tvcK8bADJMhbBAJIx1JxxV/TLC1g1ifUdVs4keG1WG2uEBdiuCZOOejdDioITFHFIl7qUtsTKskNxKCC6kZUgj1wc+g/GhbWWo1ouUbYf2fqZjsINNZDZOxSCEPbhTuBYc4+hIznkU2HTZbTWJ7WGS+klCNeJGzN5G8tzgjqR046ZGBWtcXsg0u4vpbgTxQkKssSBjIpwcDvnpxWFdWo1Pwd5bX0ti147+VcSyvDsZ87OewJABHWhP7ho2r62v57S61Ce7W3eS32RW+4MFIySylh3Hb2rNgfUbnwsdPsrppdQMSKZyf3jEABixXgHB/OjWpb63trC0gvYbiSwTz5BDHIV2Km1kLjPJJOO/t3rQspz/ZdtcRRG0kkXckqwjfCHGTuB4zz0PelsriS0KerRXltLo4s1s3nhY21zLNEA8EYXcrxAkYGRt49fbFM1Se4n1DTbqbXNUtz5vlRW9vEFhYnndLwARhcDJxyfWsvxCkUWo29j/aV0NWuol+w3dyCyFVcB92OA5BOGYbc1twSXepeGkjjhFxJBtWOW5fymlAOGznOeO56nmnskx2Vkc74v046p4GubrRtXWxikuPtVxqQDGO9MbbSJWA3KmRgYG3jjIqvJHHqqLcWVxp6are7ZpJoroTPbQogVWjxwyluv1556ehC5tpvslrb3kFuEJT7PbpuOQMlCmCNu3PPuMVzFjpFjozTzXhsLC4LF47fIfALN8hKgMysMErgYPY4yXGelgjPozf8L3uNKghkuhLJ1keD5wWA5+Yd8/lVXWGv7+9nWycRabHHsDh8yyyHuDzgD0xnOSe1c3o13pfhGW106e8l07Tr9572B7j5GcAbiNpAKKCTwQW4Ga6jUI9Vh0yJvC9naSzXCbleVsJgjJbOep4GahrllfuJ2UuZDNBJXTLi2v7iKbU33Rozvl9h6Ak9cZNM1zTrnSbH7SFe7tbS3wtvEmWkccAcDODVTSdJtri00261W2ls9agjZpbOGXfGkgYgSN3bpwQa17u/m1TTJ1sVguJ/tCph9yiNONx9zjOPc/hSbs9Ba3utjI0KOy0nVl1DU9XW3XUYBDb2nmMExySxB+6edvbp1rWMFrpcA0uyEFvG8biOEOAxI5JCnnHGc1pC0sr+Bft9gUaABIzNGC6dPuH8qyJLLSbLVDeeI7izlurhjHZmfarom3BjQDlh6/WlzczJ5ru5qS6/FBaCW6t7lXCHJSIvk4zxjrn6Vmazqtxe6dGbW21GSK9iCxragxPGH4DuTgqR6cYqe6htdd0pGs7zOJS1tJGchGHTI6n3pk+sWtnLBa6nqSG/ucKGVCoZRkDA9cnP/wCqkl2WolFX0RsaOGijW1kYS3UEKI8pGfmxyM9cZ5/GuDi8CS6FJ4h1KGN9avtSmE/l3UgCcE7UGORtycH/AOvXWeEoNQj0lU1hBF5YZDITsaYZ4kIB+Ukdeas6rrgtrcPpsD6g/GFgwwwT97d06Z/KhOUXZCTkpNRMyS3laSG+urQQyRQrHMRwsgH8OTzjJ9K5i00Owubixtm09ZUXc0csyFtpJyev9elS3sOueK7C4LSwhY0aNkimZFJDZXHoWBwfTGO9aVqZ9MsLQ6/hZ3faVib5LeIDlpH6ccD16e5q/hWj1N4y5VbqOigukvPKFuGhbd5bRnbsRRjn644xxgVdGsafY6cbjUZlNuMbCzYRj2VRjk/Wmpfzz6NLPDbCaBX22nksHa4Q5P4YBzmi30xJb67uUsZIpY4REjmckTfKMoI+igdN3WodvtETkre8edaXYXmrXev3mq2QOl3DrNYxXQAMKH5SCoPA47+x7113hfTtGh8vTmsyjXocwmGIrEQowxLKMBuO/pUet6rdXUVrp/2eHTrm5udssjDrEv3m6cDHA/OuivIIrbwlFOLp40s83CvA+FfGcc+hzWk5N7lzm+RLa5w9z4Wik1yDRPtYmsoUBktETcpbdkMx7t7V2Usg0iG4iijmP2eHK2sAUNLwAAoyBnn1xS+D7OCCxudRtB5tzdKG3uPnZiO/PrTNqudRtAq6pd3GBcRliFBA4Gei/geMVMpczs+hnKbl7r6Gdq1tJf6alq1pbxSyhXRZ2P8AowOCTKF6nI4UHB71zf2Of/nvefnD/hXUajHdW+jyw6s1oLxlZ44YJGJPTaG4/Xp6Vj7tQ/6BQ/75b/CrhKyNId0aMs+bBbOWRnskQKqR2+w8fdUHPAqbTbS2exxPPGsRIQpI3lMpOehGc55qprKXNlbJPZwvewvJ5TyQKXMR/vFQMlfUjpmrenpgxtPGkhbaSrA7N/VT+B9aXQxduW0GZs1qEVEiSb5SUZpBgtg4J/H6U6W4vNLumjSR4vKPGfQ9Tj396rWlrqEFzd3epySNfyy7mtw29YuSAFYdiMcHvU9hq0Wq3jpbxx3s9qwhdcEEH+6TjDEAH6VTXzOiOqTlqjO8Rvql7q9lGLVNTH2MXKQ3Y/dhxOAOexwT+Qrq7mBzeiTUZlV408kx7vlZ/v5X0wCRWL4iu93hg3dtcp5NsWinnJI8uN2wHHfCtgEelWrrQ31LW7DWgAI7eDyYjGeGLLtckH7uMDb+tD1Wuhg330IlkfTZr6SXyXECm42pH5RXHTLHk9uelOsX8W6VIk/mR30dwzTNaXd2skuMEqsbKoA3ZAHUAgc8mk1DQ7qbXNOng1CUQtaSWFzHz+8IO5FYHPAORn/bIz6U9PFnpNmbzXILewvGmFtawgkbVXO7ABOARng8D9KejXcTtNHU6qmnjSYkiUMdQkMiq3ylm2k4z0BAGPfHeuTvYLO7WGe4tLR7qOFbayaZQy2wHO5edqlSMnjJ2gZrq9MvZrnw/qUN232a4ikkVHuIDt2liEYrxnn+VY934KnuUu7ySeLUZbqWKZ7Yp5cIeMBQVGfXJOevvUwajoxU5JJqTLENtaTWN3byyxyyDyWluHlDi4KEHzsfwEkZ9D1qa007Q77xBY6xfW08F/CGFqZLh9qkjB4B25I6Hvms7UrXT7karpOoBLi0b5ZlIaMXLYHyMVOcADj0xU+l6lYw3FrazwzXsxaSOR5CsccLptIhROASqkYwOgJyaNbaFuLS9S3qOp3ketjSYNP+0aLLbt+9I4hYZwT3I3DH/wCqnCKwu9Nitt0NxYSQY8sgiMkZ49Rg8/WqMmtaddDUJ7pZtPWK7+zSyYLsw3kIQSOh5OB0yfar+maDptje319pd1NqEqkZsZJhsikHdRgbfp0/Gk1Za6CuorU0vtUdlpgto2WK6IRSX4Jz6fhxmsOXSbfVlv7gQC8vLtfJuLaXAQJnBOD94EYFXZIILi8vbnWtTEhljVBbW8fywFSTw3O5vXt7Uy0l1FbfT7+00/y7m6ci8tpp0Esac4PHBHQnkHkd8iltsOPuq63KVtNDpsMDGH7PJpauLOwhHlJMdrLtJ5wuW6HpjPNamnXtssHlalIlqJI0aRkZwxkbJdQSMhBwOeTUr3EdvGtrd2dtBazsF3PkEsfu8dSenvUE0UasEjmkmbazibcFaVsjKLxgDqeeSaV7ltRluhmuz3C+ZBPLD9gV1a0S3Yl2UKuC3/AifbipoLOHUrOKbRtThaW1BScLh1Ljkgn+HBzWR4m0ldPtlutPjnuvMUCO3bEe4nuzngD26n9a534fX8VvFe2tqRb3DXDGaLadzZHVuMHjj049quMbxuiuRcicGdzpcbXGom4uNXldNmUUQqgyOrA46/4VXuZbe+jn09zBMLjczQbsSeVjB5H3VGQecfjV22tIb2QXguHFpHMD5KqGGAOdw7DPPFZPiTTtCu7m/wBPtZ7jTtQuk8qS4gjba6sPulsEAZIOeBUqzZndX/rQsWNlFomjJafbJI7SBgytKwAQnGMyEknB4AHWtwafp6OJLm+82OQbNsko2s57j3+lczL4WVSX1fUYmEMaQ2shjAjB24wQe+RnI9a330Syk0yyOqBY54ArtPb5UFh3z70pW7ilLszPnim0+5VBbXM6hcMsODtYZZXJ98bcdMkVX17U7+aS0S2Sayicq2fLaVtvBKuNvyEH+H2FWdflN1aS32mzC/Yrm3jiwpypAOWz83P5ciq2hI8sNxZtdRXaW4WG6kJ6SjnaT6rgjNNLS7KTTtJ7mnFFYSWT3EANyW+QRzA7g7DJBA6ZBB6dKqWFmYLeSGKNZRIMKzPuZNvZQxJJ69PQVTuA4ur20thLLqUcQlt4LcBN4Zsf6xvlIUZwpPT9K2v6Tb3Wl6bqOuW0NpNpc/zrcOVjX5Mggr985wAV7596EvPcE7bsjsb+90a5ibVAJSfNBuoQd0qZ+RDtGA2Bn2AqfxBdWyW0TzJezoXL2M0MAkmtJWVvnC4IOFJwSDz71owNdjSrX7fDJC0YTf8AaEV3JGchiPlzz+Pamf22mhS3s+qQ6gtq0nlQi4g3FmbkhHUk7eOhAAxRe7vYH6HC/EnRI7j4cadqF2t54ka3vwxluTiWGKUhXxtAHHHUcde1eowwqnhzSrC1nMYMUccch+YhQv8APAxWQl7qGnXt3NYpaf2eQhFqcIwfB3hORntjOO/tV7S5JtQs450ha3E8gAilAAiYR842nkbs0pybSQmnbyKCx65b66lqZIDYxxmVbgKFErdkK9vTPTnNNmuNSW1SOwGn2mqyE/uZZvMjZA+QVGeTjBwDxz6VJbw6rZ6lILq0cI77IZFnBQ8dWHYegqnqdjpWp2zal5Jv2MJCRRFgJY3fGQOoGd3bkDijrqPQ2Re/Z7SLz2W6kfO+QTDagOcDOfmHbj1rmvGeqabbx2J0rw23iG5hYmGOFCTEG4cA9jgnrWd8SJbh/B9okH2G1nYqtvasCwJj5ADIflPT73A712/hnT4odCY3Wlppd9fxl7ryzu+cjBJI/rTsopSYO0VzGVoqy2dtFdtbT6RE64Wyfa7KepYMCeegweOa6e1gsLp0vZYopLiMDa8gDGMdsH6+lZU1nb6VY6RZW0g+z6ci2oY8EEKAM+2MdKgtrC4uo5jZLFxNh85AGOy+wzWcnfUHFTjzN2NfxPMsuiTRwFJDOfKGcEdOQfT0/Gsrw5dn/hGoUWzeK4f5ZUOU2DoMZ6cYwPep/FMN4S/9lIlxdoodo2xlgT/MYH4Vchlu08Pm61dkEsSMzrEm4EjgHjqfpxR9kzVlE56a/tE1aXQtCjEDKu+a6KMwjJ7JnhmHHrVjVY9P0/Rjb6xNNJb7VieNl3k7uT9SR19KvaXqkdzP55tZDarGRHcSfflf+6i+nWsLQ7u98Q6jrDzWCQX1vHsRJiHRXJPDD6YBxVW/AtX+43tPbT4JbWy0uaIi1C/uoeVjQjAz2/P0ql4m1rULVY59L09b8rOFmMD7mjj7kDvggA+map6bANO0rVdQGnSreXaqZ7eMkmUoCuV5wMjrjr2q54W0O5W4/tG5unXTpUSSHT2THlMBnczdz7GlaKdyWkvekZ3i23sba40u88QR3C2s0jQyyxMV8ln+5kjkKcAZ7c5q7byabZw2WjfbW8u53LFbt87EZJAbH0/GurvrO11bT57W8jjubK5j2Oh5DqfeubbQr7R7NF0W0sb42wC2qXHyPGmMbDJ3Hf1+tJSTXKxRqKSs9xrxXNvqs95ZSPNcXCrHaWjKqxwqOMnHYck/lSWOqyX1mzeGJIr66dzHPctEYkjKkg/KR65wP51f0Wz1WaN7jVhDY3Emd6Qv5hVc5wGIwPyql/acvly2mjWE8Vm0nkpfFR++kIO4qM5wMY3EYPajcej0Wof2RZWV1FearcG81Bfn+Y4IyemwcHrjc3T2rS/t6b/nyH/f0/4VzmmWcugXR0/SpJLyKf8Afz3V3J5jSStkfe6jaAOvrV/5P+f2L/vy3+FD+8Gov49fv/JGdDeaR9tktLFroTou597MVx/vDIx0z1PtR4T1K28Q3N/ZXSPa6vp7GOW2aQSIoJO0jGN2Rgn6iqj2+naXqE9xayxodQf5IWl2jfzxtJ5JODuAzXNeE72XTNSl12Z7Wez33CwxW6KXKHH3JM/PlgDzz/Tp5FJNolwcovl3Ou1SCbT9QKSI8NrIVkDL8wyOwPsRx35rnPEV+dJ0+11Kyikaa0uy1pZW8Jdrtn3blKryeTuz/wDWrpU8QNq+mL/bKQ6Vbzt8scpzIBngsccEnsBWbPM8d1La29vfWqEbY75SoCkjKspxyT6expRTT1RrGXu2nua/gDStRvfBjx+KrKK0u7+KSO4tlTChWyPuknBI6jNc74VnTVNAHh3U5bmw1K2Mlq16mCizQkKwbnGTlWAP3g+R7ejeF5J5tAsnvJ1ubjy8POgwshHG4D0NcncOul+K9YmtDBM2sW8c4spxtcTRfIWA7hkK8+qipjK7ZzQlKUpLqaV3p863Vpe2er2/mJKiSZXeJMKQQvP3j1xXJeLg/iy21CKC1+x/Z7xjE0kgRrpEUAlWIwpYjHPH610M91NY2txeywWw1BITJHAcKDMR98++O3b1rn9StYfG2gWs2o2U7AXWyeGRimFx8z8HkEDg++KqGj5janGzTZ0mizzX2kpPayC7tZIvIWZpRICvJYtjq27Iz0G0V0Og3F/Ks32tMxgDypMAA44IwOvTOe9eWN4A1X+21uND8S3NjbpaeWkRCNGqKSVj8vAVsZ4fr2PrT7P4l6r4dvG03xxZrazKu61uYsJFfqpGdoP3Gxg7M/8A106fN8Gopw5laNjs9TaOGU22nR3MlxpxAfz0ZY3MmWH7zHIz97HTP4VjWunThLa71sQCaIrPBuk3uHXrl8DIGTyR7Yrt/wC3oLjQ01HTle8jdFdViXe21uh2g8j1x2rz/U4g85ndY5rGC3JZY4i5fDZVE5yTyRg8c5qY3emxdBtq0uhvW0Rns5mdGuJjJuk8xAApydoVewGKitktUE7F4ftGOOQyk5GQ/p9Khiklgt4L2zaa3imPlyLO+0rjJy5AOOMcDOcg96kke61LTpBpGkwxSyssksYXyy7dMs57AD6nFFmarfyLENvPbvi4RHKklfmyjA9uOcGm3aO9lKt3C4WWFoy8EWXjXHXDHkc4yfTvU1ib6IRxSrbRSw/K5gfeisOerYJJ/wD1U3TrSOMRRyTmdyTI5lY9SemBnkg5x0GaQm+rK9hJBFHG9srXMMCCBRcRMjpgAhsnr6ZGfStJ3+12TtNuths2RJnPXO7fkd+MVDeR6ZpmlfaJ822n2jYaKMmVwCwBIU5IwTz6AGtT7TYrcXEFjMs8ixo8jt84jDn5Pnx3645OOeOMp66ojnS2WpiWNo+lJgyy3dlCrqYJBhUL+39DxyfrVmwTUrrZfJFpsNlEjxsBCTIcAFCGz0HOQetGuawum2ss12J2b/VmG1hzklsAMM9B6+lTxyXEskVpbI5SQ7mVmC7QQDk9sAY4ptvdjaurmLcWU8mqWupzDLQgI1ospWNkPO/I6tntU82u/wBjWkH2YR3BMSz2nmTbZTG7ZZWBGNqgjJyDx2qaWxLtJJczXIRSgWNSqGMJyc8cLjOf8eaurdpdwQ3FlGtxDMDs8sBgY2HZiCTzwfqKd9r6jb5tzJ1tmuI0uYjcG7mlUw28MHEyjDOpHbuM56kZ4rM0m6k119RsZzeWNjbM5eKF/LLOzEbRJ0IC85/+vXWzW80tq1o5uE81sgRhonH+6y9Bx06YFUoo3aW9LnfunYssacEd2JGQcgdOlCkrBe+hVuNG0+8t9FWyuriGytUcJKs3zOpbkhieWJzyfwzxU2rpqV3aGKe2cWazooWJgskpB5Z35H3Rk8dsU3xbd26w3RawecWhieELubfK5KjdjsBzgccitjWft66ckNpf/wBnT/K28RiUoD1GG4PoKV3pcjsZVnrwm1G707T7vatuhthLCu/EuMDAbg9RxnnFFhJc6bH9iv4tQ1W9WFrj7VcqGRpU7bV+4TngDsD04y67S1sYJ5LfSUvrhJEla2giDM8oGFJXOAcEnoMdazrG+nh177Rd2EmmXd8pXbNqQLICQeIQCSTgdPT607XWg2r9DVtZNWa8OqapcRHQbywC3VqYsG3kGdzBhyQQcYPT8Ocvwe01vq1zPFdWqeGCAbOJrssUbfkt8wyAR0AOMVNa6fIt9eXJlltRFc7rZ1vnEc7Nz86dl3EALVzTLXU7i8aOSC1t3TcLjaobznIBB64VQDj3IPpSbVmKyVxL220mApNplwAt0jFohIPnO4tvx94kHPPpWzpC/adOWzUMsaRrLHOBld+9jj8MKcdwazNUt4dKng1G6jRbpI2M1zHHyyjnbtHU89qytM1DxFqdlMNNMVjc3kpZWnTbJbpkHc0JJ6qeDn0yBU25lcbV4aM6XWtUs9Pjh/4SH7Pa73VVnkmCQ7upO5sY+h6+9eV3N7f6q9zZ+ALrz7KSZTf6pcswZjvAAgYjbxlsdevHavVPiBpsep+CtUsprcXavF/qm4LkEHr2PHWuK8OQ2fiDw7bQWyi0jgylvucny9h2hm9enf8ACrptKPN/wwUbcvMdxbafHpsbQrMHJULI7IMtnoCegyf51zxTVfDs8l68kr2d0USdriQu8RJIBXtgDHWq00M19b6faeJYxfSpJl7mCRoVI3qF3gEZGDu5/un8d6BbmbU7qK8spv7OWPalzLcI0Eqt0CqPm6468VHwg7rctQW0er6R9njnwIj+7mX5sjoD1+tOt9Fa21NWVmNqpEn3uhA6Y+vNQWn2bwqRbCG6nFw5bMEO4KMk5IHQAcZ9q27W/tr62FzY3EM8Gcb4m3D3HFQ9NVsZuclfl2ZzuowX1xA7WaK1zdqJY5wvCHABUk8DA6ZqyVubnVo7UTg+VCDI+QWII/iHY59q5rw94gv7fxNq1qu++0pruRTuTYbFhzsz0ZSOR7mui0shPEF262c2Z1H+kMP3TdMKD34+vSqknHcqSlEbc61bLeJZSxXD3SKAVhAUR5/HngdRxUKXkq6+lvpcTLatGZLi4l+6nHCqBwTnrnNLpGpXt1e3B1KyS0tFcxq+48kHAGfT3NLda5oNgTBqTC2hgG8GRtsa9/X1NJLokGq0sTxtcSW5jERjuZQYlRhxtH8X0rdkhjuLeW2lQmNk8ts8bgRjANVNIl/tD/iYqAIJUAt/ePru/Hr9MVNrNxNbabO1knmXrIVt067nxxn27n2qN2ZTu3ymLPe2XhzTxFaLFHbWykrb7meRkU4YgDJAB7/WrK+JbTyEmkSRInClZNy7fm6c54z2qpZ2aG3gDOn2qO1Ed24HBGCWyOmCSf19KwzaaFdPFZPbeRJLbeUgEpjLwk5AZTwwz0J5/WrSi9zTli/i1NbUPFmlzS3WlX8lzpd0ylVa6j2KxxxsblT9M5NZmla5q1/ZWN9bzWU8Fi5W4SGP5rlduBsDEbGHcU3xD4dTU5LF1gge18o29yjnecDgMRk5I/vA5Fa+gaANDT7MxF3G2dk0mC4b/aOOSR/F14qm4KOm47QjExnsdFg199ds49RbVtQj+e0YligYAElCcDHsetdP/ZVt/wBApv8Avpf8avwW62wkuZWQLtyyhANoHPBHaofO1T/njF+ZqHK5m5t6R6eZxIbSNRvPtk+myJfBRzcw8Io6AZHHJJxwa4fWvB2iXEk0lnaS2Zlv0MEOPKjLKAMwjrg5yfU57V3q+D7PUmaS71nUL8TWos5gr7Y8HG5to+6Wx17AmtXX9AsbuXQLUW2IbCYeSAxVUAQgAEc9BXSqig9GKNZRdl/WhyGpaxYSa1f2mo2ztaaZZFp5WjO8yA8hR/EcHPHv71ieOLgQaDplt4cv7u5W91OGzELsSDuceYCO3pk9iRXY3S6VBLc6lDG5mtZBel1zuJBZAMHrkg4HfNZuq6u1sGu7SxgljQR6hGix/OkikeYpHXLJuK+4qovayNE77HoN3pKC6tbq1nuIlsYnSK1jfbC/HG5cdsdq8d+KF/NY2+n3MEcaeIL/AE2OFrlZTG9muM7lJ6gnI45B+or2Hw5rkOv2IvLWGaO3cCSF5METRtyrqQTwR2OCDkEVZutPs3AluoI5hCpI8xQwA69/Ssac+SXvK5zUqrpy1PL7u38QQXcDXkbT6beN9liRohFLFtxmaTJOcgHp1JHAqvcatf6HaWUqxz3FtHG6NDbqefn6MMYzgggZ7+xFaMl5/a3j7X3liuftulWohgZ2zbgN8xKJ1Lep7jHStewgtNW1TTz9uu4Li1sN1zbxsBGyOx2sQQecg++K3crfEjqbslzIuLpH2fVtSu7uZftDQkW8Mkp8nYMFXK9VOcggehI61z76Pperp/YmoyxXy3UYvWaOdsxMuR50DZJUgqcc59c9KuabHe6Obm9VJdV1rVbvZGsa/u7eAcKZT1wF5Pck8DrTtMutV0T7KLm3tr+9kYxP9ghMcEEOeMkgZbn7vHes9VsydVdXOe8JhZtdstEj1kiBLZb/AEq4hzHJeWjA7kZFwu9GGCQM8ZwMmutsCzak3mxsskSnfGG5L8gtgDqSc5rn/HGhXkXhCZtKihim0u6TVNOWCAB4rdXVpY1PZj8x9+lbDagNQlvb/TdUe4tCwHlxrt2vwxBYfewGXI6AAY70S97VGsZOWnctW8hM4t2t7i68lmnEgXgNjaA5B+Yc9vTms2OygbUYtlzcX+qCEFIEB2WyE8s7dAT82B1JORWwl2UkmubB1j3YdtycFBgbV9CWPWpNQc6TbafYmZZor6YW8gij7spO5ivzY46+g54qUxyk0WLiaxs4PMurZBHGUhaUDly3CoB1JyRVWW1n1C4nj2eRA6+WREcFegwD6n/GhVs5p2sPOV2s2Ugd484Ab2649amv4WuJLBbKZbZreUMF5KzKOxzjjmp2M07FS+8P3GoanHcSFzZRb90GT+8cnhi2R0wD0ySK0kF0VcRGNrNYw22LhgRnO7t0C479aScOssmOSrhVw5wR36enSrdi1uvmSfaHgZQWKq4+YY49jik22tQe12Zz3cWq6YmpWcyCKZv3SBAVLhiHBHc8HmoreCNUeN3CxbmkwiltoAOEX1XvzVm8eWSOezjuw1ywYhmTAhcgEbjj19Kz9I1Ge8tbqaUNZ+U+FgDY3su0lySOMdhznmqW10VFdiL7ROLlo20qJrPyQI7j7Qd8knB2GPHAJ4z2981T8LaXe6BoLX2qKsd9PvvLyRiTK0pyfJRQPuouFGPvYyBWyFL2reZdCS43tIsyoEJXsABx8oOOTyRVSC7u2vLua+uYhoyiJbOQAyNM7As4Jxng+3GPrTu7WHJ2Fml19wxj0vZBd26rBcXT75IJWH8UYPCjr6+taOjI2g2MlvvlKqxmeaZsiQ4AfC/wDI4A454qU3UsenMhWV3aQMrB9xUcYxjqOKqaSj3lyLyWLfHegMbd2GEb1J64/Dt0qXqtSdWtS5bXUk083nbEtp9kizbgNqnjbjHrk5z3qhY37WujwJfwS3eqxqxuELBsKWbAL9DgAcDnHatONLW0uY7F7k/aPMUhY49oX5TjPYgjNYmjaZFYz3l7eWIYpcfKkMYYkgnGCeRxz/OhWtqFk9jOtdUg0zWtt39lhjt/9IUvC7zqkh6eYDjcN3T065rVh1TSbfxJJEbGB9WkAuUmWArvUqcHcc4fb1H1+lLMiTO1qtv5D+W8qG7XCn5sBWIPJJzwO1RahY3Y0xYjPam9nBSS6mkKhcHgIo5xg/gMdap8r3KaTepWbV9cnlknfTdIgt1cTnzboq0yE7VbJA2gjHUdfY1c1S4t9P8AL8RG7soNt1mWa3fKTRFCgjkOcsQSCPcdK0Ir5tKtrQ/Zn1GylCwyTqweXdjqQcZT6nvV37Nosmw21jZSPCwZB5ShYm6BumBj1HNTzLsQ99tDL0jUx4xtmuWsZ7C2tpG5uU+d8ZBwOynqDT9IuEudZik0iRhBFNJb3gZCC+FG1uRlh0G4n6ZqO5t5Le9numu4gMNI8rsVAAHIx1IFWfDdlDLcTTRtw+x5GUf63KnAJ9Rmk7bo0lGKjo9Dp1VipEpVuTwBwR2B/CvPrfQH0sapp8DtaRyzNJBMgBKq+MHngEEEcV2lvpttZ3VzeKzCWVQrO7ZCgfWmz7XEDLexgxuoLlhhh3BHQ5qE2tjCEuVu2xyD+HVuLyS7SUjcj71U8NldpJ/TAqXw/wCG5fCt5ptvDcPcaXHFIJTcSZImIyCPqBiu2CJJERHwpORgYwQev51zfivW7rQZLKea2aeyknWMi2gaWQM3GeDwOc1SnKXule0lP3TIGqXi21vax2khvmQyTIy5wC2AEI6YBP0/GuggjWw120gtjuhnicyYUABuCDwMc4Pv+dUr2XW49RmurCFb62jtnNvCF8stL/CrFgMDFL4E0rWbbTftPid4pNVkdnKRN8sankL06/pQ7WuOTVr3OV+IHiG08Ga+iG0BGoKLi6nVMZwdmTjv0/A1PP8AESz8jTRY2DXqtIGJRlARcfeOTwAD1rS+Lr6TB4fS91OMG5TdFbFU3OHdcBR9TiuTv/g9plzbWKypDaTyR/6RJHGSWO3ng5xjmto+ycU5o0g4yguY63SNe1LVb+e2stJjFgxOZftCTIPYFegOM45rlNL8Ja1rPjy+Hioq2mRuJraAkMsiqQNmD/CSA3+TW94VFp4Rt7KKyiRdGaJhcXkrhH8xWxmRMYXIOQc/WvSRg4IweOD7VDlyN8q3InP2b91bjURYkCIoVF4VQOAPQD0qDUoWmtW8sssifOhU4OR2/HkVHrWrWGiadLf6tdRWlpFjfLIcAZ4ArjPD3xFTxFo82pabYulussioZj8zqvGQOnP1rJQk1dGMISk7xLFxpWotqBurKNZgy/vreU7CSOQu7PIJ74/Osf8As281LGq+KLV9OuoSyG0ybiKWMH5cMPunOeM/zrP8H/ESXWdVksde00xQSP5ccofdJGxOQpK9uOo+leg3Ph+3+zzNBJOZGQldzls45A/lWsuam7SOh3g7T0Oe07xHYX2oi20O0uRcxR7BHHEY4+Rn5sjpn/8AXWx4ch1G0f8A4nEjXl8zYYRD93aqfuqpP3hjqa4+eZb21mtbl5BayLiSJXaMtzg4K85963/AOjf8I2o0rT5Xks97SyCRzIylhnO88nsPp+dRK1tC61HkizqotLghW5RN2y4zkZ4UEYwB6VQ/s3Uv+gmPyP8AjWtPHK0sbRy7VXO5MD5jjjnHb2rCzc/8+dx/38NZo5I80tbmJp+pXUeoGJoJ5bm3jD3V4V2xOC2FiB/ifjPHSt/XC91pDtabt4UTIwXJAHt64Jrm7eLUV1G0jv5LSaHawbywdxkI+U4PC4zyeev4103hxpv7GtklUrIqsM9jhiAfy5raemqMalotSRytzEb/AEoC1uop08wxyyKnBI6KSOVxzz6ipP7O0/7bPfyPLLqDQxW8wRsBgvKuV9eoBHY4q3rPgfSL9Lu5topbPUZFDu9jO0O+ReV3BSAefUcjrVW08QWsviFLRtLntpRbLNOGQBFJ/g3Dg9AcetWnde6axlzK8BPhwX0XV9b8KzMPLt2GoWKj+G3mJJX8JA//AH1TvGWuxX/g/VIbnStUWKS9/sp4wmxnUsA0gIP+r25OR2BpfBltrN/4im1zWoo7djZrbCJApy3mMx+YdQo2j65p/wARLddbuLbQWe6gklgkuIZkDmIyLgAPtHQAk898daNPaak6e219f8/xMuCLSdX01Nc05/s02pOtxcyyHDxhAFC47FVG3A9TWteeHbPV9Qsr+1V7TULSUSLdWzlftEa5wj4++nI4NR+EtC1KHw7DY69qUV9dW+9zJGgO4FsgAADcByMnqam0ywvr7VhdWeuXFvbRoEe18hV7ngr2PHXr06c0N72ZpfTfYsaJBqseuwSx3Kvoxt2DwEY8qbIA2tzuGARVvUtF1TUJp3OtSWsRlVokiQHbGCCVOeOQMZwSO1ZGqJ/Zd7Y6xeteeZC0kCxpIywgsPvtFkBzxwauT3moI8CwJJc2+N8sjybQgPQdepOeOelTruiWm3zKxT8Y3xtdPgiRzGtxceRAFO4ltjHywnUgjOcZI5rmPhfp5svAmixzRSRTzW+6WOVPm81cJk56AAdT2+taPxQ11PD+jXV48NtJe2Fr9rsUkQOBM5KKVY8hvmY8dqikvrhrzTvDLADUzYBDMxKeaDGpYqzdT1PfvmtIp8lv60OinpE2rhLhrOS3s2OZwoWdUGEXOSVGOSW4HoKtalElzoKjTDcabcLE8H2nyQssLYwDg55PJ57GlsYLtJLCC0by4mjwskqgqwA+bA7bs8U+2uXn1WXT3VkltnUeauPKkyclUPUFVGMVmRJ3ZB4aktrSzltr1Ptd75+J5pE53bASScAnA9M9amtriac22pW1ksJ3NEwvI2EqRb9q7eeDgZ565rVV5Rek2oVhJDgKw4XBwSMnoOPrUSHyl2Thy6xlwQwPzKcBjjpjjik3fUnRlX/TPOZfs05geTZ5ibCFB6gdxz14pkLzanbSHw+bZr22nAd7pCIwRwVAHJ+vqPytZmgwVPmlgwMW8IGbvlj6DnNVdQmsYNT02OE7Z70SYVLY/vgoBJdgMAD3IznvSRT10L0imS6cs/ylgH2xjLgDBb06/pVR4Y1keS7cPahTEZZG5l3KR049un1rRt7xVZ0cgpIy9xx0z+lUL63tV1KOz8y3+3CMyQRbSuxc8spOep44PWkhptaMjt7OysrRILY+XAqh/Nkyd5GMgg+yjIHPA7U29uLRN1/cqkshxizhj3PMxOFUeo9+nJzirM0izq1rbWrQ3O7kT5IDAZO0euBwf8lDFHYeTLdQTPyZFeVVbys4ztxggjjn607leXUj+0vPd5SyMNssbNuErGbfkYIH3QmN2Sec8AGqxvopbiKOS2mmmdlVy6lhsyMc+vOc4HvT7+4AWWKx2Xl1+6kkeaYxqIS23JYZJyQRj/Jhgjm09b5r17e3eSYxwC2fiFCPl3H+Jj1x6e9Ow9DQ0mwGlaleGa5cJu+Tz1AVlCgkJk9vXnpV0XInMQs4ncElgwbbvx6jua5+7ieVba4be0lpGA0nJ8th1K4zjIOCCMGrscuoNDE0OkYmZB5dxHJ8hznOFB+XjHX1NJq+onB7sbJd217r2y8aS31GNlMUEoVXCdMLkkHPPIPrVuTSbG4vbe9NrKbm3kbEr4DRkqcgegxj2qvfHSpdRtRqummS7Ziq3AG8gqeRv4OBnOPxqBLa2vLKS0S6VLQyqX2MwOOTsJU/MMHvR6CV7DdailFvBFc3lvBbSn5Ikch8k54ZeSDjoPpU81rbLbwzNdyQ7yQzuv3ML0OAMnOKoPNb3GqSzWuk2d1oWkW7LLdGNmuBJGxYxxr3xgfjWqLyxEFldbnMepOPJe5Hl5ZhlUIP3WbOBx2od0X7Ro5u40xJ1fYDIu1ttw5bIB7nJ4HOdpq5beJovDFjHdazbyxWU0YMt2rZigk3BEi29eeTu6dOa27rQLbUI4BfS3bT+WpSSOXZ5e0ggj1IPqD7iqPiawh1HS9QS4A+xXMclvOywhmX5fldVxgkMoOPrTUk7JhKqqi5bGV4tvluzb3NxrdvY6bZyx3V+2A7GJgQsWMHaCSDnHPrxV6x0nRRoL3YSK7gSyDw/aCZDJERkGTnDtnODjPOKh06CeG2nv2ntb7ULm1jhWGSMR288ikAeynPY9M1rJNc21rBDqTR3N15ipPNBHhIMnGFB6AcAHr1NDdlZClf4Ucxrfiu/wBE1bTrixPlafLASdNuyAsuAMmOTkxkZPDfKdp6V6FpF4mpWrTp9ohkOA9vMAJIGx91gPwPU1xviFtQuPFNtHb2ej3eiNGokW7QmdcFt5T2OV59q1r7UozcW1tYzQwX80e2SJH3NtBH45xnBokrpWRLjzJaGzNq8ECOA4mMXySvnagYdRn19hmsaXxnYtot3qEiSRWlszRztvGY2ABwcdiCORnrWfY21lfxPNqOl3UcenTf6Jl2RpGAzkJkL16ZPX6VNJb2F/aW17qFjLpcgf7MLeZwRMrDlCM4ORSUYrRkqMb7HMWvjHRPGstjarCVkVjcGGZOImTHAbGCeQexwa7SabWLmONdj2pWUMAjB2miA9xwTx1ri/Bmhz6B4+vYp08yC98y5srdjuSNFIAKkjhyMZ/D0rtxLd67c7rZLmyFtIU3t8u4+x/iH6VVTlUvd2NJW0S28ziNbt4dasrvw8IFsYLpXMsI3NKjZBVgpHQncDk9uK7nS9Sgt4IrH7YTdQRBBEqZ+6o4GeT271q2lhF+9knjLTyDY8rhd7gfToPb6ViXlratE11Jd+Xe2rGVWiI8/auRtY9SGxyDx+VQ5c2hLmpKxX1tba606CbVNPutTXeNytFmPn/ZB4x6461mXdlYeH9K+zaNHYmNgPIt3Vn2opJkCqOc46ZPBropbrVr20tv7ESG3R1V2aYDKA9gBwe//wBbNTPC32l5o7eE32DCswwcbhn8s8kUJ2BTa0PMNY0e7VLzVLUGy06KWE2igri4BA3MAOVwSwKt6cV6FoeotaRpFITLC3zBc5aPjj8D+lc14g07WdS068sbxYrq5kidN6Mdo6ckDA4+6T/WuR1aXUdDtNPvJ/ELG7jhj+3qkLNbxRZxuzx83IGBya2t7RJXNlaceWR6097onM15BBBMTvdZtuQT0J9jTYNVijmSKG4t1877qquAvsB3rgPEXh2DVfEFvcWkkl1a3KrM0gfCEbMLhe474Nb2m2EENnbLfGKCVXEKea3JOeCPfNZOEbJ3I9nG2rOqh8Q6fBJJDf6jZxyKfl3yBSw/3c+tav222/5+Iv8AvsV51L4UtNNkvdQ163tDFFGJIZUiLv5gzks3J6bQKsfaJv8Anmf+/T//ABNS4royHRhPWLI9DtoY4pLW1mkuHFy6iSZsGNC5P5DoDXXR6jYwZiFzGqpwRknn2rlNI0We1a6FzIJ7iad5mydoIYDaAO2B68Vk6ldLD4lt7cah/pwQAaK8ar56/wARRyOGxz/+utnFTe5hKmqj3PR7bUbS6lEcEwdx6A8fj6+1N/syz3u5hXLsXbJJGT1rA8P6haajLOmn2EtsVbLNMNjMw6kA8kcda6sZwMggmsZLldjmmnTdloNt4I7aERRArGCcAsTjnPeuI8WS3Mfi2Y2NlO92NKEcUysdjB5WDIV6Z+RTu7Z967sdOOledfEdbzRte0/xHY3iW6tB/Z80bkATEvujAY8KclsHuTj0qqWsi6Gs9TZvpRcRz2ejmBbxLb7QbRyfNDZyCCOGB5HXGcUmhy3g1iG2utPluree33tqC7Qsb8EIRncDgnkZ5qO+vhfT2V5bNYxXkJaIzNLgohI3YH+8ozTvE1leNavDYsrSTszvKAYxGm3Py+pY4HHTJNWuzNunKzUutMRNn2Jmd4EYHzD5gBP3T83GVIzj2rnbW3vUSyVNTt76/EMj2aXEm37XKq5JBIyRyATjgGqdnqmoraabBex21ncTK0ssSuGaGIEhG2Dru9eeapTw6zrRg1XSdEu4tVtWksLCC4uESCzjb71zIV+Y7gAdoJJwBgdTSi1uy1FxWpFEulahr2l+FNS0pmkiD6zfuZHkjWZGUkKTklPMLADp8uPWuqv9K0m1t47i0NzcbpC+zzd7jcSWI3nOSSOMj2rRsPDVhplvcTzuWv7hUFxd8qzbBwqjPyr1wo9ecmsybXTHbOBaC7KH5YslmRexO44J9umalycn7o4ycneF9B/ia6e+sYCJPJhjVmkkY7NpPAPPQj09+KjubeTRtPtB4fjAlk2CXz8/MnG6VvQAZ6etVdMuLu5uNQj1+3jl0p9s1gkC+Wc9wQOQRx144PWtM2mL92kvriOOeARsvVYdvAYE8DI49CRk0baFbLl6Iv3Ol2l/BFFPB5kMj7o1fO47RwTyPl6nHuKheygi1KI20k1k0cZjaBG3RT4z1U+mchuDTwqQWbKbx3mR1iimY/M2RwTgYx1PpxQ2kRNe/aZ7q4nuIhtVm6PlQeMdKhPzM72erGJP59qiW0iAtOJGd1DAqGGV2nH3sYz2zmmWVpdQstnf6l/pCEuZ2K+aY92Qucc5qnFrAiF1DBYmZkbLG2wZEj5ALLng8c47GpU1MSS20cekvNZy7mkvy6skJXACrn5ixPGO3NOzRepowSK8V18sqEnG0DbvJJ6A5O2q2t2qyWttDlcwxFRPC2GRhjIBHI5pDPZ25mmuZBPcKgeCC0zuPJztHc579B7U6/tXEUk0TRJOyiQifpGW67gMg4Hfv2pbO41bmLTBpvNYy20kxQKrMCw47K2euT6ZrKn1J2u1t7C4t3mXcmy8Zk2Sds4B44bt2qWxugBILkPGsUpKKykBxj5WJ684PHWpTYwW9zLOsKXN8zKySupBEnJAA74B6+/1pqy3HtoO0uG/nSaOQWljFFIQzwNuViV+g3YJ7jHTrUUFlaRWMiLG5uZWSSedMhJHUY3AE/KDV4rAIoV8kL5IyUkyQr9zj19M0R+W8yFiDHuJfehKk/4+1Tcd+pJDqOZ7qBtN22uA2/gh3PLbh+XNU9PiktRNLbT3FxeN80jy8qTnlAv8KgcDFPju4r57hLeOVfsriKRXOCw/hYZPQ84zUn2kW2pRqiTSIAWOR91fUn168UakK3RFJ9Lt/wC1ZNY1WRYYJEMcgnOFZSuDnjAyMDHpV/TZNPj09LHRLLZYKmIWQbUIY/w56g+vQ1TutMXVNVmhvNR36dCisYAdpJzuye2McZHNWdcuhBb3Yto/PuIlDJbxHa4C4x1OCB1z7/Sm9dBvV2MnVb1bTbosb6lbXTxZH2GMv5agn5wfw6YP8q0Li2urrR4g8cGo6jZxiWG4u4lA88co5UD5T7jkZ6VnC/1S/s7OG9X7E98HguY5cxTKwGd0ZzyMCk0C9t3toLfQrmaRrNwSHfCzqCd5x1PXrj0qmtBWZq3N1dRutxbFR8mTBIm9gxIztORgGlsZpL3R7Pzw088mTPtb5Y254PocnoP8Kt6hfadYpbC9QmRlBTC5JPYfnXODW9Qm16zR5rS30ZoJxJbxqPNllODHg9sDce3IqEm0OMW1dI0p9LstQsLu3skaKPynAKuRhtuMd8joeOc1kanHrNzrXhS0ilWGziiabUrgjmV9u1FJ6HLZJ/Ctvw7pn9jQyQzXKzF7oymR4xGy/L/Fg/NxwD06UkmqfbJ5V01xqCNOCsZGxYQqjduzjKk4Ix1zTTd9AUtTL1X+zrvUru11C5lj1B2hmAhBwAmGVozjgnkHHUEj2rHltdM0rxjZ6rDayrqOpXsaHK7mKpG24/7IClfYH3rtL2azgeya/kt4pSFTzG7j+EfXPT6msOewnvIZ7rxHaWcWpaZIWimtHd0aNgPugfMDnIwR1+tVGX3FwkkrMZa6HE1jPHY6jqKWXnfaFlE++QOWzIxZiQwOcbcYFWNaudKuGS6uWMiaNvmmmG4ohxggL3fjgdqy4LGaw06/ja5a0ikbeJXHKgc8DPPbjgVm+G7PU/Gfia5kvYdQ0zw7pt756xSARtfT4B/eDqVHB44NO17yb2CS5Xe+iO+0A3OpWthqBie2jKmWKO5XE21h0YD7px2/P0rejjCepwMAZ6CqV9rOm2EyQ3d7BFM5AWMt8xJ6cdap2finR72aSO1uvNeP721Dx+ntWPK3rYwalPVI0dU1C00mxkvNQmjt7eMEsznHv+deXaP470PUvEl1qGl/2pexTSRxyBbRvLjXH392OACMEeua7vWrPRvF1o2n3E6TKpBaNHw34j6VF4Q8FaJ4UhkTR7d1EqgOXkLBsd8HgfhVxcIxd9xwcYJ82425sfteprdxTzqWiAS3JBhAGfmIHTr074rA1zR/FWnobjwvfRSi6ctdeb85VMdYQenHRfX9Or8PXt1c2Lvf6WNMuTK6xwGRd0iKeH49RVrRLa/tbaWPUtQW/k892SQQiLbGSdqYHdRxnvSUnFic3HQ5/wAK3N+rXaT6PqY8tQqXFyyI9wQOhVTgc55/+vUesXGjaZEZfFUum2az8i1lYPvJ9V/ix6jjNHijxRqcWoSaZ4c05Lu5iVGneSYJsDNjCjHzGvNfGHwnl1TVp73UdZuxqVypkjeUeYqc/dyP4VGRVxjFu83b0NIpy1el/vPRtMt/t631/DqaQGdlWxaJ12woq4XCkYIOenfFRLp8lrc2EfiGG0vItu83SpsCMM/MV/hz3xxVjQvBMNh4KsNKW7Mt1bQ4S7A4LckNj0GeKk0eK8stIgg1q/gvNSQbJnnhHBycHGfT8O9Q2ujHda8rHaFPPdwxQRXsl7EbmQvJJFtCx/eC89eoGax/7Z8T/wDPQ/8Afhf8K0tVvLm30d/7IVNT1EtiGGMhQCDgsQvHTmn+X4m/59LP8xTWmuglFPV2Mi9v5bTWXmmvYTpksSukZybiGUkL1HJjOTyehHpWhcxW8sqSXFtaNqEUe6yu50PysegLDnGcZx2ryn4YeL4ddu7me9sI/t8FtDbwyplpXXPzg564OCcDgHrXuUkay2yw5X9/GwTIzsOOPwzz+Fa1Y+zdmc85KNkcDPcaoNS01tShto9QHmx3VrBdL5Lx7wBPublccgDgg5HoK6saVfx3DXGm6xextHkNb3UnnRsc55B5H1BrKg0+W70CxTX1tbnVBA1pdOU+Sf5wWPPYlQc+ua1r67tUtb+31RSkEq7Z/JJLZIAByOfTkdKmUr6IcrtWRu6ZcNc226UKs6HbIq9Aw649qdLFb6jaywXduJYGJR4p48q2D6HqO9ZvhcFbVl81rhcAicjG/tz74xn3rUTyoJpF8zDufM2s3Ttx7Vi9Gc8lyydjndS0Q2ip/Z06wo7bCskQcbT1BIHAPqc1mawviia4+1R6xY2NntEMQWBpt7Oy4fqBkYwG5GCeKs/ELxNNo9qYdNntIrvgSPcltqAg4GQDhjgnngAHvgGtep/YmqWeq6xepcG3jwD5XFusmFZVYDJQ4Bww42g55xW0VKybOmLk4ps52x8O29ld3l1HqFxret3ryrNeu6xTmPAPkxM+VUHttwcc8Vd0e40kWNgkdn4g0uZwbOO2+2TIEZQSd5U43D+8fzqDXNCik1Sa71W7u7vS1l84NJs2BpMKY/KxtwFHDE5+YgcnJ19TvYliuIrmxA094Ukhkkfy0ndmYeUvOd429BnOR2rRu5o+xV1fXdR0O1a4tvP1HTkdVa3/AOPq5jjbP74nO7Ktjgbhg9jzWxa2H2ize4gj/eXCrOq+aGVxjd8uOxHIz61H4Z0uDTb1tUs7aUQzxedMky/vrcgdAB1BGeOTWfo/kfbtUgt4zHZWzRXELh8boZvmZDjJBQsR9Mdah26Dg97G5pQg8QaZ9lCwm1RmSdlLKcd0X8c+3FLERY3D/Z4fOtPIPkm4kLL5Y6YJ68n3OKsmVpDLLZQW8luZjEoaMkvhQPTAGeffNQQTvLo8sQvLfUJFfyxCkigAhhlSRzu4PH4e9QTfXyLZ01LiCya5mKSBjKwXhSij7p9ueaqC21271m0v9Pu7NdImxJMjoWkCgfdQ9Bnj8M+1V7K8+2WFxK6pHqaZMdoflU8nGPUH1qxokN42nodRkQbgwlhhyu7k4YLjr0BFFmkD0NPUbm1ijd7JIluHAd5o1A2ru6sw/Gp006OJGmuJmwFO4IAqYPXAA7+o61gTX0jNd2gsLiCK1cKskikJc+y4/wA4/Grur6PPqRsmFzKq2sgcQRS+VCy7f4sDkZ6VNrbitZJXsSTahBpirPDZ3l/KzrAnloHdVI4GSfu5HJ/Oq1xO94hMT2mEbLhDkAKOVY9sD+tLcTHR4Vksbe/1K4jGSkah2bIAwASMCrEVrJeXC3H2RLae6iAugTjKYIAcA/eGSP6+j03KVlqRafd2eoQXFzbztIkEiL+7Py9jlSfvEg5zVyG4iHmT2zBfMwOTkxsDjH45/rWbbWcdnYzWmnQJHawSBiC3yhsFWBPUjHNO8OrCbWfUVt7kWjOxUuRuk5++AMbRnIA9OaTS3RUkie1v2kuTEiMXWYqcjqw4P65/CpHso3uIp1juDcxMQpDMF5PO4A4IB9ckc9KY2I/MlgbY5O4s3XJOM+/eqUx11JtRSxubEW8qEW6YKyhiMbunUde/ana+2gmuxfeWJL6G0nf7PJIGk2uvDKuOfTIJ79qW+u4rKF7l/NZSdsUY/wCWpPGQTx0rD8G2es6TZRJf3KC1VAZAUyqnAyQTyT19etXoC96b26sdRtr23HyRLGpdh2II6Y+lDikyrK9mJJcPE4mkljW08s+aixFWDcYVW7jnPOelPs9TivRJ5KEzbQW3qMt0GffnFRXi3g0iEXWoJeXEBLudgQspP3cd8dM1U1uRbG2vbu0RBHuC77hWKsccqpXpk9+nFCVzRKLjruXp2urfUra2vLIvaJCMzRBpZUJBGQSDgdiOtJfW9lo19LqdpPDaW9vBtMW0eWwbsBxhsgc/hVK01JriCGYyk3M8JlSGOUMZFXqFU9cenai2mF7ax3E1rKtsx3yO6eZiRBvUMOAFBxjH8XXpTs0Ry2NoW91dmN7lraNY4vLdHP3Sec/XHT3rm9Iu1la8g1SCwtNSaTZu0+QOskPZR+GO31qxDc3uo6rnVYfNsmQNCqqF+TIyCeQSTjjPA71fvorTSbW6l8N29mNYcAIbjsMgFQe2Bnj1FC00YJ20KIg13zrqewurCeyi/d28E8pLEDuWAzuH93p6CqunXEcohvdWtyNYti8Mbj/VyK2GIyOwIHOM/wA66Vo7ZrSJWtYkvGjIa4hAQxuwwWDAcc55qLRtL02zEMTTXDXCEyq07b8syn5lJB5xnpzRzaBzqzujPi1aCTUrePWVaSVo9wkRcpuXkFeuDycZqaC6tIbO716HSrmy+R3maRsSyqgJ+ZcndnORzmqsSCwRbPWL1ppL+6aG12wEyYblS4AGCADz0wc1pT3T6lo9/by7TaQQOkxiBLSrtI+Udjjp70mOVnrFHE63CusaJrOgaTvudVlc2yRyB1WBmUnJLdQAeWHcY5611+myzWGn2+l2zTvYWUK28l2MtNcSgYOzPX1J/LioY7uz0Twnpy2FrcQRzWiyyLIGklhgC5O7vkZx+fpVLxBLeZs000m7uLuBpbSZXKwxbdoCDHTIbJPU47CqbctOgvisizcvp8EslzNp0RA2ETyjeJXOQQnPVQBlj6jFXhpTxXaJa2VlDHNIXzECu6PjGR/eGTn26VS0q1sJYdTg86BnniMd09tKWAYrzg9A3pil1fTYE8JWulaveTwQReVBbSQMxnbbtIb3xjn2zU9bBza7mZ4otdM1W31EXrtpAsjhr6L90/Bx26g9eKd4W1PWvD4Ztav/AO1PDIiUQXhXdMhycs2PvL+vpXSz6dZajaC0vLO1uzcStKqOCUCg8M34Dipho9zEXM92t3b7SiQNCAET0GOtPn93lFzxtyyH63D9utrW90wiWYYaN15BU85H6dPWtK2mTCRB1LlSfvZye/65rkobe40++ttM0m2RLUKXEscpwPYKeh5OeabrrrphkvZl+ZMsiq2CSMDGe4IFRy3dkLkUko39Ca/ey0y7TUbuZUSdxA7zZVTnoC2OKe2sWU8T3NxOGtIX8lZJOC2Rg7fXGOtYUfiESR6b9tt2n0nVgUhYpkRSAk5OfXB681bW2fUfEk1ubJZLGGEKWZvlUDB6dM5/L86vlt8Rbj3NnwVLHBoMtrNd71gnliUyMN2zJx+lT6iRd39qiRWZspI2SS4aQLKj/wAI2nqDWWjST6qEsEtpRMJIprkuPNhfaNmE7ggEHvyDVC8i03V1ktPEJuYrm4Z4okEflqqgDjjsMgZPfvU8t3ciy5rnTmJdBTfFFBDp5xvMceWDngs3PI/Xmtb7ba/894vzrhtTvfsGs2MF5OYdIkh+yXFqI2KEj7sgkHC44yDzXU/2fcf8/Ef5D/CpatZszlFWTkefab8O9I8JapFf6eZA0S3DJuZjtV8Aryew79eK7DTNQcWyRvBi5RikIZ+GTsxOOmKvalGt5YO0bKSgYjng4GCMmuPNiviqxhl828sJiNhKyeXLEVbDD05x79e9acznrNmKftI3n0NHVrg6eIYmt2ubiQ4Gz0J+9g9utU7bTprOe9luby4e2nU+XAYy5iJGMjnlRjOOK2NRa0bXLOJZAL1odkTsTlgDuxnoM4NZgv2u7+4tL+3kZmBImIOxl/uHj0z0pq9jSEm0dB4XWaPTVjuJRJIpJyqbNw7ZFVdcs4IL671e51W4t5BbLbRIjArF8xbcqHgyN0yewAFc3beJYLHxTY+GdFJmdZQs2/cfLjK7gMnPbn2q94x8My+IbZoA0MtusgkKSqd0hGcKTu6DJ9/pRyWleWlyeS1S8nZMzPDl/qes3upi8g8q31Ni8EhUAoisoVDn+LaCeR2/CmfEDTru7S5spJ7S0gu2txaI8pSR5BJ8wY5ww+7tQDnHpxVTR21/U9W11Luy+w6RZpHaWxjj2F+PmkGewHHHStjWLoXT6VfDSZ72+Zy8NujASx7cAOVZhgd/1rTaV0btcstC/pU7ahDeW94tvqU8Z3TlM7pABgZ+UKGOD8q5xx6isG10qz1GVrvXX1KOG1vN2n2E1oVZBtGfJUDLdOMZIC9BmtG8tLa5vLeJdZurG+S4eSNxJtjIOAy9wQSANvHerE+oLBcx6WdY+26ldmaC08pBuiZP9YobGMqME7j/ADpLTYi9tmc/pVlqun6nr3ie7uryWznCzQ2kC7JXjYEiNlzyQOB0IxzjkVh+Dr9tW8Va1qtlbTWNrJpVvCUOJFO53KjcOMhdgOOxrau9O0PW20u186/ZQI5NNv8AdvivSHDPKAoA8wYI56humDW14bs5IfOtiEjM8zhYlTYkYZ2Yc9+AAMdwauUrJ33/AENYtWb9C1Zwtp9iZriQtcL+9l5Lc9D36AY49KtW1rZ6a+3SdNgitbhnu7kKzeYZm788EHg9u1ULfUtN8SR3yWF1LOj7oSsSGN41jGCRvXPLZ5xz2qHSJL/R/DNvbxzWeqaxboI4JZswC62sOoY8NsPUnkg4rJp/Mh7akk97p+n67eyXSyT3MqRxONrful4O7p69cen1rqpbhIoZEWWOOR42kj8twxk6ltvuP896xrrVHsta068urdobe6byWmKhxC5A/dkjnBIwD0/Op2sprzxMZ4DAdJa2fcnKs8rDH5bc9uuamWtmyZa6ssRQxXthapuubWea3Rmic4kUkZyy/wB4Ec/rVUefYQojuLpfvNuQkggd8jIqDStKtbGws7KYlfsxAjeRt+HPQk5zkgAZH6VvJPfQb1vILfyBGzKIAzZx25xj8aT00C/K7bmP4a0+xEfnpLfwvNvklWVypZy3JPAB68YxxTr+GaW+tV0y+ngWAtM7sAQ6uu35u5HpjkGq51LTdVNzaXF4Gng2RyxqGDjJyjDHAUgdRx2PNaqHYk3nbXngUnzYlySu75gPpx+dDundlPR3Oe0e5trrT9RQvfwFndFnnjBaPK8OijjG4H64wa09FnaPTbW1825LHbIVkQI2Ce3bqMkdials5IZ7U3ETEhBvxIMjaOi8Y7k+xNAmVphxhJX2k7ssm7PP6ZyKG7l7slkjZpTJHGrSopZRPJtHGcEkDn8KsaKY9R3yu0DjIbEORzweT7ZHFYrI+kW8cVtZ3WpoDiV4eGizgABAOTj5jnjOfWrGhW9vp9ibZ7i1jg85nZI7kZVzjqWOcg54z+dDWhDehfvrueG0le1jS5nt32x5O4MCRnOO/pjutc/qUc1pDBNpCQ2F5HcRvsxgMuTvRz6YY+/PrXR3CTailvc2mfkVlBikUo6HHOPXKjHpzXI6omt6vrksGnaNcW9v5MiLd3bbcSkjMm36dB9TinBFQaNy/t7rU1mtdQRreESPLHd5CIik5Ue7cj/Cqcc1/pVpHJezJcWN4RHI9qu+OAgkbsH1OB6d+tcpZeZa6bd2F/qz6xoslx9iPlNukjuAwIUY5xxnP8811mrYsLEWuq6hPp1veyLBFPEoIV1y6gDacKQpGCPWrceXQdrILk63p9lc3wstO1O3swradHEPLkdTjJGM4+U9O9aDXE13FHdSQtDMYARCXwof+4PxOM4qGdZna1tLa6tEZZE/eRxDzjCPvsEGfvHCg4wMn6VcujCnie3jKu+6NpA2flDDjaRjg9MfSs2SmvmR6RdyS2LrqNt5EqzFVQgko3Uj6Ht60b3F6WlsYIYXBQzNlpSemMdBkY71Vlv0tplE1tNFKrNuBIbKZyOcdQDnHp1pI21KfVYRbKs+ktEZjvC7nJPDc/Nnp04pW6jt1ILLUp9QuLuWKyMVmjCGGSbJLjGcEdVyeAfbmmaXfamt1Nc3dtDLpltmZFjwZY/lICgd2PPbPNLea9o3h2SD+0wLa5uE3LHkloxuCqW29ASRz/8AXrSkl2a7HF5iAzR+YIBj5pOTvUnkmm/Qr5aDfEGt6Zb+VBcXDjUriMGKMRsSytnAJAIXIB64pbPSZBo0sGk3k9le3MWVmnH2gICc8g4BPOPpVTTNOub/AFAtNEVgGHL56jnAHr3pY783niq5n03UQbazg2zWMkBUg7TtZH9c8EHil6BKKiuVPzLNpeX7eIV8y0WSF14ulPAxxtwfoeB61rX0ci6RO9tbLFcxAvHEhBBPQfniqFxExsLaIFcxoJdynDMvqB6gmpb+MBcXBUQ+T5cmWx8uOTnr0P6VL3IkrtNGRY6dnR4rXSrqK0uIjunghVflfnlvTOOevtWibCS5bS7i8JNxYlhuU4y7jBIHpzxn1qLwhpfhqWwSbQJUvIo/kM4lMhb/AGSx6/jzTL/7Ff6Xc2Nxf3NvFLcbmeIneQG6BlGRnA59OOlU97Du3LT8i7pUi3St5EqOlvKbaVVONgHUFu/XtVHX3iV7e0svLillO2JkkMbgd3QdwvU9qine10uK2sLRrudnjLme4YsFUHq5OORngdan1ySytdW0e48uaY6gfsEc8OX2hgWDH0XjqPWktHcXUn02OTWfD9n9vlaK5tpA0km3BfZn5uemepqv4ymtrrS1i+0WyzeWJ0dpAoIxgkc9CpPPTmtW4N1YxxlIhdM8oE7EYHlYP3R69P1rDl0O1vdZL3kduZ7lPJSMpkw2wGdo7clRzj6UJq9xR+K/QktfC9hrHhe3s7hf3CMskO0n5MdCCDzmq32LX7KICSysPJjLvPLbOfnQZCKFPIOMFs5rs9vkQxxW6qEQABTn7o9Kz5NSmOuLZRIjRiMlueQ2M9fyFJTY41JSba23OV0z+zdcvbS7gZbOS2YyNCg2sCD95ifvAn24rrJRBcSxCa1huCuSJMD5PfB6ZNYuseF3bV47/Rb+OxuD96Fo9yye2c5H4VtQ6ZKpVvtAR8cqiZU+vB5xRJp7Mmbi0mmYWpy20FrqL3cjW63TKGbOVWQcL9M4GQetXPszf89Iv++P/r1U8Tae0mk3FrfzLOjphdqYckDhm9wemK8k87xT/wA/V7/4DvWtOnzrRmtNXW57dpOqWeq2kNzZSieC4jEiugyuD2J6Z9jTr+w84GSBylyBw57/AFxXn0H9q+GvFsOpRCBfDV1Hi9UybI7f+7Iqn1wM4zye1d/ourWWs2b3Olahb30G7bviIO05PBx0P19KmcOX3o7HnTi6Urx2Mu4tCGDXNq5kUMqyRqPlJAHHsazPFGp3+l6XNLZ2FzLMVby7YKXYkDrj+6DjOPWu5GN3sKUqDgnseCKlVNbtFRr23R5Z8L/CGoWzah4j8SeY2s6uFMkagqYEU/d7ZJAXp0xXZNpq2l02o6ncHyIzuV2l2+UuTy3bHvxXRBTuB3HvwBwfrXl0N5feJfiLqzG7caZo/wDosdgrAK8mMmVvU4yB6frWicqrcmaQnKo2+hv2Xj3TrrWriOK11JbSKMbruW38uDrgYZsdc962RFpOtshX7HdXFs25Cv34mBBIz1U5xn9a57xb4efWvDY0y71C9so7iURyfZ4lYSKcjaQeo7+o4qOfwbaWtlFaaGH03UIna4guIifNZ1Cgu+eqsAFIPUHvTahunYrlh9l2JNU8E6SNEudFj0mSLSbqRbi4W0uMeZKzfMGDfwDAPX6AVdv/AAhZCT7RBdtAIbUWW7PEMGctg54JGcsfQelE0r+KLW8ttJ1c6Zq9u3k3EkCiRcgAlSp78j3Ge9atrpDN4a/srW3jv98Jt5Wb/lupB4b680nKS3YnOUd3qRWf9m2Jt7aIyXcsO2NCwBZEK8FTj7uOwq/rbiGxO3CtJIvOcEdOR+ArDt/EsYs0tNBt/wC1r+2gRvs0LeWmzeqH5yNoYcnaTnC1ox2MtheandalqEt/aXbjy7Zoc+TjICoBy2f6ZqGrbitaWpzzS6fL43lsfsAh1G3QMbhXYRtGVypbtz057g+1aF5Y214BFGLaa7gxPCsx3PA/8LEZGRnH449ajvIR5c727XWnxyRpm5kt8uoByAc9eMj5umap2YtbfZDpl1aSXCuoupHmMzqp6DI/iyCADx0rTfVG+u6ZZ0QRwWg0iS5iuruyjFxd2kEm6V3JyCFY5APXB4547Vv6tJDJYsZrmK1QxmXZOQhXHc+gyea43UNHjNtqF3p2jQwyXMqym4MvzyE8OyMeh2jgdPaphF/a+nW140t7DAu5WjntFLBRj5XDAjPGd3TnpScU9bi5LvmTNrSbC4vEubtNUM0M9qsItU27Ijzl1I5DEHHPcZqhpgktpItOsIpWsofl+0PcMZCfQ/3ic9anhvbGzku544buytosC4KoEGMZBAHUcnp3PFWJTfRLG8VlbvKYzMkMuQxH+16HnvSKS3uI89zDcNMn2SK2EWBCUO8ODnlh29qhklnlvLaK1mDbWL78KBMxXBUDOcDI5/wpdPk8i5xqz5v1+Z0t1KxRq38ALfeOMZx61YigMshuFCzeSxB+c/KCchRx+dLYrToR6hZtLBDLDcxxJgxtHLjAHfI7AeoP86g0jU45BFcw7ZW80EFl2kryDsBqAWt20TQypFfxNKSpuTgw7s4w3cDsPetV9HmuLFra5jsGtwuGIYgoP7oOOmP0p6bDukrSZFeSXr31zKjTCGVdiBF2bMDjOOpyfUflWXd6VMmugW6afPbiAPMygb42HJJ45Ge1aN7aGytlUGz+YKkcUIbaijA3YzkgCsVLe/n1ExWelCKz8xVa5uLgDMX3d4UD2yAT35xinFjhZap6Fl725kt7uK0mIhdNrRRDCqvIHljjGc849RVvQdWOm6GMyym1tAY288ZYsScMpJB2g8YIz2p1zLoqvBZ21+JLpB5cu0EtIO5J6cZzU+n6dZ31rLb6aUheGR0mYKSGYkHIB4PH5ZobVtSZ8r16DdLmsoNMitLC3eL7SrXEsiRDDPnkH3PbPapbyynv9Khj1Rha8qxRZclcNgMeMY6Z+tTNYxWlyZjPLcMkYEnA+Ubss3HQkdvTPrWRf+Gl1K+1TydYuUkvoWgyJSTEpA+4wPB+UHGPXrUpq9xXT1RqnStP0zVrTUJLKW51GSD7FHcoCxSPBbazZ6E96rXz/wBj3d3q8klxHEkJeZCnEmBklF7NgY/ziuetNGl0/T4NP/4SCdJrZzbqQTvTLFi4BHzMc8npjjAro3t5IYY4ru6uZxEm0yXWCzHbnJHQnP4UNJPcFHu7laae2jh/tySNS88QlEZJaQKR0wvU9gcVHfPa3N3p6l7i4jWbEMdu7qquOgdupABOcjHFZstw5vo1V/LHQM52gDHLE9hjJNWbPT9V+SNrq10/T4p8+fCNxuLfCsACeAp+YH6GnY2nT5NbmrdaRpmpG7iAMbTReW0yzEyb2BGR68Hg1laF4dtvDt/Hp1rrN3LLGC5t7hw3nKxH8Oece3PJroIWGoQ+Zoc1utkH/eShMuw7lT2IHAyKxrqyfVY5BLYTq8GJ1v5JAHLowwhCncMgnBNJN7N6GKk9mzo5dQhgtp1uM7UOwxgbQ2f7vt1GKyLnVphKkWmwxxiX5cBQzOe2TVWPUU1OBmjtJbeOGUr5cwwZWPJP0Oe1bVho2y5t5lVoti5bLbst2I/wqLKO5cVCmuaW5Ss7W3huInn2C5VZIgTIB5hQgZVe/U1cjnims5HQ29xbygqCvJ7KQSM8gg5x39KxtYsL681nS1002yCzvJHnuJTzGpYHCr3JIArc1DTorCxil04eQbaVWEafIjAuN2QMdckn3zTaWhEnrq9zBvHtX03SrfSbeV3jvolCWfyoGBBdmCjkbe59eaj8Ry3HhjS9c8RWVvdX96kIFpYxsWzl+flGRnJB+XPAro/EKn7JcadYOtvdXkTlWjXawPds+uO/XNZ9tPHcwxWcGVgtUCouMHAGM/XtTT6hG8l5M8Y0vQ9Q1TxNpmo+Lru6u5bh/tclnHu2Rkj5YivQZyST2xjvmvZptNvbvW9OvZbqGHSoZEeO3QYK4UgZbuCSOOnSi7hihuLaCMsrzsy/aFh3BQF3Ng9hgAZ9T+UGhXWq3F80l6I4Y8mFLVX+6oyFLA/geOnSrnUc9SpPm+HZFjXbDUpdQnnS9jjs2MTRp05Vhn88598VrWhjn1xnjIfyoMGTGCxJ/pg/nXL3Dya7eWUEkP2jSZJ5YmulbGGXONozyuQBkd63/Dlog1TV71bia4SWRYkLj5V2r82z1BYnJ9RWbVlqZtcsdSWMalca/K88cMWlxKrW8i7hKWPDK4/u9/y9KleCQ6i2orEpKps2M3KkHnGODkevNVNT8TxW0tzFZWst/Na7fNSIgFQR1x3FS+F9dttcguGgiltpopNssEqbXU4HPuD61LUrXsTaUVzW0NCGJmlWWQ72JYhiMBVPYD14HNc7qesvf3j2FhdtZ5IXzvLzvOCcA/w9OvNS6lprWF5qV+dTvn+3RrAls0mY4sdWUdjipraOOzigM0SsIYwGDcEbu5z6UKy1CKW71JTZw6fpZaWWSZ9uC7v8xPThu1ef/aNM/wChsg/7+t/jXTeJr+Kx0+d4gJoCN4jQ8ue4Udx9K47+xdH/AOgbJ/3xW1NJK8jWnTlLW53ekXksei251+NDKY2MjrHuUgE4yBnt+HFc3rR0/TZ7TWvCwUXN1JsCwxN5M5JxtlKjgcHk9DWi+gRWCWhsNWktB9oZrhvvNMOpTkkY46d803Txp13rVxNYXkyy/Z2s/J8weVGCQSTGOA59u1NWT5kckUldrb8P6/rQ6rS78XVsvmp5d2FBlhJ5Ukdj3Hv6VefzDt2FR83O4ZyO+K4HW7e4k0eU6Yxi1FIyYZzJwXHT6YI6VqeC9dfxN4ZsNXtl8qac7Zo5DwpAweBx6Gs5Q05kROlyrmWx1KP5jDYwwp+Yf56GuBurNLbVdS8PIot5dWEl2t2jBDnPAJ689O/f2rsh9linSSaWMXIBUtuwTn+Z4/CqPifTdE8Q6TJBrSwSW6fOshba0TdnVuqkYPIog+V6hTlyu3RnLDVdeMMOlNCtnPbFSbqQhw21wu3rlmK5bOAOCOtdTrk1vpuqRazdpKEt4HiLRnIZCVJyPUYGPxrz/QobSfxBDDba5LrciRz/AGW+iB820RVXeJM8SEnYqnrya6iHWrPWtCtHFvMbe8OyOOdNjRfL8yunoCp/CtZR1N5QV12My1uLjw5a6jq11BDPIbkXpe0biWCTjcVPTCqB9VrrNWt5NV/s7UtO1EpbRfvQoIEcin+JvoO1Y+mWOl3t7q15YiTzTHFaTWjD5B5ZYjbnqCGYU7w9qJtWUbFhtWfZLAASIvRl/wBkjr2HNTLXVbhL3tVujfgcW2nsdPtomLBmc2uFTzO/HvXGxS23h7SdsIvLy2klDGMb53dnJX5QOnU89a3/ABvBJDouoT291LbxvbeUoiIGyTdlHXPAJPy/lWNYaZrFxPZ6hNdlLJfJa1trc7JiSoLpO2cE5z90/Tg4oja12x07ct31N6x1No5YbGWa1lAmaB1Ck4UKSEBz8xUDkmoZLTTNQtFa1tLe2NwxcxTQgCQd2bHQ4BwT+VY3h2O30fxfqdk2hvEWtg6X7OMSknPkqBwo6nqd3OelPu7K1tNQjvILG8l1GZvLjsbRhIGXHV2bCKB1yePqaLK+g+VJ6DbnQJpjLqnhzUL77ShWKHfIPISNWG4LGdoDZBG7mul+z3LvLe6lILZZcAW0ADscAfefoScdhx61nSXVzb2kTajeQ2yHpZ248498hn4yc5yAAPrSS6tJrNneQ2MM0bW0gictH5XymMMNufvA56D0xSbbGlJtdjOuNLgGk39pJqM0zybkFw6Bn6g7cA/Njn5sgZJxxU+o+JZbnVoYbWHM2xmjjCb32YwzNz93tmm2s1hpkZk1a4jMa/IxZWAQnvkct6elWLS0t57SfUb6606OEkRw3MLNsMechcE5HzdRz0p+ps+WD1VyCTTJHls757/YpIlnATzGbgfIGzg59e2BWvpcSOst7cJKFLExRj7nQ549sDk0krvf6cYtP1ATzXLD94BlRg5ZQcYGQP0pmoWrW15ZfZ5VLINtxEA2NpHLKDxwecdTU3voyefmVm/+GIE07U3tlW8lh+0ofOS4iHloFPYjkZHGeO9K4sfEFhxNBcJbPiVInxGrg4YNkAkH0PrV691G1g+xwG5SR5gYWMiffwM8L6854qw9uWEciwBI9yP8iqoc+m3v+NK/ci76lK2nl1cSrAIbZoZB5a7AweNDgrn+E5wMjtSC6j02Ce81SRWlXCANwiEkjHv2596sTzyWkaTrazyyxMzSpEmx2B6nn730Hpx6Vi6xbrcXFpqF7Gv2eEPKwDMjncoKOpBw+OQRj0PamrNjVm7dCvosdr/a885hnjt3gS4aMvhSzHkovUrgde3SrGi67b39nPNbvLFo13G8drKQGUclScAZHORjNM1291OGXRrnRrJtYljZUkLQYMcUgPIPHOVG7rx2FazQ3Wj3mmi2to7fRfKb7TbxKrYmI4HTPJxyCBx71T13B2e5l6hqdxpt3bae+q2dnfNtD20ULCOUEfNIpwSpAOQDxkDrWlI88UFvEYvPb5VYzsFMg4ycheuM/X2pmlywybJ5IysbQgzQlcyrj+/gn6kZq0JIo5hJBfBBCPl83ldpx8vrUsdkuhDPd6XNr0VpaK0t55WDDEgHlqc5LP26dByeKhNla6bo1vaWUxkjkucRyX0mTJI5IK9OeCcfSq3huWGS5v7S11G71AyzGRoJEX/Ro+yFurDPKt1x+NXZbSz1aO3Mvk3F2kkiRTb8tCCpDFUHcDjp70PR2FqtG/6/r+mZs2nwWN3ayxNBLZQnBhiy+7kjGT1HUYrF/t/TLzV9S8J2eog6lbJtQ3UZdAcD5CRgHYpIx6gVd1m5tPCGmW1hZW7z/Z54rKHZIN37w/dxj1boP5U7QfBy6VayT+ZHFeqJT9tWMFtpOQrlsng85z2q1ZK7+Rq2uW8mamlW0+j6xYRR3MkqPbZmhXChgSP3hj7MWOBg+uelHiW2XSrO+8RKZbeYrsZZF3CNSyjdtXOTwPXGTV+K/tNG0xtV1qSL7YIQk1yq/eQH5fwyf1q3BLd291fyXN5HcxylBHCcKlv8vTPU5yDzWd3e/wDTMeZ3v/TObe7n03Wpo9SW7W0ukjitZMZXzCATkdRgkDPTkiuh8Yatd6XZwjT4DNdzuERQhYfTj19ciuN1zxPpEOvQweINYQxRXKyxyEeWqYGfKOOvIByfat+TxLeanp3m6PDDbSXCloDqMnktIoYg4AyQMcg+9VKL0bQ2rtNozbS4vLfxb4hs5g88LJb3UEW7CrIVKtHvxyAwzkevNal5fawbjT7GK1Jso08y9uLhSWkCkAIoGeTzyewpuk34mvvsk4SO4hgjknVMlFDdAhxycg+/etmG/M13fW9xDJDb2rIkZ/57BgCGBz06ipk9dhysmtDn/FB0y516PVZZ763n0JDIdqkRXCsMhf8Aaxjt61ch0iR9XkvPtNzE8yJPLCoGG4bKqD0AJGfWq9tZjxLfg3cc6aTptxvHmcLdSr0YHqUQjvwT9K6mZLW9C5kV3HzIyP8AMPXBBpOVrIlz5UonC+H9VvNW1ZhNMlsLdhKoZHQtGCQA3YEk/dxV5LOPR7K206zgkvItSncTov31VizMdzNwOT1q1daZrumy3VzpNxBqQcjyrW7cw+WuMEBwDn15Fc6tt4oPiyzluNJS1tZI2EflTI6wNtwVLdefp3x2qtHqnoWmpPR/1+Z0kt8NO1iysYRFaxRWpVInU7AAQBhh3GPyrnNA12/vvC3iizlhmgktp3srS5kGwv5meMZ+8pJ5HUYqHxnqc+lX9jqckVzcypE0L6akRYysVJ5OMAAknPvVmSeHUE0bw9flE1xE+2m1iyVim6gkn+4Gzg9TiqUfdTsPk01W/wDT/Av6Xby6JYwWsss9xMVk3zpCSI1A7n+8QCBn8Kn0Ux3viKzv7JJoI1heOSGX5W6DGfyzVa1Gn6Vf2Uaajcy6pEJfNiaRnM+fvM/YKD04xwMVY0Z7y4kurexukW4jkzK10pY4xwqrkHZyeQetQ+4m9Gzd8WyrHos7FismMR4XPzHgf/rritC1q5ltntWmeXUdoYvOCQgPQflWjf615msXGj3qL9nAEsN0pLrG2QNrd9pORntXPWd/JH4kns5oUN2z7m2jqvQEHOMAdqqEfddwpQsrP1NLT9Ki0/xzps2vX7y3V0rjToUVjHwMtuPQdeBXe7rz+9bf98N/jUWnvF/ZkIMixeXwS2Mqfx+tJ5dx/wA/Vv8A98ispycjmqScnr0MfRbtJdYu/Ob975YcBhjC/wCcViWN3ZW3inUmlimluFnV1nt7dUV0K8bmz87AcZ4OMdqvQxWwmEqRgTKQZP4iwPOB6DHGTVSGFk1u+vWhjTTy4KTR/MzsowAB0JzxitlbUlJXfoZVrZPqfiKJ9O0xrGw1EvJcSyy/vopUYEFUBxhlzu+uOvFeiaVpVjpFktnp1tFb2wYsI41wCT1P1qjYxrp1u93drm+uDnaSNwHZfYDuemfwrPn8Www6k9jHJDc30RKS28SsNj7dwHmfdJx2OMHripk5T0XQmpzVNI7GB8RtO1J9V02e1LrZoWedl4HGDz36enNGgMNVhN5cRkFgUhiBLIT3bB7kcc9hXTLr8Etoh1e0mtBIpLZ+dE57sOM81kW+/R7i7a9vZ57G5lElpJEuViTaAyZA6ZGeeetWpPl5WjenN8vK1qhui2MGmaVBbyQJG7T5cxMPMCs3AXkcE5JP86uh5G1ZBLb7n8+SO2GeFRVK7yT2OfrzUsMtjPcCTyLATj93FOIQzJF7HOSQae+r3V1fLBc6feWVmEILPErCQ9sEHp7fnUttsl8zbKhsZdIuL5tYvku7IxmaLzcCaNs88gDIxx60us63Y2ul2t9fb0tp5fKSQxlymTj5iOeoIz71TltL2+a/W5gtdNZ1EUFxEd874bqWI+UFSQQP0rZTQ4ZbZIL9ke1iUMqxMecHjPqMdjTbS1kPSOsmSWd7bxTw6PfFZLe8BW0Mg3BsDPln3ABIz1A9qvxadaz2CW1xIZoSMxhXKFAD1UgggjI5Fch46Ag8J31zZzK0loyTW7RkNsZXBXBHfGa6651Ky07Q31O6aQ2sirMdo3MA+3hR16kce9Q09GiZrROPU8r8O6fd3XxkjtJLG50+w0S32pbs5kjcEHa+8nLkkk5PrzzXq+pKYJYpLaLE5UqkxGVUn1Ue34VU01tQs9Mkk1pLdr5PNEXkBnUR7jsyxAOSNuR0qqmr6hHa2kmpJBiYkPGinO3jlc9RgmqnJzd+2hetSV4mQLRLa48tpDJfE+Y00mMlj0GQcdR07fStGxguLazn+2SZumR2Uw/vJI93GQ2ccHn+VZoREMkUPmB8lguzJ2ngZbPpVXVA76Xesn2iVYrdyI7IlpguOfLA5Lc8D1p7nY43Vmy1qN1PDoV3aPqwtTNBuiv5Ill+zdf3m09fTB571enhhu9LEN3suLMIJNh67gucjjPOc/Q4qKO30GCPT9L2y313HaLC7XeWYrjrNgY3cHJ65q/fiC1SJnlwFxHH5SD5ucBR9Mgd6VzBNO1lYr6pMottGgsSLCzl2lba3i2vuJ+UHB+QAkn+dPuLqVp7S5kuJZbW2Q/aLYg5cEHEgI4PUcH86dNoNwShtbWNAGXK3D53DPzZI9e1SXKQ26ytbQzwNuHnQ790eOnHPH4UrroO0HZLUY1xFEUu7RttvL8yI0YLc43Adx0B4NVJtcne9sfs121tFNK8QtLmDLMByXVwflAAwAferV9DJdaNbWOlbBZyyGK4wDGcHPKMDwc1IL82RulkAeSKA4iKgbm4wq+386FYlRv0uyvqdks97a6pLezQi1JijkMmEMhJy+zPzHHAB49qoefLbSIYvD97fFWXy5p26MWALlSeExz07dOa122y2UVzIkztId8LzxrviA67v8ar6fLcW2sCBZvNlk3SBAOnHALHnpgY6d6aeg7aDdNkuoJNYtvD2lyoRKxtpbpv3JbPzYB5CnnkDFai6jbX+lRzTRtBeMglkh3MfKOQCCw7ZGPfms7wjqeo29m8+tm4ZryRnt4JlRHgAJBiyMbgCCQfQ03W7a/ewkm0hhHcyyghZs7GUsC68dRgZzSa1sxct5ampeLdWq28eiafZQxPGT5zyBMHrtAAycjnNSS3VrZWmJPs93MoKzYCgZJ7noBnjmq7yoIZYpr0273BAgjkdVDY/hAPJ6dB6UltJdvFHLfRRMzM0aoMLGwPAbgHggZwSfwqSbdylemw0i1e9F1b2cAbzJpLaA5VwcBeP4efz571R0i4sdSmt9e03y3KfvJGWbbiMn5nMYHB4ZcDritbU9QaOx86w00XssQKzW0RC+YOhXDcbenX8KpPbXOn2E2pSWUcPiCW32G1gb9xxwqq3GP59eKpbeZaGX+maZNq9xq1mqy3ES/aoCW2qruoG/njpk57e1WDZWet3NreLcky237p4omOxkwS25ejAg9R9KhtL64ik1KJI0aHy4ihWPcoOWBiJ9Pw6Zq4t9b6cYXtPKuhuVrmUMmYFI3MMADAA2/KOeR1obfQck1oc1rHiXwna68LXWkjSW3CxpE+4xLkZC7QMbiOmRUPjK78U3uoWTeC9MUER7/tDyDyFJ4AZT1OP0FXfDk+k32ratrt7plxPeSOCJ5rbYggyfKVC33z8v5+ldVHeaXPYmYST6XhS5L/ALshR/Ee2OKpy5GrL7wbS3R5F4f+Ha6f4zW48RTpql7IomZpoTiJj1YDOCcjp716lZ6b/auoS3GqaTKoti0dvHMUxg53MCCevHB/Tmq1rJJcOtxol1pmrQof3hVwZVB7j0z6d6uTXOpTPLDAIIoCuyDZuDh9vO8dueaVScpPXccpN/CTLqcbqLaaJbeJGCebOoiEjcgJHnqenzDiqdjdajeXcsV5aLalVENtht7SAH759ABmsa6Cxanp93q8LajcoSllaWbNcZb+85xgYP8AEeBXSarqz6DoMuralAr37KIora3G7Ln7sY985yfb2qWraLqZ/DsR69bzJd6ZaWEqWdhaA3Mq87ZEUglSB175HvmobmOz1K1827jDRmTzDdQv5TR5O1dp4I54OfxqloL6pdyTW+v38dxqsBWQRRQgLAW7B+4GQD2PvWnBar/Zj2uqtbq1y3lNGcKhGc8diTgmh6aB8K3L8F7BbQXEc8vmm32jkYZ8jK59/wCozWJfnXTqn7nVLO3tGHmC1hj3Pz0LP7n0qvZaZfXmj6/JqOxGkudlsy87YUwoP1wDzVXVbVdMu9VsZJ47W21FIYLS6jJMxOMEE9APf3ojFJ6Maik/MsjU9eeO4hvfN0zkJDcRbZg5Y4BXIzk+9Yg8LyRXF7PYyyvr8sTWYeUbVKty24dM9ywroNC/tqPUbmyvBbzn5Xtnj+eOFVOMM3XOMdua1tQ1Oy0S9UalcRFp49nmyyDc79kCjoDz2quZxdolcyjolucN4a8OXmmamt7O8t48x23sryczAcKu70TAwBgcV2N1paXkt02pTebbsg2tBlGxxwXHfIPSrmm20dvbhmlkNpIA0m9hsV1x9zuAT/KmalFHcW7RCV0gjjLEg7WPBwSPx/LNRKblK7JlUu9NDlNa8PWZ1O2aITrazwfYYI4idgZjuDE57YJz61R+GXg3XdMubyTXcxyFysbyOJCyjOMYPHbpXRvqUOk+GrP7PDLeQRTJtngjzhd2ehOeBkc11ySxXDRYD5dBKpwRxwRmqdSajy9AlVnBWR5lrVw+lLLdXrNcfPtSFF5U5wfbGP5Vf+12v/PGH/vmpNVtpNLt79pbYXV1Nceagc4Rl354PY49Kq/bLv8A58T/AN8f/Wq7cyKUm1czbMyST3tqZpBA0MczKD1ZmBY5689PpW34c02K0vbS0hluPstvLKyRNIWU5O4Zz1wTwev1ooqqjaRi0uV/10Oo1KNXktc8CVhC49VPOPzFcppug2rrqS+ZOEvXUMquAE2gnKDHBOeTzmiis4Oy0M6P8P7vzIrTUru31+K2imK2xjTdFgYftycZ/WuzsFEd/JEgAjlQTMvbcTyaKKKq29B1klt2H3+hadenMtuEkHSSEmNx/wACXBqv/wAI1beajG81IrGuBH9rYIfcgUUVF2RCTa1ZzupXFxo+vx2STNdWsq79lyFbYc9iADj65qHw9dXd7JcfarqR4wblDFtQKVAYAHC5wBjv2ooray5bnQ0rP+uhyVrqczeANS8tY4RbXDQRiMEDaAvXJ5PzGvXYbaFNCggMavFFboFVxnoBj+VFFTX2+f8AkTXdor1ZV1L/AETTJxbl0+yyDZiRsnOCcnPP3jVEStqFpfNcBf8AQZWEIUYwOmD7UUVnEVPoyBJPtl+9tcIjK9kbl3C4Z2UjaCR1XnOPzrL8FanPf6HPcziISxhwPLjCA4fb0GOx7cUUVaXuv5Gr2aOhijitPPaCGJfkU425BJHU/nVSfc0cR8xwYpRKpBxg5z+We1FFTHccdU7mOniHVL74heItEmuiNOggt/KjRQpjLjLMGAznjua7aHR7MmSJ0Z1B4y59AT096KKdbS1uy/Qzm+WK5dDnbtGWyvEglmgUPt/dOVJGQvX/AIFn6ir2rqrTRWLAmH7CHdtxDyYZAAzA5I5P50UU3si57ozLieSHxYtjE7i3lL5UsWxjb03E4+8eOlWreAQ38V1EzpLIgU4PAGccfkKKKO3oWtine3jzeM9S0+RIzDBFBLG2CGUuzK2OcdFHb1qxr0slkWS2cpHDMQF6hhtBwfx9MUUU0tV6Ep6f15Gvb6Rp9zqcGoT2dvJdwFkjkaMEqNoPBI4P0pb63jtNFsYbQGGNbiNMKSdy7uVJOSQaKKz6mMm+axnzyl9f02zkVWg1NbmOfjBwiAjaRjFQSWfm2zWa3NzHBY3gSHbJltqrnaWOSQc4OeaKKtGsNZakuk30tsn7pYx5xBb5e/HIrF1i2jguJtKsh9kt7h5LmV4uXeY9ZCWzk9OvHA44oooh8Rol+8Kvgi8l8V+Dra31rExtbpYUlXKuQHC7ic43YJ5xXa6bZ299p92LiJW2F4R15UDGDng/jRRSq6SaXcio7Sdu5wlx4f06O+ttQ0+A6dfi3INxZsUZgoAUEcrwOOlQ+D9UvTdvp15cSXsEluj5uDll3DJAK445xg0UVstabbN5/wAJy6/8E9QtbK30zSD9hiWHbHv+XuQM4+n+NYHjq4kfRdOkyFZ7hc4AOPlPTNFFctPWSOODvNN9yDw/odpo+qW1ratM0dpAIY2lkLsU3k7STyQNxxn29KxxCl5qWpW93umhhmmljRmOEIc4x9P60UVsm9Wb/b+X6nQeP9RuPD/g5bnS2WKYMqZKhhggk8HjJrE+GF43irSrXUNSijW48oq3k7lVgHPBBJx68Y/LiiilZKlfzMo/C36koubnUfiDd+H0uJLHTLaISbLPEbSkjPzvgn8iK2k8O6XNdtqk9qstzE2xA/zICoIDbT/FjvRRSqO1rdjTaCa3t+ovimeS00uCWMglpPLwQMAfQVcht45UEzA5ls9rqDgNjpn/AL6NFFZv4UY9CjpG2W6SxKKLQMZPLHQkevcjPNbWtXD2liZogu/Kg7hkEHtRRRLcVX4kSvaw3FqkE6LLE/3lcZB4rN/4RbRf+fBP++m/xooqU2jn55R2Z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is increased cellularity of the villi with sclerosis of the villi due to collapse of the villous vessels and clumping of the involved villi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37958=[""].join("\n");
var outline_f37_4_37958=null;
var title_f37_4_37959="Computer calculation of LV mass";
var content_f37_4_37959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58732%7ECARD%2F61196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58732%7ECARD%2F61196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Computer calculation of an estimate of left ventricular mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 144px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Only four simple measurements on the 2D echocardiogram&nbsp;are required&nbsp;for&nbsp;computer&nbsp;calculation of&nbsp;an estimate of left ventricular (LV) mass. The first two measurements are of the areas subtended by the epicardium and endocardium (A1 and A2), the third of the semimajor axis a, and the fourth, the truncated semimajor axis d.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Short axis views for estimating left ventricular mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These short axis echocardiographic images&nbsp;have been hand digitized to demonstrate the method for outlining the epicardium (left) and the endocardium (right). These measurements are performed in both diastole and systole; since mass changes only 10 to 20 percent during the cardiac cycle (presumably due to myocardial blood volume) obtaining both systolic and diastolic mass estimates&nbsp;can serve as an internal check on accuracy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37959=[""].join("\n");
var outline_f37_4_37959=null;
var title_f37_4_37960="Pathogenic Escherichia coli";
var content_f37_4_37960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenic Escherichia coli",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Christine A Wanke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37960/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/4/37960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escherichia coli are normal inhabitants of the human gastrointestinal tract and are among the bacterial species most frequently isolated from stool cultures. When E. coli strains acquire certain genetic material, they can become pathogenic. E. coli are among the most frequent bacterial causes of diarrhea and are classified by clinical syndrome they produce (",
"    <a class=\"graphic graphic_table graphicRef67152 \" href=\"mobipreview.htm?6/52/6987\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of diarrheal illness caused by enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC, also called Shiga toxin-producing E. coli or STEC), enteroinvasive E. coli (EIEC), and enteroaggregative E. coli (EAEC or EAggEc) will be reviewed here. EHEC is also discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;E. coli can be cultured readily from the stool under aerobic conditions. On selective media, such as MacConkey agar, E. coli usually appear as pink colonies, indicating that the organism ferments lactose (",
"    <a class=\"graphic graphic_picture graphicRef63042 \" href=\"mobipreview.htm?29/21/30046\">",
"     picture 1",
"    </a>",
"    ). Additional biochemical identification should also be performed, since up to 10 percent of E. coli do not ferment lactose or ferment lactose relatively slowly. The most useful biochemical identification test for E. coli is the indole test, which is positive in up to 99 percent of E. coli strains.",
"   </p>",
"   <p>",
"    Pathogenic E. coli are not distinguishable from other strains or from each other by the appearance on culture plates or by the results of the usual biochemical tests. To determine whether the isolated strain is one of the pathogenic strains or merely a constituent of the normal flora, additional identification techniques must be employed, which are generally limited to research laboratory settings.",
"   </p>",
"   <p>",
"    EHEC O157 is the only pathogenic strain that can be identified readily in the clinical laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/2\">",
"     2",
"    </a>",
"    ]. Further testing on pathogenic E. coli isolates must be performed in a research or reference laboratory. This testing can include determining the serotype of the strain, performing biological assays (bioassays) that demonstrate strain virulence, and using genetic tools, such as DNA probing or polymerase chain reaction (PCR) amplification, to identify genetic material that encodes for specific virulence factors.",
"   </p>",
"   <p>",
"    The virulence traits are distinct for each category of pathogenic E. coli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/3\">",
"     3",
"    </a>",
"    ]. These virulence traits include adherence factors that allow E. coli to attach to the intestinal mucosa, and toxins that interrupt normal intestinal cell secretion and absorption (secretory toxins) or that damage the intestinal cell (cytotoxins). These adherence factors and toxins are encoded on accessory genetic elements in E. coli, such as plasmids, transposons, and bacteriophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterotoxigenic E. coli (ETEC) causes watery diarrhea in young humans and other mammals, as well as in older individuals who have not been exposed to the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/4\">",
"     4",
"    </a>",
"    ]. ETEC survive readily in water and food supplies in the developing world and is one of the most common bacterial causes of dehydrating diarrheal illness in children under two years of age in these regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/5\">",
"     5",
"    </a>",
"    ]. These strains can also cause diarrhea in travelers to tropical regions who are exposed to contaminated food and water. In addition, ETEC is emerging as a significant diarrheal pathogen in developed regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of disease due to ETEC consists of transmission of bacteria, intestinal colonization, and elaboration of virulence factor(s). ETEC must contain colonizing fimbriae to permit the attachment of the bacteria to the intestine. Antibodies to fimbrial adhesins, specifically colonization factor antigen I, have been shown to be protective in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    E. coli capable of attaching to the intestine must also be capable of elaborating virulence factors in order to cause disease. There are two major classes of secretory toxins encoded on plasmids in ETEC strains: heat-labile toxins (LT) and heat-stable toxins (ST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/10\">",
"     10",
"    </a>",
"    ]. E. coli that contain one or both of these toxin classes are classified as ETEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LT is a complex family of toxins related to cholera toxin produced by Vibrio cholerae with respect to structure, function and mechanism. LT acts by stimulating adenylate cyclase and increasing intracellular cyclic AMP, which results in secretion of chloride from intestinal crypt cells and inhibition of absorption of sodium chloride at the villus tips. Secretion of free water into the intestinal lumen follows, manifesting clinically as watery diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies suggest that LT and its secretion apparatus can cluster at one end of the bacterial organism, which may permit ETEC to focus toxin delivery to the host intestinal cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two major STs that may be present in ETEC; only one of these, STa, is associated with human disease. ST activates enterocyte cyclic GMP and also leads to the stimulation of chloride secretion and inhibition of sodium chloride absorption. The end result is secretion of free water into the intestinal lumen, which manifests clinically as watery diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10(8) to 10(10) ETEC must be ingested to induce diarrhea in an otherwise healthy individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/1\">",
"     1",
"    </a>",
"    ]. Exposure to this large inoculum occurs readily since the pathogen thrives in the environment. The illness has a short incubation period, and the onset of symptoms and signs is rapid. Patients may report nausea, but vomiting is uncommon. Diarrhea is watery and may be mild or severe. The illness may last for one to five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ETEC is currently performed in the research or reference laboratory using DNA probes that identify the genes for LT or ST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Classically these organisms were identified by bioassays for the secretory toxins: the rabbit ileal loop for LT and the suckling mouse assay for ST.",
"   </p>",
"   <p>",
"    Treatment of diarrheal illness due to ETEC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link&amp;anchor=H11#H11\">",
"     \"Travelers' diarrhea\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENTEROPATHOGENIC ESCHERICHIA COLI (EPEC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteropathogenic E. coli (EPEC) strains are defined by the characteristic &ldquo;attaching and effacing&rdquo; effect they elicit upon interaction with epithelial cells and by the fact that they do not produce Shiga toxin (",
"    <a class=\"graphic graphic_figure graphicRef56217 \" href=\"mobipreview.htm?42/22/43374\">",
"     figure 1",
"    </a>",
"    ). EPEC have been associated with sporadic diarrheal illness and diarrhea outbreaks, most commonly among children less than six months of age in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease due EPEC strains has been described among adults, although overt illness is much less common. This is true even among adults in the developing world who frequently develop diarrhea due to ETEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPEC proteins do not behave like classic toxins; the following observations have furthered our understanding of how bacterial organisms can affect cell physiology through adherence, even in the absence of toxin production. The steps in pathogenesis of EPEC for initiation of diarrheal illness include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial localized adherence of the organisms to the enterocyte",
"     </li>",
"     <li>",
"      Induction of signal transduction in the enterocyte by EPEC protein secretion",
"     </li>",
"     <li>",
"      Development of intimate adherence with the enterocyte",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signal transduction is initiated by bacterial secretion of proteins directly into the enterocyte [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/22\">",
"     22",
"    </a>",
"    ]. This causes mobilization of intracellular calcium, activation of protein kinase C and the myosin-light-chain kinase, and induction of tyrosine phosphorylation of proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/23\">",
"     23",
"    </a>",
"    ]. Activation of these signal transduction pathways produces changes in the enterocyte (resulting in the classic &ldquo;attaching and effacing&rdquo; lesion), alterations in water and electrolyte secretion, and increased permeability of intestinal tight junctions. The genes that encode these virulence traits are located on a plasmid (bundle forming pili) or within a chromosomal pathogenicity island of the organism. Atypical EPEC do not produce bundle forming pili.",
"   </p>",
"   <p>",
"    EspF is a secreted protein that is not involved with attaching and effacing; it appears to disrupt intestinal barrier function by increasing monolayer permeability via alteration of electrical resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/24\">",
"     24",
"    </a>",
"    ]. EspF has several protein-protein interaction domains that may function by interacting with endocytic regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/25\">",
"     25",
"    </a>",
"    ]. Two other secreted proteins, EspG and EspG2, inhibit luminal membrane chloride absorption by decreasing surface expression of the",
"    <span class=\"nowrap\">",
"     Cl-/OH-",
"    </span>",
"    exchanger via disruption of microtubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diarrhea associated with EPEC in children can be severe, with concomitant vomiting and dehydration. If diarrhea persists, malnutrition can be a devastating complication, particularly in the developing world where resources for supportive therapy may be limited. Cell culture data suggest that EPEC infection inhibits absorption of thiamine; this may be one mechanism by which EPEC infection contributes to malnutrition of some micronutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for identification of EPEC is the detection by DNA probe or polymerase chain reaction (PCR) of the EPEC adherence factor (EAF). These diagnostic assays are available only in research or reference laboratories.",
"   </p>",
"   <p>",
"    EPEC was originally categorized and recognized by serotype and later, by its ability to adhere in a localized fashion to epithelial cells in a tissue culture adherence assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Subsequently, it was identified by its ability to mobilize cellular actin in a fluorescent actin staining (FAS) assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/30\">",
"     30",
"    </a>",
"    ]. Using these older techniques, the absence of EHEC toxins also had to be demonstrated in a putative EPEC organism because some strains of EHEC also develop attaching and effacing lesions.",
"   </p>",
"   <p>",
"    Treatment of diarrheal illness due to EPEC is discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5625?source=see_link&amp;anchor=H1159942460#H1159942460\">",
"     \"Approach to the child with acute diarrhea in developing countries\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ENTEROHEMORRHAGIC ESCHERICHIA COLI (EHEC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterohemorrhagic E. coli (EHEC) strains are capable of producing Shiga toxin and like EPEC strains, demonstrate an &ldquo;attaching and effacing&rdquo; lesion (",
"    <a class=\"graphic graphic_figure graphicRef56217 \" href=\"mobipreview.htm?42/22/43374\">",
"     figure 1",
"    </a>",
"    ). A subset of EHEC organisms are serotype O157:H7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. In May 2011, a new Shiga toxin-producing EHEC similar to EAEC 55989 was identified as the cause of an outbreak in Germany and in other countries in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This strain, O104:H4, has the typical plasmid adherence genes of EAEC bacteria as well as Shiga toxin genes seen in EHEC, and has demonstrated aggressive virulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also Shiga toxin-negative O157 strains; in a review of O157 isolates from stool specimens related to sporadic cases of diarrhea, 4 percent were Shiga toxin-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/36\">",
"     36",
"    </a>",
"    ]. These strains were either inherently Shiga toxin-negative and did not cause bloody diarrhea or HUS or were descended from EHEC strains by the loss of Shiga toxin genes. These strains may still cause HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EHEC strains, especially those belonging to serotype O157:H7, have been responsible for large outbreaks of bloody diarrhea, some associated with hemolytic uremic syndrome (HUS), a triad of microangiopathic anemia, renal failure, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EHEC infection is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shiga toxin associated hemolytic uremic syndrome is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ENTEROINVASIVE ESCHERICHIA COLI (EIEC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroinvasive E. coli (EIEC) is closely related to Shigella and causes disease that is similar to shigellosis. EIEC invades the intestinal cell, multiplies intracellularly, and extends into the adjacent intestinal cells. The same genes facilitate pathogenesis of both EIEC and Shigella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/40\">",
"     40",
"    </a>",
"    ]. EIEC may be differentiated from Shigella principally by the fact that EIEC strains ferment glucose and xylose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical EIEC infection appears to be uncommon, although it may be underdiagnosed. Clinical disease with EIEC begins as watery diarrhea and may or may not proceed to bloody diarrhea. The organisms can be detected by DNA probe, although this tool is not routinely available in clinical laboratories.",
"   </p>",
"   <p>",
"    The clinical approach is as outlined separately for Shigella infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=see_link\">",
"     \"Treatment and prevention of Shigella infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ENTEROAGGREGATIVE ESCHERICHIA COLI (EAEC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroaggregative E. coli (EAEC or EAggEc) was first described in the 1980s, when collections of E. coli from studies of diarrhea in the developing world were examined in tissue culture adherence assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/41\">",
"     41",
"    </a>",
"    ]. E. coli that had a distinctive cascading adherence on Hep-2 cells were observed more frequently in the stools of children with diarrhea than children without diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/42\">",
"     42",
"    </a>",
"    ]. There has been a consistent association between persistent diarrhea among children and the presence of EAEC in the stool in studies from Chile, Brazil, Mexico, India, and Bangladesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/43-49\">",
"     43-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EAEC appears to be a cause of acute diarrheal illness among many different subpopulations in both developing and industrialized regions. Surveys of E. coli from diarrhea outbreaks in Europe have demonstrated the presence of EAEC in both outbreaks and sporadic cases of diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. EAEC have also been associated with persistent diarrhea in adults with HIV infection in the United States and Switzerland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In these studies, EAEC diarrhea was more common in patients with advanced immune compromise.",
"   </p>",
"   <p>",
"    In a US prospective study of diarrheal illness among patients and controls, EAEC was observed in 4.5 percent of cases and occurred significantly more frequently among cases than controls; there was no association with travel or immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/54\">",
"     54",
"    </a>",
"    ]. A meta-analysis noted a positive correlation between acute diarrheal illness and EAEC excretion in the following groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children residing in both developing and industrialized regions",
"     </li>",
"     <li>",
"      Adults with HIV infection residing in developing regions",
"     </li>",
"     <li>",
"      Adults residing in developing regions",
"     </li>",
"     <li>",
"      International travelers to developing regions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of diarrhea caused by EAEC is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/42\">",
"     42",
"    </a>",
"    ]. EAEC are capable of inducing the release of interleukin (IL)-8 from Caco-2 human colonic epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/56\">",
"     56",
"    </a>",
"    ]. Investigators have cloned and sequenced a soluble factor from EAEC responsible for IL-8 release and identified it to be a novel flagellin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/57\">",
"     57",
"    </a>",
"    ]. Strains of EAEC that lack this flagellin do not promote IL-8 release, which may be implicated in the induction of chronic intestinal inflammation.",
"   </p>",
"   <p>",
"    A variety of other pathogenetic mechanisms have been postulated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adherence fimbriae",
"      <span class=\"nowrap\">",
"       (AAF/1",
"       <strong>",
"        -",
"       </strong>",
"       AAF/III)",
"      </span>",
"      have been identified, but the majority of EAEC strains do not express these adherence factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/58\">",
"       58",
"      </a>",
"      ]. The genes for these fimbriae are encoded in a virulence plasmid that appears to be present in most EAEC strains regardless of whether or not",
"      <span class=\"nowrap\">",
"       AAF/I",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       AAF/II",
"      </span>",
"      is expressed. The aggR gene encodes a protein labeled dispersin, which acts to disperse the bacteria on the colonic mucosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mucosal destruction has been demonstrated in clinical specimens and in tissue culture assays, and a cytotoxin has been identified in EAEC strains.",
"     </li>",
"     <li>",
"      Other groups have identified EAEC strains that invade tissue culture cells and induce IL-8 production via mitogen activated protein kinase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A \"package\" of plasmid borne and chromosomally mediated virulence factors is thought to be predictive of pathogenesis. It is postulated that this \"package\" is under the control of a transcriptional activator called AggR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/62\">",
"     62",
"    </a>",
"    ]. These virulence factors appear to be associated with the presence of diarrhea in individuals with EAEC strains in the stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/63\">",
"     63",
"    </a>",
"    ]. A newly identified HdaA gene cluster also appears to confer aggregative adherence and may explain the aggregative adherence that has not been associated with the other recognized adhesins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of EAEC is the tissue culture adherence assay. There is no DNA probe that reliably identifies EAEC strains; thus, EAEC can only be diagnosed in research or reference laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated that diarrhea resolved when EAEC was cleared from the stool with antibiotic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In a placebo-controlled trial including 29 patients with EAEC, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    reduced the duration of diarrhea compared to placebo (35 versus 56 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/65\">",
"     65",
"    </a>",
"    ]. In a cross-over trial of 24 HIV-infected patients with EAEC, treatment with ciprofloxacin eradicated the organism from stool and reduced daily stool output by 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37960/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since identification of EAEC requires reference laboratory tools, patients with suspected EAEC infection in the absence of diagnostic confirmation should be managed syndromically as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29976?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5625?source=see_link\">",
"     \"Approach to the child with acute diarrhea in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER ESCHERICHIA COLI STRAINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no good data supporting the association of other types of E. coli (eg, diffusely adherent E. coli, detaching E. coli) with diarrhea. However, since E. coli are ubiquitous and have a demonstrated capacity for acquiring the DNA for virulence traits from other organisms, additional groups of E. coli will probably be associated with diarrheal disease in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/3/20530?source=see_link\">",
"       \"Patient information: Travelers&rsquo; diarrhea (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/63/31730?source=see_link\">",
"       \"Patient information: E. coli (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2830629\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Escherichia coli are normal inhabitants of the human gastrointestinal tract and are among the bacterial species most frequently isolated from stool cultures. When E. coli strains acquire certain genetic material, they can become pathogenic. E. coli are among the most frequent bacterial causes of diarrhea and are classified by clinical syndrome they produce (",
"      <a class=\"graphic graphic_table graphicRef67152 \" href=\"mobipreview.htm?6/52/6987\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      E. coli can be cultured readily from the stool under aerobic conditions. Pathogenic E. coli are not distinguishable from other strains or from each other by their appearance on culture plates or by the results of the usual biochemical tests. To distinguish pathogenic strains from normal flora, additional identification techniques must be employed in a research or reference laboratory. EHEC O157 is the only pathogenic strain that can be identified readily in the clinical laboratory. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enterotoxigenic E. coli (ETEC) causes watery diarrhea. ETEC survives readily in water and food and is one of the most common bacterial causes of dehydrating diarrheal illness in children under two years of age in developing regions. ETEC can also cause diarrhea among travelers to tropical regions who are exposed to contaminated food and water and, in addition, is emerging as a pathogen in developed regions. There are two major classes of secretory toxins encoded on plasmids in ETEC strains: heat-labile toxins (LT) and heat-stable toxins (ST). These toxins activate cyclic AMP or GMP respectively, leading to stimulation of chloride secretion, inhibition of sodium chloride absorption, and secretion of free water into the intestinal lumen, manifesting as watery diarrhea. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Enterotoxigenic Escherichia coli (ETEC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteropathogenic E. coli (EPEC) strains are defined by the characteristic &ldquo;attaching and effacing&rdquo; effect they elicit upon interaction with epithelial cells and by the fact that they do not produce Shiga toxin. EPEC have been associated with sporadic diarrheal illness and diarrhea outbreaks, most commonly among children less than six months of age in developing countries. EPEC proteins do not behave like classic toxins; rather, they affect cell physiology through adherence and induction of signal transduction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enteropathogenic Escherichia coli (EPEC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enterohemorrhagic E. coli (EHEC) strains are capable of producing Shiga toxin and like EPEC strains, demonstrate an &ldquo;attaching and effacing&rdquo; lesion. A subset of EHEC organisms are serotype O157:H7. EHEC strains, especially those belonging to serotypes O157:H7 (and subsequently, O104:H4) have been responsible for large outbreaks of bloody diarrhea, some associated with hemolytic uremic syndrome. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Enterohemorrhagic Escherichia coli (EHEC)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"       \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteroinvasive E. coli (EIEC) is closely related to Shigella and causes disease that is similar to shigellosis. EIEC invades the intestinal cell, multiplies intracellularly, and extends into the adjacent intestinal cells. The same genes facilitate pathogenesis of both EIEC and Shigella. Clinical disease with EIEC begins as watery diarrhea and may or may not progress to bloody diarrhea. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Enteroinvasive Escherichia coli (EIEC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteroaggregative E. coli (EAEC) was first described in the 1980s, when collections of E. coli from studies of diarrhea in developing world settings were examined in tissue culture adherence assays. E. coli that had a distinctive cascading adherence on Hep-2 cells were observed more frequently in the stools of children with diarrhea than children without diarrhea. EAEC appears to be a cause of persistent and acute diarrheal illness among many demographic groups in both developing and developed regions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Enteroaggregative Escherichia coli (EAEC)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/1\">",
"      Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/2\">",
"      March SB, Ratnam S. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol 1986; 23:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/3\">",
"      Cassels FJ, Wolf MK. Colonization factors of diarrheagenic E. coli and their intestinal receptors. J Ind Microbiol 1995; 15:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/4\">",
"      Black RE, Merson MH, Rowe B, et al. Enterotoxigenic Escherichia coli diarrhoea: acquired immunity and transmission in an endemic area. Bull World Health Organ 1981; 59:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/5\">",
"      Black RE, Brown KH, Becker S, et al. Contamination of weaning foods and transmission of enterotoxigenic Escherichia coli diarrhoea in children in rural Bangladesh. Trans R Soc Trop Med Hyg 1982; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/6\">",
"      Beatty ME, Adcock PM, Smith SW, et al. Epidemic diarrhea due to enterotoxigenic Escherichia coli. Clin Infect Dis 2006; 42:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/7\">",
"      Devasia RA, Jones TF, Ward J, et al. Endemically acquired foodborne outbreak of enterotoxin-producing Escherichia coli serotype O169:H41. Am J Med 2006; 119:168.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/8\">",
"      Yoder JS, Cesario S, Plotkin V, et al. Outbreak of enterotoxigenic Escherichia coli infection with an unusually long duration of illness. Clin Infect Dis 2006; 42:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/9\">",
"      Alves AM, L&aacute;saro MO, Pyrrho AS, et al. Antibody response in mice immunized with a plasmid DNA encoding the colonization factor antigen I of enterotoxigenic Escherichia coli. FEMS Immunol Med Microbiol 1999; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/10\">",
"      Evans DG, Evans DJ Jr, Pierce NF. Differences in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins of Escherichia coli. Infect Immun 1973; 7:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/11\">",
"      Levine MM, Caplan ES, Waterman D, et al. Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun 1977; 17:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/12\">",
"      Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 1996; 60:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/13\">",
"      Dorsey FC, Fischer JF, Fleckenstein JM. Directed delivery of heat-labile enterotoxin by enterotoxigenic Escherichia coli. Cell Microbiol 2006; 8:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/14\">",
"      Moseley SL, Echeverria P, Seriwatana J, et al. Identification of enterotoxigenic Escherichia coli by colony hybridization using three enterotoxin gene probes. J Infect Dis 1982; 145:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/15\">",
"      Begaud E, Germani Y. Detection of enterotoxigenic Escherichia coli in faecal specimens by acetylaminofluorene-labelled DNA probes. Res Microbiol 1992; 143:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/16\">",
"      Rothbaum R, McAdams AJ, Giannella R, Partin JC. A clinicopathologic study of enterocyte-adherent Escherichia coli: a cause of protracted diarrhea in infants. Gastroenterology 1982; 83:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/17\">",
"      Ulshen MH, Rollo JL. Pathogenesis of escherichia coli gastroenteritis in man--another mechanism. N Engl J Med 1980; 302:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/18\">",
"      Donnenberg MS, Calderwood SB, Donohue-Rolfe A, et al. Construction and analysis of TnphoA mutants of enteropathogenic Escherichia coli unable to invade HEp-2 cells. Infect Immun 1990; 58:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/19\">",
"      Donnenberg MS, Tzipori S, McKee ML, et al. The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. J Clin Invest 1993; 92:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/20\">",
"      Dytoc M, Fedorko L, Sherman PM. Signal transduction in human epithelial cells infected with attaching and effacing Escherichia coli in vitro. Gastroenterology 1994; 106:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/21\">",
"      Finlay BB, Rosenshine I, Donnenberg MS, Kaper JB. Cytoskeletal composition of attaching and effacing lesions associated with enteropathogenic Escherichia coli adherence to HeLa cells. Infect Immun 1992; 60:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/22\">",
"      Rabinowitz RP, Lai LC, Jarvis K, et al. Attaching and effacing of host cells by enteropathogenic Escherichia coli in the absence of detectable tyrosine kinase mediated signal transduction. Microb Pathog 1996; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/23\">",
"      Rosenshine I, Donnenberg MS, Kaper JB, Finlay BB. Signal transduction between enteropathogenic Escherichia coli (EPEC) and epithelial cells: EPEC induces tyrosine phosphorylation of host cell proteins to initiate cytoskeletal rearrangement and bacterial uptake. EMBO J 1992; 11:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/24\">",
"      McNamara BP, Koutsouris A, O'Connell CB, et al. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest 2001; 107:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/25\">",
"      Weflen AW, Alto NM, Hecht GA. Tight junctions and enteropathogenic E. coli. Ann N Y Acad Sci 2009; 1165:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/26\">",
"      Gill RK, Borthakur A, Hodges K, et al. Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli. J Clin Invest 2007; 117:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/27\">",
"      Ashokkumar B, Kumar JS, Hecht GA, Said HM. Enteropathogenic Escherichia coli inhibits intestinal vitamin B1 (thiamin) uptake: studies with human-derived intestinal epithelial Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 2009; 297:G825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/28\">",
"      Scaletsky IC, Silva ML, Trabulsi LR. Distinctive patterns of adherence of enteropathogenic Escherichia coli to HeLa cells. Infect Immun 1984; 45:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/29\">",
"      Baldini MM, Nataro JP, Kaper JB. Localization of a determinant for HEp-2 adherence by enteropathogenic Escherichia coli. Infect Immun 1986; 52:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/30\">",
"      Knutton S, Baldwin T, Williams PH, McNeish AS. Actin accumulation at sites of bacterial adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic Escherichia coli. Infect Immun 1989; 57:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/31\">",
"      Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis 2006; 43:1587.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.rki.de/EN/Home/homepage__node.html (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/media/releases/2011/s0601_ecoligermany.html?s_cid=2011_s0601_ecoligermany (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/34\">",
"      Rasko DA, Webster DR, Sahl JW, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/35\">",
"      Rohde H, Qin J, Cui Y, et al. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med 2011; 365:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/36\">",
"      Friedrich AW, Zhang W, Bielaszewska M, et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/37\">",
"      Mellmann A, Bielaszewska M, Zimmerhackl LB, et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis 2005; 41:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/38\">",
"      Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/39\">",
"      Karmali MA, Petric M, Lim C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/40\">",
"      Tulloch EF Jr, Ryan KJ, Formal SB, Franklin FA. Invasive enteropathic Escherichia coli dysentery. An outbreak in 28 adults. Ann Intern Med 1973; 79:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/41\">",
"      Nataro JP, Kaper JB, Robins-Browne R, et al. Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J 1987; 6:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/42\">",
"      Vial PA, Robins-Browne R, Lior H, et al. Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis 1988; 158:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/43\">",
"      Bhan MK, Khoshoo V, Sommerfelt H, et al. Enteroaggregative Escherichia coli and Salmonella associated with nondysenteric persistent diarrhea. Pediatr Infect Dis J 1989; 8:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/44\">",
"      Bhan MK, Raj P, Levine MM, et al. Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis 1989; 159:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/45\">",
"      Bhatnagar S, Bhan MK, Sommerfelt H, et al. Enteroaggregative Escherichia coli may be a new pathogen causing acute and persistent diarrhea. Scand J Infect Dis 1993; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/46\">",
"      Cravioto A, Reyes RE, Ortega R, et al. Prospective study of diarrhoeal disease in a cohort of rural Mexican children: incidence and isolated pathogens during the first two years of life. Epidemiol Infect 1988; 101:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/47\">",
"      Gunzburg ST, Chang BJ, Elliott SJ, et al. Diffuse and enteroaggregative patterns of adherence of enteric Escherichia coli isolated from aboriginal children from the Kimberley region of Western Australia. J Infect Dis 1993; 167:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/48\">",
"      Henry FJ, Udoy AS, Wanke CA, Aziz KM. Epidemiology of persistent diarrhea and etiologic agents in Mirzapur, Bangladesh. Acta Paediatr Suppl 1992; 381:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/49\">",
"      Wanke CA, Schorling JB, Barrett LJ, et al. Potential role of adherence traits of Escherichia coli in persistent diarrhea in an urban Brazilian slum. Pediatr Infect Dis J 1991; 10:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/50\">",
"      Scotland SM, Smith HR, Cheasty T, et al. Use of gene probes and adhesion tests to characterise Escherichia coli belonging to enteropathogenic serogroups isolated in the United Kingdom. J Med Microbiol 1996; 44:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/51\">",
"      Cobelji�� M, Miljkovi��-Selimovi�� B, Paunovi��-Todosijevi�� D, et al. Enteroaggregative Escherichia coli associated with an outbreak of diarrhoea in a neonatal nursery ward. Epidemiol Infect 1996; 117:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/52\">",
"      Mayer HB, Wanke CA. Enteroaggregative Escherichia coli as a possible cause of diarrhea in an HIV-infected patient. N Engl J Med 1995; 332:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/53\">",
"      Wanke CA, Mayer H, Weber R, et al. Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. J Infect Dis 1998; 178:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/54\">",
"      Nataro JP, Mai V, Johnson J, et al. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect Dis 2006; 43:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/55\">",
"      Huang DB, Nataro JP, DuPont HL, et al. Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis 2006; 43:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/56\">",
"      Steiner TS, Lima AA, Nataro JP, Guerrant RL. Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells. J Infect Dis 1998; 177:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/57\">",
"      Steiner TS, Nataro JP, Poteet-Smith CE, et al. Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J Clin Invest 2000; 105:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/58\">",
"      Nataro JP, Deng Y, Cookson S, et al. Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis 1995; 171:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/59\">",
"      Sheikh J, Czeczulin JR, Harrington S, et al. A novel dispersin protein in enteroaggregative Escherichia coli. J Clin Invest 2002; 110:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/60\">",
"      Benjamin P, Federman M, Wanke CA. Characterization of an invasive phenotype associated with enteroaggregative Escherichia coli. Infect Immun 1995; 63:3417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/61\">",
"      Khan K, Konar M, Goyal A, Ghosh S. Enteroaggregative Escherichia coli infection induces IL-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in INT-407 cells. Mol Cell Biochem 2010; 337:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/62\">",
"      Nataro JP. Enteroaggregative Escherichia coli pathogenesis. Curr Opin Gastroenterol 2005; 21:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/63\">",
"      Jiang ZD, Greenberg D, Nataro JP, et al. Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol 2002; 40:4185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/64\">",
"      Boisen N, Struve C, Scheutz F, et al. New adhesin of enteroaggregative Escherichia coli related to the Afa/Dr/AAF family. Infect Immun 2008; 76:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/65\">",
"      Glandt M, Adachi JA, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin Infect Dis 1999; 29:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37960/abstract/66\">",
"      Wanke CA, Gerrior J, Blais V, et al. Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J Infect Dis 1998; 178:1369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2720 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37960=[""].join("\n");
var outline_f37_4_37960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2830629\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENTEROPATHOGENIC ESCHERICHIA COLI (EPEC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ENTEROHEMORRHAGIC ESCHERICHIA COLI (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ENTEROINVASIVE ESCHERICHIA COLI (EIEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ENTEROAGGREGATIVE ESCHERICHIA COLI (EAEC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER ESCHERICHIA COLI STRAINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2830629\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2720|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/22/43374\" title=\"figure 1\">",
"      Relationship between EPEC and STEC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2720|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/21/30046\" title=\"picture 1\">",
"      MacConkey agar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/52/6987\" title=\"table 1\">",
"      E coli diarrhea syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29976?source=related_link\">",
"      Approach to the adult with acute diarrhea in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5625?source=related_link\">",
"      Approach to the child with acute diarrhea in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=related_link\">",
"      Pathogenesis of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/63/31730?source=related_link\">",
"      Patient information: E. coli (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/3/20530?source=related_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39334?source=related_link\">",
"      Treatment and prevention of Shigella infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37961="Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer";
var content_f37_4_37961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Harold Burstein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37961/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/4/37961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is a global health problem and the most common cancer in both the developed and developing world. The lifetime probability of developing breast cancer is one in six overall (one in eight for invasive disease). It is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behaviors and responses to therapy.",
"   </p>",
"   <p>",
"    The use of adjuvant systemic therapy is responsible, at least in part, for the reduction in cause-specific mortality from breast cancer seen in almost every Western nation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/1\">",
"     1",
"    </a>",
"    ]. Whether tumors are estrogen (ER) or progesterone (PR) receptor positive or negative, the choice of agents used as adjuvant chemotherapy (ie, the administration of cytotoxic treatment following primary surgery) is the same. Treatment directed against the human epidermal growth factor receptor 2 (HER2) is incorporated for those patients with HER2 overexpression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the role of chemotherapy in the adjuvant treatment of early stage breast cancer, how to estimate the benefit and risk of chemotherapy, the indications for adjuvant chemotherapy, and the dosing and timing of treatment. Adjuvant medical therapy for patients with early stage HER2-positive breast cancer, adjuvant endocrine therapy, the treatment of male breast cancer, and breast cancer in older patients are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link\">",
"       \"Breast cancer in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34826?source=see_link\">",
"       \"Adjuvant systemic therapy for older women with early stage breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17650?source=see_link\">",
"       \"Treatment protocols for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other topics related to the topic of breast cancer are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115555550\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to use adjuvant medical therapy for human epidermal growth factor receptor 2 (HER2) negative breast cancer takes into account tumor histology, expression of estrogen (ER)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone (PR) receptors, tumor size, and nodal status. However, genomic analysis and benefit-risk calculators are also being employed to help determine appropriate candidates for adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    The following describes the role these factors play in determining appropriate candidates for adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71308074\">",
"    <span class=\"h2\">",
"     Tumor histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast can give rise to various histologic types of cancer. Among them are favorable histologies including both tubular and mucinous (colloid) carcinomas. Patients diagnosed with pure tubular or mucinous (colloid) breast cancer have an excellent prognosis following surgical treatment. Therefore, in the absence of pathologic node involvement, we suggest not administering chemotherapy. In the presence of pathologically involved lymph nodes, a decision regarding the use of adjuvant chemotherapy is based on other factors discussed below. The role of chemotherapy for other histologic types of breast cancer is based on other factors such as node status and tumor size, among others. A more detailed discussion on the pathology of breast cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71308103\">",
"    <span class=\"h2\">",
"     Tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with node-negative breast cancer, tumor size is a known independent prognostic factor for patients with newly diagnosed breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. According to statistics from the American Cancer Society, the five-year relative survival based on tumor size alone is 95, 82, and 63 percent for tumors &le;2 cm, 2.1 to 5 cm, and &gt;5 cm, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional evidence of tumor size as a risk factor for recurrence and death from breast cancer is illustrated in a European Organization for Research and Treatment of Cancer (EORTC) study involving over 1000 patients under 40 years. Pathologic tumor size (&gt;2 cm) was associated with both distant disease-free survival (hazard ratio [HR] for recurrence 1.61, 95% CI 1.14-2.25) and overall survival (HR for mortality 1.68, 95% CI 1.12-2.52) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to patients with ER-positive tumors, patients with hormone receptor-negative and HER2-negative (ie, &ldquo;triple negative&rdquo;) tumors have a worse prognosis even when diagnosed at a very small tumor size. This was illustrated in a study involving 421 breast cancers &le;1 cm in tumor size, of which 29 (7 percent) were triple negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/4\">",
"     4",
"    </a>",
"    ]. The recurrence rate was 11, 1, and 7 percent among triple-negative, ER-positive, and HER2-positive patients, respectively. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71308132\">",
"    <span class=\"h2\">",
"     Node status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of breast cancer recurrence is substantially increased in patients with breast cancer and pathologically involved lymph nodes (defined as one or more nodes with greater than a 2 mm focus of cancer). Compared to patients with localized disease (ie, cancer confined to the breast only), those with regional disease (ie, spread to the lymph nodes) have a lower rate of survival at five years (84 versus 99 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note that the staging system for breast cancer includes stringent classification of node findings and defines the presence of isolated tumor cells (a small cluster of cells within the node no greater than 0.2 mm) or micrometastases (&gt;0.2 mm but no greater than 2.0 mm) as node-positive disease. The finding of isolated tumor cells is not clinically significant. However, node micrometastases may carry a modest negative impact on breast outcomes and are treated as pathological node-positive breast cancer.",
"   </p>",
"   <p>",
"    A discussion of nodal evaluation, isolated tumor cells, and node micrometastases are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link&amp;anchor=H6264723#H6264723\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Isolated tumor cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link&amp;anchor=H1583503#H1583503\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Micrometastases'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3290814\">",
"     'Genomic profiling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3290799\">",
"    <span class=\"h1\">",
"     ESTIMATING RISKS AND BENEFITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3290814\">",
"    <span class=\"h2\">",
"     Genomic profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with ER-positive breast cancer, genomic profiling may be useful to select patients who should (or should not) receive adjuvant chemotherapy. A more complete discussion of genomic profiling of breast cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link\">",
"     \"Prognostic molecular profiles of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the best validated prognostic assays is the 21-gene recurrence score (RS, Oncotype DX&reg;). We utilize the RS in patients without pathological node involvement who are undecided about whether to proceed with adjuvant chemotherapy. However, for patients who wish to undergo adjuvant chemotherapy, or for those who are not candidates for chemotherapy (ie, due to medical comorbidities), we suggest not obtaining the RS because it would not assist in decision making about treatment. In addition, limited data suggest that the RS predicts the benefit of chemotherapy in patients with breast cancer and up to three pathologically involved nodes (N1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/6\">",
"     6",
"    </a>",
"    ]. However, we await the results from prospective studies, such as the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT01272037\">",
"     Southwest Oncology Group S1007 RxPONDER trial",
"    </a>",
"    , to better inform the role of the RS among women with node-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link&amp;anchor=H3#H3\">",
"     \"Prognostic molecular profiles of breast cancer\", section on 'Recurrence score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3290925\">",
"    <span class=\"h2\">",
"     Benefit-risk calculators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of patients who are most likely to benefit from treatment requires review of an individual&rsquo;s risk for breast cancer recurrence and death. Risk calculators have been developed to estimate a specific patient's risk of breast cancer recurrence and mortality and the benefit that may be derived from chemotherapy (and where appropriate, endocrine therapy). Of these, Adjuvant! Online is the most widely studied and has been validated in multiple populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. Other calculators include",
"    <a class=\"external\" href=\"file://www.lifemath.net/cancer/index.html\">",
"     Cancermath.net",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and",
"    <a class=\"external\" href=\"file://www.finprog.org/default.asp\">",
"     The FinProg project",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. While all these provide similar information regarding relapse risk, we prefer Adjuvant! Online.",
"   </p>",
"   <p>",
"    Adjuvant! Online is a web-based program that determines both recurrence risk and probability of survival based on population-wide data from the Surveillance, Epidemiology and End Results (SEER) database and overviews on the benefits of adjuvant therapy by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), individual clinical trial results (if not covered in the overview), and the general published literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The estimates provided by Adjuvant! Online have been validated using a large, population-based dataset and are similar to those derived from other large patient datasets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547491819\">",
"    <span class=\"h1\">",
"     DEFINING PATIENTS WHO SHOULD RECEIVE ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general approach to treatment of HER2-negative early stage breast cancer uses a risk stratified approach based on the presence of factors associated with an increased risk of recurrence (",
"    <a class=\"graphic graphic_algorithm graphicRef63161 \" href=\"mobipreview.htm?19/62/20463\">",
"     algorithm 1",
"    </a>",
"    ). We administer chemotherapy for patients with HER2-negative breast cancer and:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormone receptor-negative breast cancer with tumor size &gt;0.5 cm or with pathological node involvement (regardless of tumor size). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link&amp;anchor=H97090207#H97090207\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Adjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hormone receptor-positive breast cancer in the presence of pathologically involved lymph nodes, large tumor size, high tumor grade, presence of lymphovascular invasion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high recurrence score (RS &gt;31 on the 21-gene recurrence assay). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link&amp;anchor=H3#H3\">",
"       \"Prognostic molecular profiles of breast cancer\", section on 'Recurrence score'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with hormone receptor-positive breast cancer should receive adjuvant endocrine therapy regardless of whether adjuvant chemotherapy is administered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22388777\">",
"    <span class=\"h1\">",
"     RATIONALE FOR ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data to support the administration of adjuvant chemotherapy for patients with breast cancer come from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), which meets every five years to review data from global breast cancer trials. In the 2011 EBCTCG meta-analysis, adjuvant chemotherapy using either an anthracycline-based regimen or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (CMF) were compared to no treatment with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to no treatment, the use of an anthracycline-containing regimen was associated with the following outcomes at 10 years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant improvement in the risk of recurrence (RR 0.73, 95% CI 0.68-0.79), which translated into an absolute gain of 8.0 percent.",
"     </li>",
"     <li>",
"      Significant reduction in breast cancer mortality (RR 0.79, 95% CI 0.72-0.85), which translated into an absolute gain of 6.5 percent.",
"     </li>",
"     <li>",
"      Significant reduction in overall mortality (RR 0.84, 95% CI 0.78-0.91), which translated into an absolute gain of 5.0 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to no treatment, the use of CMF was associated with the following outcomes at 10 years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant improvement in the risk of recurrence (RR 0.70, 95% CI 0.63-0.77), which translated into an absolute gain of 10.2 percent.",
"     </li>",
"     <li>",
"      Significant reduction in breast cancer mortality (RR 0.76, 95% CI 0.68-0.84), which translated into an absolute gain of 6.2 percent.",
"     </li>",
"     <li>",
"      Significant reduction in overall mortality (RR 0.84, 95% CI 0.76-0.93), which translated into an absolute gain of 4.7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is clear that not all patients with breast cancer benefit from adjuvant chemotherapy equally. As an example, in an analysis of three randomized trials that involved a total of 6644 women with node-positive breast cancer, compared to those with ER-positive breast cancer, patients with ER-negative breast cancer had the following significant outcomes at five years following adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A larger reduction in the risk of recurrence (55 versus 26 percent). This translated into a higher absolute improvement in disease-free survival (DFS, 23 versus 7 percent).",
"     </li>",
"     <li>",
"      A larger reduction in the risk of death (55 versus 23 percent). This translated into a higher absolute improvement in overall survival (OS, 17 versus 4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data emphasize that while there is an established role for adjuvant chemotherapy in patients with early stage breast cancer, patient selection for appropriate candidates who should receive adjuvant chemotherapy is important. All patients with an indication for chemotherapy should be offered treatment, regardless of hormone receptor status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71308660\">",
"    <span class=\"h1\">",
"     CHOICE OF CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3291201\">",
"    <span class=\"h2\">",
"     The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Meta-Analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2012 meta-analysis, the role of taxanes was incorporated into the analysis on the use of adjuvant chemotherapy for early breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Results from this analysis suggest standard dosing of anthracycline-based therapy is equivalent to CMF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ), though less effective than more anthracycline-intensive regimens. They also affirm the benefit of taxanes when incorporated into an adjuvant regimen. These results are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3291249\">",
"    <span class=\"h3\">",
"     Adjuvant taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) are among the most effective single agents against early breast cancer. The effect of adjuvant taxanes was analyzed in the EBCTCG 2012 meta-analysis by trial design to take into account heterogeneity in treatment comparisons used in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trials where the same control regimen was used in both arms (n = 11,167 women), incorporation of taxanes to an anthracycline regimen resulted in the following eight-year outcomes when compared to an anthracycline regimen not using a taxane:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A reduction in the risk of recurrence (relative risk [RR], 0.84, 95% CI 0.78-0.91). This translated into an absolute gain in recurrence-free survival (RFS) of 4.6 percent.",
"     </li>",
"     <li>",
"      A reduction in the risk of breast cancer mortality (RR 0.86, 95% CI 0.79-0.93), which translated into a 2.8 percent improvement in breast cancer specific OS.",
"     </li>",
"     <li>",
"      A reduction in the risk of overall mortality (RR 0.86, 95% CI 0.79-0.93), which translated into a 3.2 percent improvement in OS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trials where the number of cycles in the control anthracycline regimen was doubled to mirror the addition of four cycles of taxanes to anthracyclines in the experimental arm (n = 33,084 women), the incorporation of taxanes was associated with the following results at five years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A reduction in the risk of recurrence (RR 0.86, 95% CI 0.82-0.91), which translated into an absolute gain of 2.9 percent.",
"     </li>",
"     <li>",
"      A reduction in the risk of breast cancer mortality (RR 0.88, 95% CI 0.81-0.95), which translated into an absolute improvement of 1.4 percent.",
"     </li>",
"     <li>",
"      A reduction in overall mortality (RR 0.90, 95% CI 0.84-0.97), which translated into an absolute improvement of 1.2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits of taxane incorporation seen were independent of age, nodal status, tumor size, tumor grade, and ER-status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results affirm the benefit of taxanes when incorporated into the adjuvant setting for women with newly diagnosed breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3291256\">",
"    <span class=\"h3\">",
"     Anthracyclines versus CMF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EBCTCG 2011 meta-analysis compared the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (CMF) to the use of various doses of anthracyclines, defined as either standard doses (eg, cumulative dose of 240",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) or higher doses (ie, to cumulative dose &gt;240",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of doxorubicin or 360",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of standardly dosed anthracyclines was associated with the following outcomes at 10 years compared to CMF (n = 5122 women):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No improvement in the risk of recurrence (RR 0.99, 95% CI 0.90-1.08).",
"     </li>",
"     <li>",
"      No improvement in breast cancer mortality (RR 0.98, 95% CI 0.89-1.08).",
"     </li>",
"     <li>",
"      No improvement in overall mortality (RR 0.97, 95% CI 0.89-1.07).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of higher cumulative doses of anthracyclines compared to CMF (n = 9527 women) was associated with the following outcomes at 10 years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A reduction in the risk of recurrence (RR 0.89, 95% CI 0.82-0.96), which translated into an absolute gain of 2.6 percent.",
"     </li>",
"     <li>",
"      A reduction in breast cancer mortality (RR 0.80, 95% CI 0.72-0.88), which translated into an absolute gain of 4.1 percent.",
"     </li>",
"     <li>",
"      A reduction in overall mortality (RR 0.84, 95% CI 0.76-0.92), which translated into an absolute gain of 3.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This suggests standard dosing of anthracycline-based therapy is equivalent to CMF, though less effective than more anthracycline-intensive regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377341\">",
"    <span class=\"h2\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single standard adjuvant chemotherapy regimen in the treatment of breast cancer. Commonly used regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACT &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      for four cycles) followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for four cycles). Cycles are given every two weeks with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      support (dose-dense therapy) (",
"      <a class=\"graphic graphic_table graphicRef55933 \" href=\"mobipreview.htm?27/5/27742\">",
"       table 1",
"      </a>",
"      ). Alternatively, the paclitaxel can be given at 80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TAC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles, administered every three weeks with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      support [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMF &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles, administered every three weeks. Alternatively, cyclophosphamide may be given orally (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 to 14 of each cycle) (",
"      <a class=\"graphic graphic_table graphicRef69601 \" href=\"mobipreview.htm?42/50/43821\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FEC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles, administered every three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FEC-Taxane &mdash; FEC every three weeks for three cycles followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for three cycles; FEC for four cycles followed by weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for four cycles, administered every three weeks (",
"      <a class=\"graphic graphic_table graphicRef56545 \" href=\"mobipreview.htm?2/43/2750\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most women, we recommend an anthracycline- and taxane-containing adjuvant regimen over non-anthracycline-based therapy because the EBCTCG meta-analysis demonstrated an absolute improvement in risk of recurrence and death at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preliminary results of a phase III trial involving 4894 women (65 percent with pathologically-involved nodes and 80 percent with ER-positive disease) randomly assigned to treatment with dose-dense ACT, dose-dense AC followed by the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (ACTG), or TAC were presented at the 2012 American Society of Clinical Oncology meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/28\">",
"     28",
"    </a>",
"    ]. The major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year disease free survival rate was similar across treatment groups (82 percent with dose-dense ACT, 81 percent with dose-dense ACTG, and 80 percent with TAC).",
"     </li>",
"     <li>",
"      The five-year OS rate was also similar (89, 90, and 90 percent, respectively).",
"     </li>",
"     <li>",
"      TAC was associated with significantly more serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity, including febrile neutropenia (9 versus 4 percent in both ACT an ACTG arms) and diarrhea (8 versus 2 percent with ACT or ACTG). However, it was associated with significantly less grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      neurotoxicity (&lt;1 versus 7 and 6 percent with ACT or ACTG, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, dose-dense ACT is the preferred regimen for patients who are candidates for an anthracycline plus taxane based regimen.",
"   </p>",
"   <p>",
"    For women with contraindications to anthracycline-based therapy, CMF and TC are acceptable alternatives. A more detailed review of the side effects related to chemotherapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3291201\">",
"     'The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Meta-Analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Dose density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, adjuvant chemotherapy was administered in cycles on an every three-week schedule. However, studies that decreased the duration between successive cycles to an every two-week treatment (ie, dose-dense therapy) aimed to improve the results of treatment over standard dosing schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/29\">",
"     29",
"    </a>",
"    ]. A meta-analysis of dose-dense versus standard dosing including data from 10 trials and over 11,000 women reported the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three trials that evaluated similar dosing in the treatment arms, dose-dense treatment was associated with an improvement in DFS (hazard ratio [HR] 0.83, 95% CI 0.73-0.94) and OS (HR 0.84, 95% CI 0.72-0.98).",
"     </li>",
"     <li>",
"      In seven trials in which modified doses or regimens were evaluated, improvement in DFS (HR 0.81, 95% CI 0.73-0.88) and OS (HR=0.85, 95% CI 0.75-0.96) was also demonstrated.",
"     </li>",
"     <li>",
"      The benefit in DFS was seen in women with ER-negative disease (HR 0.71, 95% CI 0.56-0.98), but not in women with ER-positive disease (HR 0.92, 95% CI 0.75-1.12).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The meta-analysis supports the use of dose-dense treatment as a standard of care for women with HER2-negative breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27692287\">",
"    <span class=\"h3\">",
"     Is an anthracycline necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether the benefit seen from adding a taxane in the adjuvant setting will obviate the need for anthracyclines in a subset of patients. Given a lack of prospective randomized data addressing this issue, we continue to recommend an anthracycline- and taxane-containing regimen for most women, particularly those with higher stage tumors, and for those with triple-negative or HER2-positive cancers. While confirmation in larger prospective trials is necessary, one randomized trial supports the use of a nonanthracycline regimen.",
"   </p>",
"   <p>",
"    US Oncology Trial 9735 enrolled 1016 women with stage I to III HER2-negative breast cancer and randomly assigned therapy with AC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) or TC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus cyclophosphamide) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/31\">",
"     31",
"    </a>",
"    ]. With a median follow-up of seven years, TC resulted in a significantly higher disease free survival (DFS, 81 versus 75 percent) and overall survival (87 versus 82 percent).",
"   </p>",
"   <p>",
"    It has been proposed that the target for anthracycline therapy is within the HER2 amplicon on chromosome 17q21, known as topoisomerase 2a (TOP2A) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/32\">",
"     32",
"    </a>",
"    ]. Further discussion of TOP2A is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H760200091#H760200091\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Topoisomerase 2-alpha (TOP2A)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358618390\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment varies by the regimen used. As examples (see",
"    <a class=\"local\" href=\"#H1377341\">",
"     'Regimen'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ACT is administered over 16 weeks (if delivered as dose-dense treatment) or 32 weeks (if delivered every three weeks).",
"     </li>",
"     <li>",
"      Four cycles of TC is administered over 12 weeks.",
"     </li>",
"     <li>",
"      Six cycles of CMF is administered over 18 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women deemed to be at a low risk of recurrence (eg, invasive breast cancer with no more than three pathologically involved nodes), the Cancer and Leukemia Group B 40101 trial (CALGB 40101) suggests that a longer treatment duration (ie, 12 to 18 weeks) of AC alone or single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    does not improve survival outcomes compared to shorter treatment (ie, 8 to 12 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/33\">",
"     33",
"    </a>",
"    ]. However, these results do not inform the use of other combinations, such as ACT, or the treatment of women with more aggressive pathologic features (eg, larger tumors or those with four or more pathologically involved nodes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2718971\">",
"    <span class=\"h3\">",
"     High dose chemotherapy with autologous hematopoietic stem cell transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither individual trials nor a meta-analysis of 15 trials conducted in the adjuvant setting have shown that high dose chemotherapy followed by autologous hematopoietic cell transplantation improves outcomes compared to standard adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/34\">",
"     34",
"    </a>",
"    ]. Notably, patients enrolled on the high dose chemotherapy arms of these trials experienced lower survival after relapse. Given the risks and lack of survival benefit, this approach is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1404371166\">",
"    <span class=\"h1\">",
"     SEQUENCING CHEMOTHERAPY AND RADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is typically started within four to six weeks after surgery. Earlier treatment is not better, but a delay of more than 12 weeks may be detrimental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. For patients who are also going to receive adjuvant radiation therapy, standard clinical practice is to proceed with chemotherapy before radiation therapy. The use of concomitant radiation and chemotherapy is investigational.",
"   </p>",
"   <p>",
"    A randomized trial presented at the 2011 European Multidisciplinary Cancer Congress enrolled 2396 women with early breast cancer who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    with (54 percent) or without (46 percent) an anthracycline and who were then treated with either concomitant or sequential radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/37\">",
"     37",
"    </a>",
"    ]. With a median follow-up of 8.8 years, five-year local recurrence rates were significantly improved with concomitant treatment (2.8 versus 5.1 percent). However, there was no difference in overall or disease free survival. Concomitant treatment was associated with a significant increase in acute skin toxicity (25 versus 16 percent) and in the occurrence of moderate or severe skin telangiectasia (2.5 versus 1.3 percent). Given the lack of a survival advantage and an increase in acute toxicity, as well as the use of a non-taxane containing adjuvant regimen, concomitant treatment is not likely to replace the sequential administration of chemotherapy followed by radiation therapy in the locoregional management of early-stage breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538835844\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2719008\">",
"    <span class=\"h2\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are fewer data for use of chemotherapy in women over age 70, and the decision to use adjuvant chemotherapy in older women is complicated due to an increased number of comorbidities, which means that the impact of chemotherapy on daily function may be greater and the benefits of chemotherapy tend to be lower. However, prospective trials have clearly demonstrated the efficacy of chemotherapy in older patients, and age itself is not a definitive reason for not giving chemotherapy. Prior to making a decision regarding chemotherapy, older women should be evaluated using a comprehensive geriatric assessment.",
"   </p>",
"   <p>",
"    Adjuvant chemotherapy is generally recommended for older women with a good performance status. Prospective studies have shown that older women tolerate CMF and AC chemotherapy reasonably well, and clinical experiences suggest that older women can also tolerate taxane-based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/38\">",
"     38",
"    </a>",
"    ]. Specific issues related to the adjuvant treatment of older women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34826?source=see_link\">",
"     \"Adjuvant systemic therapy for older women with early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2719048\">",
"    <span class=\"h2\">",
"     Male breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is a rare diagnosis in men but decisions regarding adjuvant chemotherapy do not differ by gender. In addition, the prognosis for men and women with breast cancer is similar. Male breast cancer is covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2719088\">",
"    <span class=\"h2\">",
"     Breast cancer in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most chemotherapy agents for breast cancer are United States Food and Drug Administration (FDA) pregnancy category D, meaning they carry a risk of teratogenicity in humans. Chemotherapy can be administered after the first trimester. Reports from small series of patients at major cancer centers suggest that chemotherapy treatment during pregnancy can be reasonably well tolerated without major short-term impact on the mother or child. Breast cancer during pregnancy is covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2602?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2719140\">",
"    <span class=\"h2\">",
"     Patients with cardiac risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with the development of chemotherapy-related cardiotoxicity include exposure to known cardiotoxic drugs such as anthracyclines (cumulative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    greater than 360",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    greater than 900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . Older age, prior history of cardiac disease, and chest wall radiation therapy are also risk factors for treatment-related cardiotoxicity. The short-term incidence of anthracycline associated cardiomyopathy is rare (about 1 percent). Prior to anthracycline or trastuzumab treatments, patients should have baseline assessment of cardiac function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2719278\">",
"    <span class=\"h2\">",
"     Obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that obese women (typically defined as a body mass index [BMI] &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    with hormone-positive breast cancer have a worse prognosis compared to women with a normal BMI despite administration of chemotherapy followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an aromatase inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. In the largest study to demonstrate this association, the Eastern Cooperative Group (ECOG) examined the relationship between obesity and survival outcomes (DFS and OS) using information from three randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ECOG 1199 &mdash; A trial that assigned 4770 women to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by randomization to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (administered every three weeks or weekly). All women received endocrine therapy following treatment (over 90 percent of whom received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      alone or tamoxifen followed by an AI).",
"     </li>",
"     <li>",
"      ECOG 1158 &mdash; A trial that assigned 1502 premenopausal women to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (CAF) followed by randomization to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      or goserelin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      ECOG 3189 &mdash; A trial of 613 women with hormone-receptor negative, HER2-negative breast cancer randomly assigned to treatment with one of two different chemotherapy regimens (CAF or a 16-week regimen comprised of CAF plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After adjustment for prognostic factors (including age, race, menopausal status, tumor size, number of pathologically involved axillary nodes, and type of surgery), obesity was associated with inferior DFS (HR 1.24, 95% CI 1.06-1.46) and OS (HR 1.37, 95% CI 1.13-1.67) among women with hormone receptor-positive breast cancer, but not among women with triple-negative or HER2-positive disease. These results indicate that obesity is associated with a poor prognosis among women with hormone receptor-positive disease. Whether prognosis can be modified by dietary and lifestyle interventions requires further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H541711995#H541711995\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Promoting a health lifestyle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These results should not lead to the administration of chemotherapy in obese women in the absence of indications for treatment (see",
"    <a class=\"local\" href=\"#H115555550\">",
"     'Indications for treatment'",
"    </a>",
"    above). However, if chemotherapy is indicated, we suggest that standard, weight-based drug doses be administered to all patients regardless of BMI. This is consistent with clinical practice guidelines from the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37961/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the morbidity and mortality risks associated with obesity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/2/39970?source=see_link\">",
"       \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant systemic therapy is an important component of treatment for patients with HER2-negative early breast cancer. Its widespread use is thought to be in large part responsible for the improvements in breast cancer-specific survival seen in almost every Western nation over the last decade. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to administer adjuvant chemotherapy in HER2-negative breast cancer is largely based upon tumor size, nodal status, and estrogen-receptor (ER) expression. (See",
"      <a class=\"local\" href=\"#H115555550\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hormone receptor-negative (and HER2-negative) breast cancer, with a tumor size &gt;0.5 cm or pathologically involved lymph nodes (regardless of tumor size), we recommend adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H547491819\">",
"       'Defining patients who should receive adjuvant chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link&amp;anchor=H98882362#H98882362\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Treatment approach to triple-negative breast cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with hormone receptor-positive breast cancer with pathologically involved lymph nodes, large tumor size, high tumor grade, presence of lymphovascular invasion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high recurrence score (RS &gt;31 on the 21-gene recurrence assay), we suggest chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Regardless of whether adjuvant chemotherapy is administered, we recommend adjuvant endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H547491819\">",
"       'Defining patients who should receive adjuvant chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjuvant! Online is a web-based program that determines both recurrence risk and probability of survival based on population-wide data and can be used to frame discussions of risks and benefits with patients. (See",
"      <a class=\"local\" href=\"#H3290925\">",
"       'Benefit-risk calculators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are eligible for adjuvant chemotherapy, we recommend an anthracycline- and taxane-based combination rather than a non-anthracycline-based treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer the dose-dense regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every two weeks for four cycles, followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every two weeks for four cycles (ACT) (",
"      <a class=\"graphic graphic_table graphicRef55933 \" href=\"mobipreview.htm?27/5/27742\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1377341\">",
"       'Regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are other active regimens that can be used rather than dose-dense ACT. A decision on the treatment administered should take into account patient convenience and the side effects of each combination. &nbsp;(See",
"      <a class=\"local\" href=\"#H1377341\">",
"       'Regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Dose density'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard, weight-based drug doses should be administered to all patients regardless of body mass index. (See",
"      <a class=\"local\" href=\"#H2719278\">",
"       'Obese women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/1\">",
"      Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Breast Cancer Facts &amp; Figures 2011-2012., Atlanta 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/3\">",
"      van der Hage JA, Mieog JS, van de Velde CJ, et al. Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res 2011; 13:R68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/4\">",
"      Amar S, McCullough AE, Tan W, et al. Prognosis and outcome of small (&lt;=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 2010; 15:1043.",
"     </a>",
"    </li>",
"    <li>",
"     5-Year Relative Survival (Percent) 2001-2007 by Stage at Diagnosis. file://seer.cancer.gov/csr/1975_2008/index.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/6\">",
"      Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/7\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! Breast Cancer Help Files. www.adjuvantonline.com/index.jsp (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/9\">",
"      Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/10\">",
"      Baum M, Ravdin PM. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer 2002; 38:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/11\">",
"      Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/12\">",
"      Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/13\">",
"      Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/14\">",
"      Michaelson JS, Chen LL, Bush D, et al. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat 2011; 128:827.",
"     </a>",
"    </li>",
"    <li>",
"     file://cancer.lifemath.net/ (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/16\">",
"      Lundin J, Lundin M, Isola J, Joensuu H. A web-based system for individualised survival estimation in breast cancer. BMJ 2003; 326:29.",
"     </a>",
"    </li>",
"    <li>",
"     www.finprog.org/default.asp (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/18\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/19\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/20\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/21\">",
"      Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/22\">",
"      Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/23\">",
"      Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 20:4621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/24\">",
"      Brufman G, Colajori E, Ghilezan N, et al. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 1997; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/25\">",
"      Roch&eacute; H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24:5664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/26\">",
"      Mart&iacute;n M, Rodr&iacute;guez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/27\">",
"      Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381.",
"     </a>",
"    </li>",
"    <li>",
"     Swain SM, Tang G, Geyer CE, et al. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC&rarr;paclitaxel (P) plus gemcitabine (G) with DD AC&rarr;P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. J Clin Oncol 30, 2012 (suppl; abstr LBA1000).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/29\">",
"      Citron ML. Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives. Breast Care (Basel) 2008; 3:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/30\">",
"      Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/31\">",
"      Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/32\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/33\">",
"      Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 2012; 30:4071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/34\">",
"      Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/35\">",
"      Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 2003; 21:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/36\">",
"      Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006; 24:4888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/37\">",
"      Fernando IN, Bowden SJ, Brookes CL, et al. Synchronous chemo-radiation can reduce local recurrence in early stage breast cancer: results of the SECRAB trial. 2011 European Multi-Disciplinary Cancer Conference, Stockholm, Sweden. September 2011. Eur Multidisciplinary Cancer Conference.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/38\">",
"      Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/39\">",
"      Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/40\">",
"      Pfeiler G, K&ouml;nigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/41\">",
"      Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012; 118:5937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/42\">",
"      Dignam JJ, Wieand K, Johnson KA, et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003; 95:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37961/abstract/43\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 788 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37961=[""].join("\n");
var outline_f37_4_37961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115555550\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71308074\">",
"      Tumor histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71308103\">",
"      Tumor size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71308132\">",
"      Node status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3290799\">",
"      ESTIMATING RISKS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3290814\">",
"      Genomic profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3290925\">",
"      Benefit-risk calculators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H547491819\">",
"      DEFINING PATIENTS WHO SHOULD RECEIVE ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22388777\">",
"      RATIONALE FOR ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71308660\">",
"      CHOICE OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3291201\">",
"      The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Meta-Analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3291249\">",
"      - Adjuvant taxanes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3291256\">",
"      - Anthracyclines versus CMF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1377341\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Dose density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27692287\">",
"      - Is an anthracycline necessary?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H358618390\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2718971\">",
"      - High dose chemotherapy with autologous hematopoietic stem cell transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1404371166\">",
"      SEQUENCING CHEMOTHERAPY AND RADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538835844\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2719008\">",
"      Older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2719048\">",
"      Male breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2719088\">",
"      Breast cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2719140\">",
"      Patients with cardiac risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2719278\">",
"      Obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/788|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/62/20463\" title=\"algorithm 1\">",
"      Adjuvant medical treatment of HER2-negative early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/5/27742\" title=\"table 1\">",
"      Dose dense AC-T breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/50/43821\" title=\"table 2\">",
"      Oral CMF for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/43/2750\" title=\"table 3\">",
"      TC regimen for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34826?source=related_link\">",
"      Adjuvant systemic therapy for older women with early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=related_link\">",
"      Prognostic molecular profiles of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17650?source=related_link\">",
"      Treatment protocols for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37962="Overview of preventive medicine in adults";
var content_f37_4_37962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of preventive medicine in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     Russell Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/4/37962/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/4/37962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality healthcare for individuals includes two fundamental elements: appropriate treatment for current illness and appropriate preventive care to lessen future health decline. Over the last century, preventive health care has become an important aspect of medical practice, leading to significant improvements in overall health in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several complex issues are involved in providing effective preventive care. Clinicians need to decide on priorities for the many available preventive services: which to recommend for individual patients and which to discourage to prevent net harm from inappropriate tests or interventions. Additionally, clinicians must identify how to deliver preventive services efficiently within the context of a busy clinical practice.",
"   </p>",
"   <p>",
"    An overview of primary prevention and screening recommendations in adults will be presented here. Disease-specific screening recommendations are reviewed in more detail on the appropriate topic reviews. Basic epidemiologic principles of screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIORITIZING PREVENTIVE SERVICES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two general principles are helpful in deciding which preventive services to prioritize (",
"    <a class=\"graphic graphic_table graphicRef65157 \" href=\"mobipreview.htm?15/38/15980\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Start with the condition (not the test or intervention), identifying those conditions that cause the largest burden of suffering for patients.",
"     </li>",
"     <li>",
"      For targeted conditions, prioritize preventive services that have demonstrated effectiveness in improving patient outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of conditions that meet these criteria is not long; a small number of modifiable factors underlies a large number of deaths and disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/2\">",
"     2",
"    </a>",
"    ]. Priority health problems and effective interventions are shown in the table for patients younger than age 50 years (",
"    <a class=\"graphic graphic_table graphicRef72728 \" href=\"mobipreview.htm?39/54/40812\">",
"     table 2",
"    </a>",
"    ) and in a table for patients age 50 and older (",
"    <a class=\"graphic graphic_table graphicRef69700 \" href=\"mobipreview.htm?41/50/42797\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF USPSTF RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) has systematically reviewed and published evidence-based recommendations for multiple clinical preventive services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/3\">",
"     3",
"    </a>",
"    ]. Screening and counseling recommendations for targeted patient populations that the USPSTF has determined improve patient outcome and provide net benefit, based on evidence of high certainty (USPSTF 'A' level recommendation) and moderate certainty (USPSTF 'B' level recommendation), are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef58423 \" href=\"mobipreview.htm?34/16/35085\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://epss.ahrq.gov/ePSS/search.jsp\">",
"     ePSS",
"    </a>",
"    is a convenient tool to identify patient-specific preventive services recommended by the USPSTF, based on the patient&rsquo;s sex, age, pregnancy status, tobacco use, and whether he or she is sexually active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPECIFIC CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk assessment and effective prevention are discussed below for conditions that cause an important burden of suffering for many US adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because cardiovascular disease (CVD) is the most common cause of death in the United States, clinicians should consider counseling for prevention of heart attack and stroke in all patients ages 35 and older. Patients who are obese or physically inactive and patients with cardiovascular risk factors should be especially targeted.",
"   </p>",
"   <p>",
"    A small number of preventive services, if delivered routinely, could have a major impact on mortality and morbidity from CVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess each patient's absolute risk of having a CVD event (also called \"global CVD risk\") using one of several widely available statistical tools [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/4\">",
"       4",
"      </a>",
"      ]. In general, one should intervene most aggressively to reduce risk factors among patients at high global risk (ie, &ge;20 percent 10-year risk) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Patients with low risk need little intervention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients at moderate to high CVD risk (ie, 10 to 19 percent 10-year risk), three pharmacologic interventions have been shown to reduce the risk of CVD: antihypertensive drugs for patients who are not at blood pressure goal, statin therapy, and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . The risks of aspirin use should be balanced against its benefits, particularly in patients at intermediate risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The net benefit of assessing risk with nontraditional risk factors has not been established, and we do not recommend general population screening for these factors, which may include highly-sensitive C-reactive protein (hs-CRP), ankle-brachial index (ABI), white blood count, fasting glucose, presence of periodontal disease, carotid artery intima-media thickness, electron beam CT scan (EBCT), homocysteine, or lipoprotein (a) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link\">",
"       \"Screening for cardiovascular risk with C-reactive protein\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lifestyle education should be provided to all patients to promote maintenance of healthy weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/10\">",
"       10",
"      </a>",
"      ] and physical activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/11\">",
"       11",
"      </a>",
"      ]. To help obese or sedentary patients adopt a healthier lifestyle, more intensive behavioral counseling is needed. Clinicians should refer obese and sedentary patients who are at higher cardiovascular risk and have a greater readiness for change to intensive behavioral change programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"       \"Screening for and clinical evaluation of obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"       \"Overview of the benefits and risks of exercise\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"       \"Exercise and fitness in the prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brief counseling within primary care for smoking cessation increases quit rates and decreases CVD risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A routine electrocardiogram (ECG), even for a &ldquo;baseline,&rdquo; is not indicated in asymptomatic adults at low risk for CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the evidence is insufficient to determine the benefits and harms of routine ECG in patients at intermediate or increased risk, it is reasonable to reserve ECG to situations where the findings would likely change treatment. While the detection of ECG abnormalities (eg, ST-segment or T-wave abnormalities) is associated with increased risk for CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], such ECG findings do not add further prediction beyond traditional risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for coronary heart disease\", section on 'Resting ECG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension in the US accounts for 35 percent of myocardial infarctions and strokes, 49 percent of episodes of heart failure, and 24 percent of premature deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/16\">",
"     16",
"    </a>",
"    ]. High blood pressure is diagnosed when systolic blood pressure (SBP) is &ge;140 mmHg or diastolic blood pressure (DBP) is &ge;90 mmHg on two or more visits over a period of several weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link&amp;anchor=H10946091#H10946091\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\", section on 'Need for multiple measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is clear evidence that treatment of high blood pressure can decrease the incidence of cardiovascular disease. Thus, the benefits of screening for and treating high blood pressure in adults substantially outweigh the harms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal interval for screening for hypertension is not known. The 2007 United States Preventive Services Task Force (USPSTF) guidelines recommend screening every two years for persons with SBP and DBP below 120 mmHg and 80 mmHg, respectively, and yearly for persons with SBP 120 to 139 mmHg or DBP 80 to 89 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Abdominal aortic aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ruptured abdominal aortic aneurysm (AAA) is a catastrophic but uncommon event. The great majority of the 9000 annual US deaths from AAA rupture are in men between the ages of 65 and 75 years who are current or former smokers. Open surgical repair of AAA &ge;5.5 cm reduces deaths associated with AAA rupture, at a cost of increased surgical procedures.",
"   </p>",
"   <p>",
"    We recommend one-time ultrasound screening in men ages 65 to 75 years who are current or former smokers. One-time screening for AAA has been recommended by some for men ages 65 to 75 who have never smoked but who have a first-degree relative who required repair of or died from an AAA. The prevalence of AAA is much lower in other non-smokers, younger men, and all women, and screening is not recommended for these groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16586863\">",
"    <span class=\"h3\">",
"     Carotid artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that carotid artery stenosis overall is the cause of fewer than 15 percent of strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/21\">",
"     21",
"    </a>",
"    ]. Potential benefit from screening for carotid artery stenosis is limited by the effectiveness of medical treatment for patients at increased risk (eg, anticoagulation for patients in atrial fibrillation, and appropriate antihypertensive,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and statin treatment). Furthermore, both evaluation by carotid angiography and surgical treatment of carotid artery stenosis carry the risk of stroke as a complication. &nbsp;",
"   </p>",
"   <p>",
"    Since the benefits of identifying and treating asymptomatic carotid artery stenosis do not clearly outweigh the harms, the US Preventive Services Task Force (USPSTF) and UpToDate recommend against screening (either by auscultation for carotid bruit or by carotid ultrasound) in asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34361?source=see_link\">",
"     \"Screening for asymptomatic carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16587158\">",
"    <span class=\"h3\">",
"     Peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with lower extremity peripheral artery disease (PAD) are at significantly increased risk of cardiovascular and cerebrovascular mortality, and evidence suggests that the majority of cases of PAD are undetected in routine clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. PAD can be reliably diagnosed by a low ankle-branchial index (ABI &lt;0.9) using Doppler ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Preventive Services Task Force (USPSTF) examined the issue of screening for PAD with ankle-brachial index (ABI) in 2005 and 2007. In 2005, they recommended against screening to reduce morbidity (eg, claudication, amputation, impaired ambulation) from PAD and in 2007 found insufficient evidence to screen with ABI to guide treatment to reduce coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/24\">",
"     24",
"    </a>",
"    ]. Although others recommend using ABI screening for people with intermediate risk (ie, 10 to 19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/25\">",
"     25",
"    </a>",
"    ], it remains to be determined whether interventions for asymptomatic patients identified at increased risk by ABI score will be effective in reducing morbidity and mortality, and randomized trials are awaited. Pending results of such trials, we suggest not screening for PAD or CVD risk with ABI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24200?source=see_link\">",
"     \"Screening for lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cancer morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cancers that are responsible for the greatest mortality in the US are lung, colorectal, breast, and prostate.",
"   </p>",
"   <p>",
"    Prevention is most effective for cancers that are strongly and causally associated with tobacco use: cancers of the oropharynx, bladder, esophagus, and lung. Colon polyp removal with screening colonoscopy can prevent colorectal carcinoma. Treatment of precursor lesions detected at screening can prevent cervical cancer. Vaccination for HPV should also decrease the incidence of cervical cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link\">",
"     \"Cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for breast, cervical, or colorectal cancer can decrease cancer mortality. Although screening for these cancers is recommended by the USPSTF, screening rates in the United States do not meet targets. For 2010, the overall breast cancer screening rate was 72.4 percent, cervical cancer screening was 83.0 percent, and colorectal cancer screening was 58.6 percent, based upon data from a representative household sample of individuals in the community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/26\">",
"     26",
"    </a>",
"    ]. Screening rates for colorectal cancer have increased over time, with no change in breast cancer screening and a slight downward trend for cervical cancer screening. Over time, cervical cancer mortality has been greatly decreased by widespread screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/27\">",
"     27",
"    </a>",
"    ]. Screening rates vary with race, ethnicity, education, and health care access, with a need to particularly target minority groups for improved screening participation.",
"   </p>",
"   <p>",
"    There are harms associated with screening for all conditions, including cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/28\">",
"     28",
"    </a>",
"    ]. These harms include anxiety produced by false-positive screening tests, harms associated with diagnostic testing after a positive screening test, and overdiagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/29\">",
"     29",
"    </a>",
"    ] of conditions that may be treated but would never have become clinically apparent. Clinicians should make sure that patients are aware of these harms before screening; in some cases, patients may weigh potential benefits and harms and decide against screening. This is a reasonable decision that should be accepted by clinicians. Thus, the optimal screening rate is less than 100 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite controversy, the USPSTF concluded that breast cancer screening with mammography between the ages of 50 and 75 reduces mortality from breast cancer to a small but clinically-important degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Clinicians should target women 50 to 75 years old for discussion of the potential benefits and potential harms of screening. Screening should also be discussed with women in their 40s, although fewer women in this age group are likely to benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/32\">",
"     32",
"    </a>",
"    ]. Screening every two years provides about the same benefit as annual screening, with many fewer false positive tests and less overdiagnosis of cancers that would never become clinically apparent.",
"   </p>",
"   <p>",
"    Overdiagnosis is an especially important problem for women over age 75; screening women beyond this age may cause more harm than good. The absolute benefit (in terms of the number per 10,000 screened who will have their lives extended) increases with age, while the harms of false positives decrease with age and the harms of overdiagnosis increase at older age. Thus, there is a need to discuss the potential benefits and potential harms with women from age 40 to 75. Once a patient is informed and has decided on a particular screening approach, there is no need to continue to engage in extended discussions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also suggest regular clinical breast examinations (CBE), although this is supported by weaker evidence than mammography. Some breast cancers are not detected by mammography; a positive CBE requires further investigation, even if the mammogram is negative. Taking time for a careful CBE increases sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teaching breast self-examination (BSE) takes time and does not result in lower breast cancer mortality. We do not recommend teaching BSE.",
"   </p>",
"   <p>",
"    Clinicians should ask about a woman's history of breast or ovarian cancer. Women with a strong family history should receive counseling for options which may include genetic testing for BRCA1 and BRCA2 and more intensive screening for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians should target women with an intact cervix, starting at age 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/34\">",
"     34",
"    </a>",
"    ]. Starting screening before age 21 adds little or no benefit but leads to more procedures with potential harms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for cervical cancer is done by cytological examination (for women aged 21 and older) or, in women over age 30, by a combination of cytological examination and testing for human papillomavirus (HPV). HPV testing has a greater sensitivity for detecting high-grade precancerous lesions but is associated with more false-positive tests and higher referral rates for colposcopy than cytology alone. Thus, although the combination of cytology plus HPV testing may be used for screening in women over age 30 years, cytology alone is also a reasonable strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/34\">",
"     34",
"    </a>",
"    ]. HPV testing is useful to determine how to triage women with atypical squamous cells of undetermined significance (ASCUS) findings on cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal frequency of screening for cervical cancer is not clear, but modeling studies suggest that cytological screening every three years achieves about as much benefit as annual screening with fewer false positives and fewer procedures. Co-testing with cytology and HPV tests (in women over age 30) allows the interval to be extended to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/35,37\">",
"     35,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have had a total hysterectomy for reasons other than cervical cancer or high-grade cervical cancer precursors should not be screened. Cervical cancer develops very slowly; women older than age 65 years who have had repeated negative Pap smears and are not at increased risk do not need to be screened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/38\">",
"     38",
"    </a>",
"    ]. Mortality from cervical cancer is greatest among women who have not had prior adequate screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/35,39,40\">",
"     35,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be asked about first- and second-degree relatives who have had colorectal cancer. Screening and prevention recommendations for patients with a family history of colorectal cancer, as well as genetic screening, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for colorectal cancer reduces mortality from this disease. Regular screening should be initiated at age 50 for patients with an average risk for colorectal cancer and earlier for those with increased risk. Several screening strategies are available, and guidelines differ somewhat in recommended testing (",
"    <a class=\"graphic graphic_table graphicRef62904 \" href=\"mobipreview.htm?23/8/23693\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75708 \" href=\"mobipreview.htm?12/44/13005\">",
"     table 6",
"    </a>",
"    ). Patients should participate in the decision of which test to undergo. Although there has been a trend in the United States toward screening with colonoscopy rather than other tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/41\">",
"     41",
"    </a>",
"    ], it is reasonable for patients without increased risk to choose screening with fecal occult blood test (FOBT), flexible sigmoidoscopy, or the combination of the two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing the risk of lung cancer should focus on those people who smoke tobacco and on targeted populations (ie, adolescents) who are at risk of initiating tobacco use. Avoidance and cessation of tobacco use could potentially reduce the incidence and mortality from lung cancer by about 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brief assessment and counseling in primary care is effective in increasing quit rates. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Tobacco'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Published studies of chest x-ray screening for lung cancer have not shown screening with plain x-rays to be effective. However the National Lung Screening Trial (NLST) found a 20.0 percent decrease in cancer mortality and 6.7 percent decrease in all cause mortality with annual low-dose helical CT screening, compared to chest x-ray screening, in a highly-selected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/42\">",
"     42",
"    </a>",
"    ]. Among abnormal results (24.2 percent of CT scans and 6.9 percent of radiographs), 96 percent were false positive (that is, did not lead to a diagnosis of lung cancer) and 11 percent of the positive results led to an invasive study. Further analysis of these data in terms of the cost-effectiveness and unwanted effects of screening, as well as other randomized trials, are ongoing. It may be premature to screen for lung cancer until these further analyses are completed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for prostate cancer is controversial. The benefits of screening (ie, reducing prostate cancer mortality) are small in that they accrue to only a small number of men (no more than one in 1400) and only after nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/43\">",
"     43",
"    </a>",
"    ]. Benefits may be outweighed by the significant harms of screening that affect many more men (need for biopsy, and impotence or incontinence occurring in at least 50 percent of men who undergo treatment for a disease that may be indolent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/7,44\">",
"     7,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is interest in screening for prostate cancer among some men; individual and informed patient preferences for identified health outcomes should guide decisions about screening. Thus, although screening for prostate cancer should generally be discouraged, it is reasonable, at least once, to initiate a discussion about screening with average risk men between 50 and 69 years of age. Other UpToDate authors suggest a somewhat different age cutoff (men with a life expectancy of at least 10 years or age 75). We suggest not initiating screening discussions earlier for men at higher risk (African Americans, those with a positive family history), given that age is the primary determinant of cancer risk and screening earlier increases the risk of harm; earlier discussion with men at higher risk has been advised by some. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H35#H35\">",
"     \"Screening for prostate cancer\", section on 'Age to begin screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discussions of screening for prostate cancer should present patients with information on the harms and benefits of screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/44\">",
"     44",
"    </a>",
"    ]. If, after being informed, men choose to request screening, then we suggest that screening be performed with prostate specific antigen (PSA) tests. We suggest not performing digital rectal examination as part of screening.",
"   </p>",
"   <p>",
"    When a decision is made to screen, the optimal interval for PSA testing is uncertain. We suggest intervals of four years, stopping no later than age 69. Others, including authors for UpToDate, have suggested intervals of every two to four years, stopping no later than age 75. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although screening may increase the number of melanomas diagnosed, there is no evidence that increased detection leads to reduced mortality or morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/45\">",
"     45",
"    </a>",
"    ]. Population studies have shown a large increase in skin biopsies and incidence of early-stage melanoma with little change in melanoma mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/46\">",
"     46",
"    </a>",
"    ], suggesting overdiagnosis. Counseling can effectively modify behavior, including increased use of sunscreen and avoidance of tanning salons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/47\">",
"     47",
"    </a>",
"    ]. The USPSTF found insufficient evidence to determine whether counseling can prevent skin cancer, including melanoma, in adults older than 24, but that counseling can increase sun-protective behaviors in adolescents and young adults and therefore recommends counseling to minimize ultraviolet radiation exposure for fair skinned adolescents and young adults (ages 10 to 24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/48\">",
"     48",
"    </a>",
"    ]. Findings from 10-year follow-up of an Australian RCT of sunscreen use found a small absolute reduction in the incidence of invasive melanoma, but the number of melanomas was small and there may have been some methodologic flaws in the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF has found a lack of sufficient evidence to determine whether benefits outweigh harms in relation to whole body skin examination or teaching average-risk patients to do skin self-examination to detect melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/45\">",
"     45",
"    </a>",
"    ]. Other expert groups have recommended at least a baseline total body skin examination with heightened surveillance in patients at greater risk for melanoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should remain alert for skin lesions with malignant features and refer those patients to dermatologists, but it remains controversial whether routine, whole-body skin examinations are beneficial. Patient counseling in primary care can increase sun protective behaviors, including increased use of sunblocking agents and decreased exposure to midday sun and indoor tanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend screening all adults for depression. When screening is combined with systems of care that assure further evaluation, treatment, and follow-up, the burden of suffering from depression can be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brief, simple approaches are available that accurately detect people who should be further evaluated for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/52\">",
"     52",
"    </a>",
"    ]. Asking two simple questions about mood and anhedonia (\"Over the past two weeks, have you felt down, depressed, or hopeless?\" and \"Over the past two weeks, have you felt little interest or pleasure in doing things?\") may be as effective as using longer instruments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Screening for depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and management of late-life depression\", section on 'Screening instruments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials examining the effectiveness of screening for diabetes. Models suggest that screening for diabetes in people with elevated blood pressure may be cost-effective because of effects of blood pressure management on cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, these models are based on evidence that people with diabetes benefit from tighter blood pressure control than people without diabetes. Recent trials (eg, ACCORD-BP) cast doubt on this assumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/56\">",
"     56",
"    </a>",
"    ]. A 2011 report from a cluster-randomized trial of intensive risk factor interventions in people with newly screen-detected diabetes found no statistically significant reduction in cardiovascular events in the intervention group compared with the routine care group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/57\">",
"     57",
"    </a>",
"    ]. An earlier report from the same study found small increases in several negative psychological states in the intensive intervention group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF recommends targeted screening for people with sustained blood pressure",
"    <span class=\"nowrap\">",
"     &ge;135/80",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/59\">",
"     59",
"    </a>",
"    ]. This recommendation was based on evidence suggesting that aggressive blood pressure management would reduce cardiovascular mortality in patients with diabetes, although recent trials have not been considered in this evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/60\">",
"     60",
"    </a>",
"    ]. The American Diabetes Association (ADA) recommends screening for diabetes for patients age 45 and older without risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/61\">",
"     61",
"    </a>",
"    ]. The ADA also recommends testing for diabetes in adults who are overweight or obese (BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and have one or more additional risk factors for diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that the balance between benefits and harms of screening for diabetes is uncertain at present and any net benefit is likely to be small. Screening for diabetes is unlikely to be as important as being alert for early symptoms and appropriately treating cardiovascular disease risk factors in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunization schedule for adults, recommended by the CDC, is shown in a table (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ). An overview of adult immunization is presented separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend annual influenza vaccination. In 2010, the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices expanded the recommendation for influenza vaccination to include all individuals six months of age and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H775052687#H775052687\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals who report egg allergy should receive an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    that was not produced in eggs (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"mobipreview.htm?41/31/42494\">",
"     table 7",
"    </a>",
"    ). If an egg-free vaccine is not available, an inactivated influenza vaccine produced in eggs can be used with some precautions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link&amp;anchor=H12#H12\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Administration protocols'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Antiviral agents can be used as prophylaxis following exposure in people who have not been vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;All people with chronic illness and those ages 65 years and older should be immunized against Streptococcus pneumoniae infection. Additionally, the United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) advises pneumococcal vaccination for cigarette smokers (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the benefits of immunization for pneumococcus are less clear than for influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/65\">",
"     65",
"    </a>",
"    ], pneumococcal vaccine, like influenza vaccine, has few adverse effects. People with chronic disease who receive pneumococcal vaccination before age 65 should be revaccinated after age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/64\">",
"     64",
"    </a>",
"    ]. Pneumococcal vaccination otherwise needs to be given only once, except for those who are in the highest risk groups: asplenia, chronic renal disease, or immunocompromised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Zoster vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A live attenuated vaccine for herpes zoster was licensed by the US Food and Drug Administration in 2006 for use in people age 60 years and older. An estimated 30 percent of people develop herpes zoster at some point in their lives, the risk increasing with age. Post-herpetic neuralgia develops in about 40 percent of people who develop zoster over the age of 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/66\">",
"     66",
"    </a>",
"    ]. Preliminary data also suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    is effective in reducing the incidence of zoster in persons 50 to 59 years of age.",
"   </p>",
"   <p>",
"    In a randomized trial of over 38,000 adults over 60 years of age, clinical zoster and post-herpetic neuralgia were reduced by 51 and 66 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/67\">",
"     67",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    is most beneficial for people ages 65 to 75. Dependent on the cost of vaccine and anticipated length of vaccine efficacy, the cost-effectiveness may exceed usual thresholds for patients over age 80 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/68\">",
"     68",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices (ACIP) recommends a one-time dose of zoster vaccine for people aged 60 years and older, whether or not they have a history of herpes zoster infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/64\">",
"     64",
"    </a>",
"    ]. Although the vaccine was approved by the US Food and Drug Administration in 2011 for use in individuals 50 to 59 years, the ACIP has not changed its recommended age threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120985990\">",
"    <span class=\"h3\">",
"     Hepatitis B vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the ACIP voted to recommend the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    for diabetic adults younger than 60 years and for diabetic patients older than 60 years based on their likelihood of acquiring hepatitis B, of need for assisted blood glucose monitoring, and likelihood of an immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link&amp;anchor=H8#H8\">",
"     \"Hepatitis B virus vaccination\", section on 'Other high-risk groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120986110\">",
"    <span class=\"h3\">",
"     Tetanus, diphtheria, and acellular pertussis vaccination (Td/Tdap)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF recommends booster doses of adult-type tetanus and diphtheria toxoid every 10 years, although longer intervals are probably adequate for those vaccinated in childhood or young adulthood. Studies have demonstrated the efficacy and cost-effectiveness of a single booster in producing sustained immunity to both tetanus and diphtheria among older patients (aged 50 to 70) who had received a primary booster series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices (ACIP) still recommends a booster every 10 years, while the American College of Physicians (ACP) supports a single Td booster in late life (age &gt;50 years) in patients who have completed the primary series and have not had a booster within the last 10 years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A one-time dose of Tdap should be given in place of Td for adults. In fall 2010, the ACIP voted to recommend that a single dose of Tdap vaccine may be given in place of Td for adults &ge;65 years who have not received Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Tdap should be administered regardless of the interval since the last dose of Td.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Injury prevention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Falls and bone fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should target people ages 65 years and older or younger people with special risk factors (eg, previous falls or fractures).",
"   </p>",
"   <p>",
"    Effectively reducing bone fractures among older people involves both preventing falls and increasing bone and muscle strength. Fall prevention includes minimizing psychotropic medications, encouraging weight-bearing physical activity and muscle strengthening, and vitamin D supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older people should be asked about recent falls. Those with a history of a fall may benefit by assessing integrated musculoskeletal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/78\">",
"     78",
"    </a>",
"    ], such as the \"Timed Up and Go (TUG)\" test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/79\">",
"     79",
"    </a>",
"    ] or assessing gait speed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/80\">",
"     80",
"    </a>",
"    ]. People with unsteadiness or recurrent falls should be considered for a more in-depth fall evaluation, perhaps including a home assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/77,81\">",
"     77,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing bone strength involves screening women older than 65 years (or women ages 60 to 64 who are at high risk) for bone mineral density (BMD). Bisphosphonate therapy for low bone mineral density reduces fractures in women ages 65 and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/82-87\">",
"     82-87",
"    </a>",
"    ]. Because of the low risk of fractures in younger women, routine BMD screening is unlikely to be useful in this age group. For women 65 years of age and older with normal or slightly-low bone mass (T-score -1.01 to -1.49) at baseline measurement and no risk factors for accelerated bone loss, follow-up DXA is not needed for 10 to 15 years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Motor vehicle crashes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries from motor vehicle crashes are highest for drivers at both ends of the age spectrum. Motor vehicle deaths in the United States have declined since 1990, due to the use of lap and shoulder safety belts, a decline in alcohol-impaired driving, highway redesign, and national education campaigns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No counseling approach in the clinical encounter has been shown to increase the use of lap and shoulder safety belts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/88\">",
"     88",
"    </a>",
"    ]. Evidence is stronger that screening and brief behavioral counseling can reduce inappropriate alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/89\">",
"     89",
"    </a>",
"    ]. However, whether counseling is effective in decreasing alcohol-related driving is also not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is reasonable to evaluate older drivers for problems that could increase their risk of being involved in a motor vehicle crash. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Intimate partner violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence (IPV) affects people of all socioeconomic groups and all ethnicities. Women and older adults are at highest risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intimate partner violence is defined as intentional controlling or violent behavior by a person who is or was in an intimate relationship with the victim. The behavior may involve physical abuse, emotional abuse, sexual assault, economic control,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    social isolation of the victim. A systematic review to update USPSTF recommendations found that screening instruments can identify patients who are experiencing IPV and that counseling for certain groups, such as pregnant women, can improve health outcomes and decrease IPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/90\">",
"     90",
"    </a>",
"    ]. Specific findings in the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical examination should make a clinician consider and ask about domestic violence (",
"    <a class=\"graphic graphic_table graphicRef53373 \" href=\"mobipreview.htm?0/48/779\">",
"     table 9",
"    </a>",
"    ). Identified victims of domestic violence should be informed of local resources for assistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Lifestyle-related problems",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Obesity and physical inactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity (BMI &gt;30) and physical inactivity are associated with hypertension, diabetes, increased cardiovascular events, and increased all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intentional weight reduction and increased physical activity are associated with decreased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/11,97-100\">",
"     11,97-100",
"    </a>",
"    ]. Unfortunately, brief counseling interventions in clinical settings have little long-term effect on reducing weight or increasing physical activity. More intensive interventions that include nutrition education, individualized goal-setting, behavioral approaches, walking groups, and other social activities can be modestly successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF recommends that clinicians screen their adult patients for obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients with a body mass index &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    should be offered or referred to intensive, multidisciplinary programs for obesity and physical inactivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sexually-transmitted and other blood-borne infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Chlamydia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually active women ages 15 to 25 years, and older women who have behavioral risk factors, are at highest risk of complications from chlamydia.",
"   </p>",
"   <p>",
"    Genital chlamydia trachomatis is common, often asymptomatic, and can lead to serious complications including pelvic inflammatory disease, ectopic pregnancy, infertility, and chronic pelvic pain. Chlamydial infection is also highly treatable. Urine-based nucleic acid amplification tests make screening simple and accurate.",
"   </p>",
"   <p>",
"    We recommend screening sexually active women ages 15 to 25 years and older women who have behavioral risk factors (eg, new or multiple sexual partners, inconsistent use of barrier methods) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Gonorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of asymptomatic gonorrhea in young women in the US is much lower than chlamydia infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/104\">",
"     104",
"    </a>",
"    ], and tends to be centered in high risk areas. Thus, the most appropriate target group for gonorrhea screening is younger, sexually active women in high-risk areas. Clinicians therefore need to determine whether they are practicing in a high risk area, either by office testing or by consultation with the local health department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend screening sexually active women ages 15 to 29 years who live in areas of high prevalence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1175358\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Starting in 2012, the Centers for Disease Control and Prevention (CDC) recommends one time birth cohort screening for hepatitis C virus (HCV) antibodies for all persons in the United States born between 1945 and 1965 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/106\">",
"     106",
"    </a>",
"    ]. Studies estimate the prevalence of HCV in this cohort to be 3.25 percent, accounting for approximately 75 percent of cases of chronic HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/107\">",
"     107",
"    </a>",
"    ]. Some studies suggest that screening in this population may be cost effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/108,109\">",
"     108,109",
"    </a>",
"    ], but others point out that these determinations were based on high assumptions about progression to decompensated liver disease or hepatocellular carcinoma and optimistic assumptions about benefit with lower cost treatments. Several UpToDate authors support the CDC recommendation for birth cohort screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Who should be tested'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This author suggests taking a careful history regarding risk factors, and selectively screening this population. In 2004, the USPSTF recommended against screening for HCV in average-risk patients; it also found insufficient evidence to determine the balance of benefits and harms of screening patients at increased risk. This recommendation is undergoing review in 2013 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to screening for HIV infection are discussed in detail elsewhere, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at increased risk for human immunodeficiency virus (HIV) infection are those who report at least one individual risk factor: men who have sex with men, people who have unprotected sex with multiple partners, past or present injection drug users, sexual contact with HIV-infected others, and people with other sexually transmitted infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Screening should be considered for patients seen in high-risk or high-prevalence clinical settings such as sexually transmitted diseases clinics, correctional facilities, homeless shelters, emergency rooms, or tuberculosis clinics.",
"   </p>",
"   <p>",
"    Screening may be cost-effective in populations with an HIV-seroprevalence rate of 0.2 to 0.3 percent or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/113\">",
"     113",
"    </a>",
"    ]. Asymptomatic people can harbor HIV infection in immunologically advanced stages and can benefit from highly active antiretroviral treatment (HAART) and prophylaxis against opportunistic infections.",
"   </p>",
"   <p>",
"    Institution of routine HIV screening programs must be accompanied by scrupulous attention to patient confidentiality and appropriate counseling for post-test results. In 2005, the USPSTF recommended screening for people at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. A subsequent systematic review found growing evidence that antiretroviral therapy can reduce the risk of sexual transmission of HIV and reduce morbidity and mortality in all HIV-infected patients, including those who may be asymptomatic and only identified through screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/114\">",
"     114",
"    </a>",
"    ]. The USPSTF has issued a draft revised recommendation to screen individuals in the general population, aged 15 to 65 years, that is undergoing review in 2013 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, the US Centers for Disease Control (CDC) recommended voluntary but universal \"opt-out\" HIV screening (in which a patient is screened unless he or she specifically elects not to be) for adults ages 13 to 64 years, based on the difficulty of knowing the prevalence of HIV infection in a given population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Substance-abuse related problems",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol misuse is common in all age groups, all socioeconomic levels, and in both genders. Alcohol consumption, above recommended daily, weekly, or per occasion amounts, is associated with multiple health problems including motor vehicle crashes, suicide, violence, hypertension, mental disorders, and development of alcohol dependence. Brief interventions in primary care, including feedback, goal setting, and follow-up with short contacts, are effective in reducing alcohol consumption to safer levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend screening adults for alcohol problems. Short questionnaires (eg, the AUDIT-C) can detect alcohol misuse (",
"    <a class=\"graphic graphic_table graphicRef74262 \" href=\"mobipreview.htm?11/33/11804\">",
"     table 10",
"    </a>",
"    ). The \"5As\" approach (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"mobipreview.htm?40/33/41500\">",
"     table 11",
"    </a>",
"    ), developed for tobacco smoking cessation, is a good model for this counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Tobacco",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should ask all patients whether they use tobacco, and in what form.",
"   </p>",
"   <p>",
"    Tobacco contributes to over 400,000 deaths each year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/2\">",
"     2",
"    </a>",
"    ]. Stopping smoking carries both immediate and long-term benefits. We recommend brief assessment and counseling for tobacco cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/119\">",
"     119",
"    </a>",
"    ]. A useful approach to counseling is the \"5As\" approach (",
"    <a class=\"graphic graphic_table graphicRef74262 \" href=\"mobipreview.htm?11/33/11804\">",
"     table 10",
"    </a>",
"    ). A combination of pharmacologic and behavioral approaches is appropriate for most smokers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most importantly, clinicians should realize that stopping smoking is a process that requires time. Smokers will often \"relapse\" several times before stopping permanently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Other drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;All new patients should be asked whether they use or have used drugs that have the potential for abuse. The frequency, dose, and route of drug administration should be asked for those who acknowledge drug use. A drug history should also be reviewed for patients who present with new symptoms such as unexplained weight loss, or new mood or behavioral issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injection drug users should be screened for serologic evidence of immunity to hepatitis B virus, and vaccinated for hepatitis B if nonimmune. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Center for Disease Control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/120\">",
"     120",
"    </a>",
"    ], the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/121\">",
"     121",
"    </a>",
"    ], and other groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/122\">",
"     122",
"    </a>",
"    ] recommend that persons who ever injected drugs should be tested for hepatitis C virus (HCV) infection, while the US Preventive Services Task Force notes insufficient evidence to recommend for or against routine screening for HCV in adults at high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Vision and hearing problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision and hearing problems, severe enough to affect a patient's function, become more common after age 65 years. Despite the fact that simple tests can detect these problems, few well-conducted studies have examined the effect of screening for these problems on function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because many older adults are unaware of correctable vision and hearing problems that may significantly affect their functional abilities, we think it is reasonable to periodically screen people ages 65 and older for vision and hearing problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simply questioning whether the patient has had difficulty with hearing or vision is inadequate to detect important problems. Several available tests can be easily performed in the primary care setting. Vision testing with a Snellen chart can detect refractive error and important cataracts. Either a 10-item self-administered questionnaire (the Hearing Handicap Inventory for the Elderly, Screening: HHIE-S) or a small hand-held combination audiometer and otoscope are adequate screening tests for hearing problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/127-130\">",
"     127-130",
"    </a>",
"    ]. The \"whispered voice test\", when conducted in a standardized way, can also be a reasonable screening test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/125,126,131\">",
"     125,126,131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     WHAT NOT TO DO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive services that are ineffective, targeted to rare conditions, or lead to a greater probability of harms than benefits should not be delivered. The USPSTF has identified a group of such services that they would discourage, unless there are unusual additional considerations, and rate these interventions as \"Grade D\".",
"   </p>",
"   <p>",
"    As an example, there is reasonable evidence that screening with spirometry for chronic obstructive pulmonary disease (COPD) would provide little benefit, require some resources, and may lead to false positive tests and overtreatment. Thus, screening with spirometry is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, although screening asymptomatic people with ultrasound for carotid artery stenosis would occasionally prevent a stroke, it would also cause some strokes (due to complications of angiography or to carotid endarterectomy), and require many resources. The USPSTF recommends",
"    <strong>",
"     not",
"    </strong>",
"    screening asymptomatic individuals for carotid artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34361?source=see_link\">",
"     \"Screening for asymptomatic carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other preventive services probably provide some benefit but the benefits and harms are closely matched. These services need not be prioritized and are given a \"Grade C\" by the USPSTF.",
"   </p>",
"   <p>",
"    The USPSTF \"Grade I\" identifies services for which the USPSTF has found a lack of sufficient evidence to determine the balance between benefits and harms. These services should only be provided when the patient is helped to understand the uncertainty in our knowledge of benefits and harms, and still desires the service.",
"   </p>",
"   <p>",
"    USPSTF C, D, and I recommendations are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef78892 graphicRef58200 graphicRef72269 \" href=\"mobipreview.htm?16/32/16911\">",
"     table 12A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other services have not been examined by the USPSTF but should be discouraged on the basis of our current knowledge. Some screening tests, as an example, have an unclear target condition. Total-body CT scanning, urine dipstick screening, and multi-channel chemistry profiles have uncertain benefit but probable harm if widely implemented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     HOW TO EFFICIENTLY DELIVER PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive services are more likely to be discussed when patients have an established relationship with an identified clinician. In a study of 155,590 adults who received care in an academic network of health center and hospital-based practices in the United States, an algorithmic model identified that 59.3 percent of patients were connected to a specific clinician, 34.5 percent to a specific practice, and 6.2 percent were not clearly connected to either clinician or practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/134\">",
"     134",
"    </a>",
"    ]. Rates of preventive care services (breast, colorectal, and cervical cancer screening) were highest for clinician-connected patients, even when adjusted for differences in age, sex, race, and ethnicity between connected and non-connected patients.",
"   </p>",
"   <p>",
"    Most preventive services are considered at the time of a periodic health maintenance visit (a periodic check-up visit) in primary care practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. For people who have no chronic conditions and rarely see a clinician, a periodic health evaluation visit may be the only opportunity to discuss needed preventive care. In a population of HMO enrollees, having a periodic health examination was associated with a three-fold increase in completing colorectal cancer testing and a significant, but smaller, increase in undergoing screening mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a systematic review and meta-analysis of 14 randomized trials (182,880 participants) of periodic health checks found no beneficial effect of general health checks on total mortality (risk ratio [RR] 0.99, 95% CI 0.95-1.03), cardiovascular mortality (RR 1.03, CI 0.91-1.17), or cancer mortality (RR 1.01, CI 0.92-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/138\">",
"     138",
"    </a>",
"    ]. Additionally, health checks increased the number of new diagnoses, the prevalence of hypertension and hypercholesterolemia, and use of antihypertensives, without altering cardiovascular mortality. Some studies were old so that treatment did not reflect current practice (such as use of statins), and there was heterogeneity among studies.",
"   </p>",
"   <p>",
"    Periodic visits may have other benefits, such as developing the patient-clinician relationship, relieving patient \"worry,\" and educating patients about how to access the health care system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/136,139\">",
"     136,139",
"    </a>",
"    ]. There are no strict guidelines for the optimal frequency of these periodic visits, and no evidence on which to base optimal frequency recommendations. Annual examinations are not indicated for most younger patients, although people with chronic health issues (such as diabetes) warrant regular visits, with or without a periodic health maintenance visit, independent of age. In the absence of such indications, we suggest periodic health maintenance visits every three years for adult patients &le;49 years without chronic conditions, and annually for adults 50 years and older.",
"   </p>",
"   <p>",
"    Many people, however, do not have regular check-up visits. In the US, Medicare will reimburse for a one-time \"welcome to Medicare\" preventive care visit and also for an annual &ldquo;wellness&rdquo; visit. Some preventive care (eg, monitoring high blood pressure or smoking counseling), however, cannot be accomplished in a single annual visit.",
"   </p>",
"   <p>",
"    Thus, routine \"check-up\" visits may be an efficient way to discuss most, but not all, components of preventive care. These visits cannot address the preventive care needs of all patients. Prevention, therefore, should be considered at nearly every visit and the \"periodic health maintenance visit\" becomes the \"continuous health maintenance evaluation.\" This is particularly true for young adults (age &lt;30 years) who are less likely to have preventive care visits than other age groups, are less likely to have medical insurance, and are at increased risk for depression and suicide, sexually transmitted disease and HIV infection, and substance abuse including binge drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second issue is the design of the periodic check-up visit. Rather than perform a standardized comprehensive exam on all patients, clinicians need to individualize the visit to meet the specific needs of the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/141\">",
"     141",
"    </a>",
"    ]. Rarely is there a need for a standard head to toe physical examination.",
"   </p>",
"   <p>",
"    Creative approaches using office systems can assist in delivering needed preventive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/142\">",
"     142",
"    </a>",
"    ]. As an example, practices have successfully used databases of eligible patients (eg, for flu shots, mammograms, diabetic eye exams, etc) and automatic reminders to outreach to patients and assist in delivering routine preventive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/143\">",
"     143",
"    </a>",
"    ]. In one study of interventions to promote screening for colorectal cancer, mailings to patients were somewhat more effective than electronic reminders to clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/144\">",
"     144",
"    </a>",
"    ]. Finally, using decision aids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    training medical assistants to discuss important preventive services before a visit with a clinician can be more efficient and effective in helping patients make informed decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/4/37962/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key issue that should determine the content of preventive care is which of the preventive services is appropriate for the individual patient. A primary care practice that is conscientiously organized to deliver effective and appropriate preventive care, whether through a periodic or a continuing approach (or some combination), will be making an important contribution to the health of the patient and to the public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=see_link\">",
"       \"Patient information: Breast cancer screening (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/13/11475?source=see_link\">",
"       \"Patient information: Lung cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate screening and prevention interventions need to be prioritized both for effectiveness in modifying target outcomes and for risk of the condition in the individual patient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prioritizing preventive services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age-specific recommendations for routine screening and prevention are presented in tables (",
"      <a class=\"graphic graphic_table graphicRef72728 \" href=\"mobipreview.htm?39/54/40812\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69700 \" href=\"mobipreview.htm?41/50/42797\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prioritizing preventive services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may not receive appropriate screening and prevention interventions if the time for addressing these needs is limited to seeing the patient for a \"routine physical examination.\" Creative solutions for delivering preventive care involving use of patient databases and mechanisms for patient outreach, as well as using incorporating preventive care into patient sick visits, need to be developed. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'How to efficiently deliver prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999; 48:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/2\">",
"      Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291:1238.",
"     </a>",
"    </li>",
"    <li>",
"     AHRQ. The Guide to Clinical Preventive Services. www.preventiveservices.ahrq.gov/#uspstf (Accessed on November 29, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/4\">",
"      Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/5\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/6\">",
"      Pignone M, Mulrow CD. Evidence based management of hypertension: Using cardiovascular risk profiles to individualise hypertensive treatment. BMJ 2001; 322:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/7\">",
"      US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/8\">",
"      Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/9\">",
"      Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:496.",
"     </a>",
"    </li>",
"    <li>",
"     NHLBI Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; Department of Health and Human Services, Bethesda, MD 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/11\">",
"      Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/12\">",
"      Moyer VA, U.S. Preventive Services Task Force. Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/13\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/14\">",
"      Chou R, Arora B, Dana T, et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/15\">",
"      Auer R, Bauer DC, Marques-Vidal P, et al. Association of major and minor ECG abnormalities with coronary heart disease events. JAMA 2012; 307:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/16\">",
"      Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001; 322:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/17\">",
"      U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007; 147:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/18\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/19\">",
"      U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med 2005; 142:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/20\">",
"      Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/21\">",
"      Wolff T, Guirguis-Blake J, Miller T, et al. Screening for carotid artery stenosis: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 147:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/22\">",
"      Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/23\">",
"      Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172:95.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Screening for peripheral arterial disease: recommendation statement 2005. Available at: www.preventiveservices.ahrq.gov (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/25\">",
"      Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/27\">",
"      Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/28\">",
"      Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA 2012; 307:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/29\">",
"      Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/30\">",
"      U.S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002; 137:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/31\">",
"      Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/32\">",
"      Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/33\">",
"      Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999; 282:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/34\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/35\">",
"      Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/36\">",
"      Solomon D, Schiffman M, Tarone R, ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/37\">",
"      Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:687.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Available: www.ahrq.gov/clinic/uspstf/uspscerv.htm (Accessed on September 22, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/39\">",
"      Sung HY, Kearney KA, Miller M, et al. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000; 88:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/40\">",
"      Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999; 180:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/41\">",
"      Holden DJ, Jonas DE, Porterfield DS, et al. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med 2010; 152:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/42\">",
"      National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/43\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/44\">",
"      Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/45\">",
"      U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/46\">",
"      Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/47\">",
"      Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 154:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/48\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force. Behavioral Counseling to Prevent Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/49\">",
"      Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/50\">",
"      U.S. Preventive Services Task Force. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009; 151:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/51\">",
"      O'Connor EA, Whitlock EP, Beil TL, Gaynes BN. Screening for depression in adult patients in primary care settings: a systematic evidence review. Ann Intern Med 2009; 151:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/52\">",
"      Williams JW Jr, No&euml;l PH, Cordes JA, et al. Is this patient clinically depressed? JAMA 2002; 287:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/53\">",
"      Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/54\">",
"      Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/55\">",
"      Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/56\">",
"      ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/57\">",
"      Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/58\">",
"      Eborall HC, Griffin SJ, Prevost AT, et al. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/59\">",
"      U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/60\">",
"      Norris SL, Kansagara D, Bougatsos C, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/61\">",
"      American Diabetes Association. Standards of medical care in diabetes--2009. Diabetes Care 2009; 32 Suppl 1:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/62\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. Available at: www.cdc.gov/media/pressrel/2010/r100224.htm (Accessed on May 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/64\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. Ann Intern Med 2011; 154:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/65\">",
"      Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; :CD000422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/66\">",
"      Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/67\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/68\">",
"      Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011; 60:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/70\">",
"      Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/71\">",
"      Solomonova K, Vizev S. Secondary response to boostering by purified aluminium-hydroxide-adsorbed tetanus anatoxin in aging and in aged adults. Immunobiology 1981; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/72\">",
"      Balestra DJ, Littenberg B. Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med 1993; 8:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/73\">",
"      Marlovits S, Stocker R, Efstratiou A, et al. Effect on diphtheria immunity of combined tetanus and diphtheria booster vaccination in adults. Eur J Clin Microbiol Infect Dis 2000; 19:506.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/recs/acip/slides-oct10.htm (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     file://www.reuters.com/article/idUSTRE69Q5UL20101027  (Accessed on November 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/76\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/77\">",
"      Michael YL, Whitlock EP, Lin JS, et al. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/78\">",
"      Moyer VA, U.S. Preventive Services Task Force. Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/79\">",
"      Zhu K, Devine A, Lewis JR, et al. \"'Timed up and go' test and bone mineral density measurement for fracture prediction. Arch Intern Med 2011; 171:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/80\">",
"      Viccaro LJ, Perera S, Studenski SA. Is timed up and go better than gait speed in predicting health, function, and falls in older adults? J Am Geriatr Soc 2011; 59:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/81\">",
"      Chang JT, Morton SC, Rubenstein LZ, et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 2004; 328:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/82\">",
"      Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/83\">",
"      NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/84\">",
"      Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/85\">",
"      Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry: clinical applications. JAMA 2002; 288:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/86\">",
"      U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011; 154:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/87\">",
"      Jena AB, Goldman DP, Kamdar A, et al. Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. Ann Intern Med 2010; 153:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/88\">",
"      Williams SB, Whitlock EP, Edgerton EA, et al. Counseling about proper use of motor vehicle occupant restraints and avoidance of alcohol use while driving: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 147:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/89\">",
"      Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/90\">",
"      Nelson HD, Bougatsos C, Blazina I. Screening women for intimate partner violence: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 156:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/91\">",
"      Wathen CN, MacMillan HL. Interventions for violence against women: scientific review. JAMA 2003; 289:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/92\">",
"      Rhodes KV, Levinson W. Interventions for intimate partner violence against women: clinical applications. JAMA 2003; 289:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/93\">",
"      Nelson HD, Nygren P, McInerney Y, et al. Screening women and elderly adults for family and intimate partner violence: a review of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 2004; 140:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/94\">",
"      Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/95\">",
"      Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/96\">",
"      Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/97\">",
"      Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003; 138:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/98\">",
"      Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/99\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/100\">",
"      Gregg EW, Cauley JA, Stone K, et al. Relationship of changes in physical activity and mortality among older women. JAMA 2003; 289:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/101\">",
"      Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/102\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/103\">",
"      Hu D, Hook EW 3rd, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med 2004; 141:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/104\">",
"      Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Available at: www.ahrq.gov/clinic/uspstf/uspsgono.htm (Accessed on September 22, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/106\">",
"      Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     Smith BD, Patel N, Beckett GA, et al. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999&ndash;2008 [Abstract]. American Association for the Study of Liver Disease; San Francisco, CA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/108\">",
"      Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/109\">",
"      McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55:1344.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Screening for hepatitis C virus infection in adults. file://www.uspreventiveservicestaskforce.org/uspstf12/hepc/hepcscrdraft.pdf (Accessed on August 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/111\">",
"      US Preventive Services Task Force. Screening for HIV: recommendation statement. Ann Intern Med 2005; 143:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/112\">",
"      Chou R, Huffman LH, Fu R, et al. Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/113\">",
"      Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/114\">",
"      Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 157:706.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.uspreventiveservicestaskforce.org/uspstf13/hiv/hivdraftrec.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/116\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/117\">",
"      U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/118\">",
"      Bertholet N, Daeppen JB, Wietlisbach V, et al. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med 2005; 165:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/119\">",
"      Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm (Accessed on September 22, 2005).",
"    </li>",
"    <li>",
"     file://consensus.nih.gov/2002/2002HepatitisC2002116html.htm (Accessed on June 12, 2002).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/122\">",
"      Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147.",
"     </a>",
"    </li>",
"    <li>",
"     www.ahrq.gov/clinic/uspstf/uspshepc.htm (Accessed on September 22, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/124\">",
"      Chou R, Clark EC, Helfand M, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/125\">",
"      Chou R, Dana T, Bougatsos C. Screening older adults for impaired visual acuity: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/126\">",
"      Chou R, Dana T, Bougatsos C, et al. Screening adults aged 50 years or older for hearing loss: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011; 154:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/127\">",
"      Yueh B, Shapiro N, MacLean CH, Shekelle PG. Screening and management of adult hearing loss in primary care: scientific review. JAMA 2003; 289:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/128\">",
"      Bogardus ST Jr, Yueh B, Shekelle PG. Screening and management of adult hearing loss in primary care: clinical applications. JAMA 2003; 289:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/129\">",
"      Rowe S, MacLean CH, Shekelle PG. Preventing visual loss from chronic eye disease in primary care: scientific review. JAMA 2004; 291:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/130\">",
"      Goldzweig CL, Rowe S, Wenger NS, et al. Preventing and managing visual disability in primary care: clinical applications. JAMA 2004; 291:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/131\">",
"      Bagai A, Thavendiranathan P, Detsky AS. Does this patient have hearing impairment? JAMA 2006; 295:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/132\">",
"      U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/133\">",
"      U.S. Preventive Services Task Force. Screening for carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 147:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/134\">",
"      Atlas SJ, Grant RW, Ferris TG, et al. Patient-physician connectedness and quality of primary care. Ann Intern Med 2009; 150:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/135\">",
"      Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract 2000; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/136\">",
"      Boulware LE, Marinopoulos S, Phillips KA, et al. Systematic review: the value of the periodic health evaluation. Ann Intern Med 2007; 146:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/137\">",
"      Fenton JJ, Cai Y, Weiss NS, et al. Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med 2007; 167:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/138\">",
"      Krogsb&oslash;ll LT, J&oslash;rgensen KJ, Gr&oslash;nh&oslash;j Larsen C, G&oslash;tzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2012; 10:CD009009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/139\">",
"      Laine C. The annual physical examination: needless ritual or necessary routine? Ann Intern Med 2002; 136:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/140\">",
"      Fortuna RJ, Robbins BW, Halterman JS. Ambulatory care among young adults in the United States. Ann Intern Med 2009; 151:379.",
"     </a>",
"    </li>",
"    <li>",
"     AHRQ. The Guide to Clinical Preventive Services 2006. Available at: www.preventiveservices.ahrq.gov/#uspstf (Accessed on October 28, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/142\">",
"      Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med 2002; 136:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/143\">",
"      Szilagyi P, Vann J, Bordley C, et al. Interventions aimed at improving immunization rates. Cochrane Database Syst Rev 2002; :CD003941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/144\">",
"      Sequist TD, Zaslavsky AM, Marshall R, et al. Patient and physician reminders to promote colorectal cancer screening: a randomized controlled trial. Arch Intern Med 2009; 169:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/4/37962/abstract/145\">",
"      Ghorob A, Bodenheimer T. Sharing the care to improve access to primary care. N Engl J Med 2012; 366:1955.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7574 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37962=[""].join("\n");
var outline_f37_4_37962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIORITIZING PREVENTIVE SERVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF USPSTF RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPECIFIC CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16586863\">",
"      - Carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16587158\">",
"      - Peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cancer morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Zoster vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H120985990\">",
"      - Hepatitis B vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H120986110\">",
"      - Tetanus, diphtheria, and acellular pertussis vaccination (Td/Tdap)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Injury prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Falls and bone fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Motor vehicle crashes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Lifestyle-related problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Obesity and physical inactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sexually-transmitted and other blood-borne infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Chlamydia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Gonorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1175358\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Substance-abuse related problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Tobacco",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Other drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Vision and hearing problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      WHAT NOT TO DO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      HOW TO EFFICIENTLY DELIVER PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7574|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7574|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/38/15980\" title=\"table 1\">",
"      Criteria periodic health exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/54/40812\" title=\"table 2\">",
"      Screening under fifty years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/50/42797\" title=\"table 3\">",
"      Screening over fifty years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/16/35085\" title=\"table 4\">",
"      USPSTF grade AB recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/8/23693\" title=\"table 5\">",
"      Scrn CRC MSTF recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/44/13005\" title=\"table 6\">",
"      Scrn CRC USPSTF recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/31/42494\" title=\"table 7\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 8\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/48/779\" title=\"table 9\">",
"      Patients to ask about violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/33/11804\" title=\"table 10\">",
"      AUDIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/33/41500\" title=\"table 11\">",
"      Five As for smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/40/5772\" title=\"table 12A\">",
"      USPSTF grade C recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/13/21725\" title=\"table 12B\">",
"      USPSTF grade D recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/25/38301\" title=\"table 12C\">",
"      USPSTF grade I recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=related_link\">",
"      Geriatric health maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/13/11475?source=related_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/13/17626?source=related_link\">",
"      Pharmacotherapy for smoking cessation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34361?source=related_link\">",
"      Screening for asymptomatic carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24200?source=related_link\">",
"      Screening for lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_4_37963="ORT replacement guide";
var content_f37_4_37963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of oral rehydration solution to give child (over 4 hours) for mild dehydration, based on weight",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       English system",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Metric system",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Weight, lbs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Volume, ounces",
"      </td>",
"      <td class=\"subtitle2\">",
"       Weight, kilograms",
"      </td>",
"      <td class=\"subtitle2\">",
"       Volume, milliliters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       7.5",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       200",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       300",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       400",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       500",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       22.5",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       600",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       26.5",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       700",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       800",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       900",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37963=[""].join("\n");
var outline_f37_4_37963=null;
var title_f37_4_37964="Empiric oral antibiotics animal bites";
var content_f37_4_37964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric oral antibiotic therapy for animal bites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antibiotic agents",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adults",
"      </td>",
"      <td class=\"subtitle1\">",
"       Children",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Agent of choice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Amoxicillin-clavulanate",
"      </td>",
"      <td>",
"       875/125 mg twice daily",
"      </td>",
"      <td>",
"       20 mg/kg per dose (amoxicillin component) two times daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose) &bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Alternate empiric regimens include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       One of the following agents with activity against",
"       <em>",
"        P. multocida",
"       </em>",
"       :",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Doxycycline*",
"      </td>",
"      <td>",
"       100 mg twice daily",
"      </td>",
"      <td>",
"       Not recommended in children &lt;8 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       TMP-SMX*",
"      </td>",
"      <td>",
"       1 double strength tablet twice daily",
"      </td>",
"      <td>",
"       4-5 mg/kg (trimethoprim component) per dose twice daily (maximum 160 mg trimethoprim per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Penicillin VK",
"      </td>",
"      <td>",
"       500 mg four times daily",
"      </td>",
"      <td>",
"       12.5 mg/kg per dose four times daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cefuroxime",
"      </td>",
"      <td>",
"       500 mg twice daily",
"      </td>",
"      <td>",
"       10 mg/kg per dose twice daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Moxifloxacin",
"      </td>",
"      <td>",
"       400 mg once daily",
"      </td>",
"      <td>",
"       Use with caution in children &lt;18 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent3\" colspan=\"3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       One of the following agents with anaerobic activity:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Metronidazole",
"      </td>",
"      <td>",
"       500 mg three times daily",
"      </td>",
"      <td>",
"       10 mg/kg per dose three times daily (maximum 500 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Clindamycin*",
"      </td>",
"      <td>",
"       450 mg three times daily",
"      </td>",
"      <td>",
"       10 mg/kg per dose three times daily (maximum 450 mg per dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       The following agents have poor activity against",
"       <em>",
"        P. multocida",
"       </em>",
"       and should be avoided:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Cephalexin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Dicloxacillin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Erythromycin",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May also be active against MRSA (check susceptibility testing).",
"     <br>",
"      TMP-SMX: Trimethoprim-sulfamethoxazole",
"      <br>",
"       &bull; In patients with infected bites, the clinician may increase the dose to 45 mg/kg per dose (amoxicillin component) twice daily (maximum 875 mg amoxicillin and 125 mg clavulinic acid per dose).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37964=[""].join("\n");
var outline_f37_4_37964=null;
var title_f37_4_37965="Contents: Primary care calculators";
var content_f37_4_37965=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/20/19776\">",
"           Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33796\">",
"           Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/3/41023\">",
"           Calculator: International Prostatism Symptom Score (IPSS)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/55/36722\">",
"           Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/3/10291\">",
"           Calculator: Post-test probability from likelihood ratios and multiple test results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/24/19841\">",
"           Calculator: SI unit conversions for immunology lab values",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3E5091D109-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_4_37965=[""].join("\n");
var outline_f37_4_37965=null;
var title_f37_4_37966="Contents: Prostate cancer";
var content_f37_4_37966=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Prostate cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Prostate cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24394\">",
"           Interpretation of prostate biopsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13288\">",
"           Active surveillance for men with early prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10055\">",
"           Follow-up surveillance during and after treatment for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/9/30874\">",
"           Molecular biology of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/19/26937\">",
"           Precancerous lesions of the prostate: Pathology and clinical implications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41736\">",
"           Chemoprevention strategies in prostate cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/55/38770\">",
"           Patient information: Prostate cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/8/42122\">",
"           Screening for prostate cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Staging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24394\">",
"           Interpretation of prostate biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9704\">",
"           Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/18/13608\">",
"           Bisphosphonates and denosumab in patients with metastatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/41/41622\">",
"           Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32824\">",
"           Brachytherapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/7/16503\">",
"           Castrate resistant prostate cancer: Treatments targeting the androgen pathway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/8/6280\">",
"           Chemotherapy in castrate-resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/29/25049\">",
"           Clinical features, diagnosis, and treatment of radiation proctitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/63/43000\">",
"           Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/47/23290\">",
"           External beam radiation therapy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10055\">",
"           Follow-up surveillance during and after treatment for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1254\">",
"           Immunotherapy for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/36/16969\">",
"           Initial approach to low-risk clinically localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1353\">",
"           Initial hormone therapy for metastatic prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/26/21930\">",
"           Initial management of regionally localized intermediate and high risk prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/59/20405\">",
"           Investigational approaches for the treatment of advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/8/36999\">",
"           Management of bone metastases in advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/12/10442\">",
"           Overview of the treatment of disseminated prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/9/33943\">",
"           Pathologic stage T3 and margin positive prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/39/40565\">",
"           Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/41/42643\">",
"           Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24313\">",
"           Radical prostatectomy for localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1656\">",
"           Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/48/30470\">",
"           Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/48/33544\">",
"           Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/31/20983\">",
"           Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/0/38918\">",
"           Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38520\">",
"           Secondary endocrine therapies for castration resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21993\">",
"           Side effects of androgen deprivation therapy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-9D5B50B1A3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_4_37966=[""].join("\n");
var outline_f37_4_37966=null;
var title_f37_4_37967="ART outcome in women age 50 and older using donor eggs";
var content_f37_4_37967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Live births per transfer and singleton live births per transfer for ART cycles using fresh embryos from donor eggs, by ART patient's age, 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The above figure shows percentages of transfers resulting in live births and singleton live births for ART cycles using fresh embryos from donor eggs among women of different ages. For all ages, the percentage of transfers resulting in singleton live births (average 31 percent) was lower than the percentage of transfers resulting in live births (average 52 percent). Singleton live births are an important measure of success because they have a much lower risk than multiple-infant births for adverse infant health outcomes, including prematurity, low birth weight, disability, and death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2005 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_4_37967=[""].join("\n");
var outline_f37_4_37967=null;
